BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42:44-52. [PMID: 15895401 DOI: 10.1002/hep.20734] [Cited by in Crossref: 818] [Cited by in F6Publishing: 761] [Article Influence: 48.1] [Reference Citation Analysis]
Number Citing Articles
1 Kinoshita M, Kubo S, Tanaka S, Takemura S, Nishioka T, Hamano G, Ito T, Tanaka S, Ohsawa M, Shibata T. The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: A hospital based case-control study: NASH and Intrahepatic Cholangiocarcinoma. J Surg Oncol 2016;113:779-83. [DOI: 10.1002/jso.24223] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
2 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820-32. [DOI: 10.1002/hep.23594] [Cited by in Crossref: 871] [Cited by in F6Publishing: 819] [Article Influence: 72.6] [Reference Citation Analysis]
3 Sanyal AJ. NASH: A global health problem: NASH: A global health problem. Hepatology Research 2011;41:670-4. [DOI: 10.1111/j.1872-034x.2011.00824.x] [Cited by in Crossref: 99] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
4 Chiloiro M, Caruso MG, Cisternino AM, Inguaggiato R, Reddavide R, Bonfiglio C, Guerra V, Notarnicola M, De Michele G, Correale M, Noviello MR, Misciagna G. Ultrasound evaluation and correlates of fatty liver disease: a population study in a Mediterranean area. Metab Syndr Relat Disord 2013;11:349-58. [PMID: 23758075 DOI: 10.1089/met.2012.0169] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
5 Bradford V, Dillon J, Miller M. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease. Hepat Med. 2014;6:1-10. [PMID: 24826079 DOI: 10.2147/hmer.s34472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
6 Hariri M, Zohdi S. Effect of Vitamin D on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Randomized Controlled Clinical Trials. Int J Prev Med 2019;10:14. [PMID: 30774848 DOI: 10.4103/ijpvm.IJPVM_499_17] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Dureja P, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A. NAFLD recurrence in liver transplant recipients. Transplantation. 2011;91:684-689. [PMID: 21248661 DOI: 10.1097/tp.0b013e31820b6b84] [Cited by in Crossref: 105] [Cited by in F6Publishing: 31] [Article Influence: 9.5] [Reference Citation Analysis]
8 Zhang Y, Zhang T, Zhang C, Tang F, Zhong N, Li H, Song X, Lin H, Liu Y, Xue F. Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ Open. 2015;5:e008204. [PMID: 26395497 DOI: 10.1136/bmjopen-2015-008204] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 4.9] [Reference Citation Analysis]
9 Ahmed MH, Husain NE, Almobarak AO. Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians? J Family Med Prim Care. 2015;4:45-52. [PMID: 25810989 DOI: 10.4103/2249-4863.152252] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
10 Yi M, Chen RP, Yang R, Chen H. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China. Diabet Med 2017;34:505-13. [PMID: 27334577 DOI: 10.1111/dme.13174] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
11 Martin-Rodriguez JL, Gonzalez-Cantero J, Gonzalez-Cantero A, Arrebola JP, Gonzalez-Calvin JL. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. Medicine (Baltimore). 2017;96:e6770. [PMID: 28445310 DOI: 10.1097/md.0000000000006770] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
12 Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, Chen MH, Hu PJ. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007; 13(47): 6419-6424 [PMID: 18081233 DOI: 10.3748/wjg.v13.i47.6419] [Cited by in CrossRef: 111] [Cited by in F6Publishing: 125] [Article Influence: 7.4] [Reference Citation Analysis]
13 Ding ZM, Xiao Y, Wu X, Zou H, Yang S, Shen Y, Xu J, Workman HC, Usborne AL, Hua H. Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy. Front Pharmacol. 2018;9:410. [PMID: 29765319 DOI: 10.3389/fphar.2018.00410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
14 Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab 2007;3:458-69. [PMID: 17515890 DOI: 10.1038/ncpendmet0505] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 4.8] [Reference Citation Analysis]
15 Tajima R, Kimura T, Enomoto A, Saito A, Kobayashi S, Masuda K, Iida K. No association between fruits or vegetables and non-alcoholic fatty liver disease in middle-aged men and women. Nutrition 2019;61:119-24. [PMID: 30710884 DOI: 10.1016/j.nut.2018.10.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
16 Del Ben M, Baratta F, Polimeni L, Angelico F. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Intern Emerg Med. 2012;7 Suppl 3:S291-S296. [PMID: 23073870 DOI: 10.1007/s11739-012-0819-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
17 Loguercio C, Tiso A, Cotticelli G, Blanco Cdel V, Arpino G, Laringe M, Napoli L, Piccinocchi G, Bonfrate L, Grattagliano I. Management of chronic liver disease by general practitioners in southern Italy: unmet educational needs. Dig Liver Dis. 2011;43:736-741. [PMID: 21616733 DOI: 10.1016/j.dld.2011.04.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
18 Leporq B, Lambert SA, Ronot M, Vilgrain V, Van Beers BE. Quantification of the triglyceride fatty acid composition with 3.0 T MRI: QUANTIFICATION OF TRIGLYCERIDE FATTY ACID COMPOSITION WITH MRI. NMR Biomed 2014;27:1211-21. [DOI: 10.1002/nbm.3175] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
19 Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51:444-450. [PMID: 18058083 DOI: 10.1007/s00125-007-0897-4] [Cited by in Crossref: 198] [Cited by in F6Publishing: 174] [Article Influence: 13.2] [Reference Citation Analysis]
20 Wang C, Gong J, Wu H. Development of gene polymorphisms in meditators of nonalcoholic fatty liver disease. Biomed Rep 2017;7:95-104. [PMID: 28804621 DOI: 10.3892/br.2017.926] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
21 Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia–Pacific region. Nat Rev Gastroenterol Hepatol 2019;16:57-73. [DOI: 10.1038/s41575-018-0055-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 21.5] [Reference Citation Analysis]
22 Angulo P. Obesity and nonalcoholic fatty liver disease. Nutr Rev. 2007;65:S57-S63. [PMID: 17605315 DOI: 10.1111/j.1753-4887.2007.tb00329.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 79] [Article Influence: 0.7] [Reference Citation Analysis]
23 Kimura T, Deshpande GA, Urayama KY, Masuda K, Fukui T, Matsuyama Y. Association of weight gain since age 20 with non-alcoholic fatty liver disease in normal weight individuals. J Gastroenterol Hepatol 2015;30:909-17. [PMID: 25469977 DOI: 10.1111/jgh.12861] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
24 Maconi G, Furfaro F, Fries W, Dell'Era A, Bezzio C, Costantino G, Giuliano V, Alibrandi A, Guzowski T, Bassotti G. Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessment. Liver Int 2017;37:141-7. [PMID: 27375263 DOI: 10.1111/liv.13198] [Reference Citation Analysis]
25 Andrade GCD, Fujise LH, Santana Filho JED, Oliveira F, Silva RDCMAD. Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study – sample of São José do Rio Preto. Rev Assoc Med Bras 2016;62:218-26. [DOI: 10.1590/1806-9282.62.03.218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
26 Briseño-Bass P, Chávez-Pérez R, López-Zendejas M. Prevalence of hepatic steatosis and its relation to liver function tests and lipid profile in patients at medical check-up. Rev Gastroenterol Mex (Engl Ed) 2019;84:290-5. [PMID: 30292582 DOI: 10.1016/j.rgmx.2018.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
27 Misciagna G, del Pilar Díaz M, Caramia DV, Bonfiglio C, Franco I, Noviello MR, Chiloiro M, Abbrescia DI, Mirizzi A, Tanzi M, Caruso MG, Correale M, Reddavide R, Inguaggiato R, Cisternino AM, Osella AR. Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial. J Nutr Health Aging 2017;21:404-12. [DOI: 10.1007/s12603-016-0809-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 8.8] [Reference Citation Analysis]
28 Gheflati A, Adelnia E, Nadjarzadeh A. The clinical effects of purslane ( Portulaca oleracea ) seeds on metabolic profiles in patients with nonalcoholic fatty liver disease: A randomized controlled clinical trial. Phytotherapy Research 2019;33:1501-9. [DOI: 10.1002/ptr.6342] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
29 Edens MA, van Ooijen PM, Post WJ, Haagmans MJ, Kristanto W, Sijens PE, van der Jagt EJ, Stolk RP. Ultrasonography to quantify hepatic fat content: validation by 1H magnetic resonance spectroscopy. Obesity (Silver Spring). 2009;17:2239-2244. [PMID: 19461588 DOI: 10.1038/oby.2009.154] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
30 Yousefi Rad E, Eslampour E, Falahi E, Mardani M, Hekmatdoost A, Asbaghi O, Saboori S. Effects of carnitine supplementation on liver aminotransferase enzymes: A systematic review and meta-analysis of randomized controlled clinical trials. Indian J Gastroenterol 2019;38:470-9. [PMID: 31828538 DOI: 10.1007/s12664-019-00983-2] [Reference Citation Analysis]
31 Foschi FG, Domenicali M, Giacomoni P, Dall'Aglio AC, Conti F, Borghi A, Bevilacqua V, Napoli L, Mirici F, Cucchetti A, Ercolani G, Gardini AC, Bellentani S, Gastaldelli A, Giuffrè M, Tiribelli C, Bedogni G; Bagnacavallo Study Group. Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population? Ann Hepatol 2020;19:380-7. [PMID: 32451205 DOI: 10.1016/j.aohep.2020.04.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
32 Wang YG, Yang TL. Liraglutide reduces fatty degeneration in hepatic cells via the AMPK/SREBP1 pathway. Exp Ther Med 2015;10:1777-83. [PMID: 26640549 DOI: 10.3892/etm.2015.2741] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
33 Sadeghi F, Amanat S, Bakhtiari M, Asadimehr H, Okhovat MA, Hosseinzadeh M, Mazloomi SM, Gholamalizadeh M, Doaei S. The effects of high fructose fruits and honey on the serum level of metabolic factors and nonalcoholic fatty liver disease. J Diabetes Metab Disord 2021;20:1647-54. [PMID: 34900816 DOI: 10.1007/s40200-021-00916-x] [Reference Citation Analysis]
34 Ghani RA, Saqlain M, Zafar MM, Jabeen S, Naqvi SM, Raja GK. Identification of Metabolic risk phenotypes predisposing to Non-Alcoholic Fatty Liver Disease in a Pakistani Cohort. Pak J Med Sci 2017;33:121-6. [PMID: 28367184 DOI: 10.12669/pjms.331.11445] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
35 Shin J, Kim MJ, Shin HJ, Yoon H, Kim S, Koh H, Lee MJ. Quick assessment with controlled attenuation parameter for hepatic steatosis in children based on MRI-PDFF as the gold standard. BMC Pediatr 2019;19:112. [PMID: 30987634 DOI: 10.1186/s12887-019-1485-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
36 Fraenkel E, Takács R, Hamvas J, Lengyel G, Fehér J. [Common occurrence of non-alcoholic fatty liver disease and cholecystolithiasis]. Orv Hetil. 2007;148:793-798. [PMID: 17452309 DOI: 10.1556/hmj.1.2007.3.8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Qu HQ, Li Q, Grove ML, Lu Y, Pan JJ, Rentfro AR, Bickel PE, Fallon MB, Hanis CL, Boerwinkle E. Population-based risk factors for elevated alanine aminotransferase in a South Texas Mexican-American population. Arch Med Res. 2012;43:482-488. [PMID: 22959976 DOI: 10.1016/j.arcmed.2012.08.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
38 Byrne CD. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. Diabet Med. 2012;29:1098-1107. [PMID: 22672330 DOI: 10.1111/j.1464-5491.2012.03732.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
39 Zelber-sagi S, Toker S, Armon G, Melamed S, Berliner S, Shapira I, Halpern Z, Santo E, Shibolet O. Elevated alanine aminotransferase independently predicts new onset of depression in employees undergoing health screening examinations. Psychol Med 2013;43:2603-13. [DOI: 10.1017/s0033291713000500] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
40 Xu L, Ma H, Miao M, Li Y. Impact of subclinical hypothyroidism on the development of non-alcoholic fatty liver disease: a prospective case-control study. J Hepatol 2012;57:1153-4. [PMID: 22940010 DOI: 10.1016/j.jhep.2012.05.025] [Cited by in Crossref: 59] [Cited by in F6Publishing: 32] [Article Influence: 5.9] [Reference Citation Analysis]
41 Ahmed MH, Noor SK, Bushara SO, Husain NE, Elmadhoun WM, Ginawi IA, Osman MM, Mahmoud AO, Almobarak AO. Non-Alcoholic Fatty Liver Disease in Africa and Middle East: An Attempt to Predict the Present and Future Implications on the Healthcare System. Gastroenterology Res 2017;10:271-9. [PMID: 29118867 DOI: 10.14740/gr913w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
42 Im AR, Yang WK, Park YC, Kim SH, Chae S. Hepatoprotective Effects of Insect Extracts in an Animal Model of Nonalcoholic Fatty Liver Disease. Nutrients 2018;10:E735. [PMID: 29880728 DOI: 10.3390/nu10060735] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
43 Naukkarinen J, Heinonen S, Hakkarainen A, Lundbom J, Vuolteenaho K, Saarinen L, Hautaniemi S, Rodriguez A, Frühbeck G, Pajunen P, Hyötyläinen T, Orešič M, Moilanen E, Suomalainen A, Lundbom N, Kaprio J, Rissanen A, Pietiläinen KH. Characterising metabolically healthy obesity in weight-discordant monozygotic twins. Diabetologia 2014;57:167-76. [PMID: 24100782 DOI: 10.1007/s00125-013-3066-y] [Cited by in Crossref: 103] [Cited by in F6Publishing: 97] [Article Influence: 11.4] [Reference Citation Analysis]
44 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285. [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x] [Cited by in Crossref: 1806] [Cited by in F6Publishing: 1693] [Article Influence: 164.2] [Reference Citation Analysis]
45 Shimada M, Kawahara H, Ozaki K, Fukura M, Yano H, Tsuchishima M, Tsutsumi M, Takase S. Usefulness of a combined evaluation of the serum adiponectin level, HOMA-IR, and serum type IV collagen 7S level to predict the early stage of nonalcoholic steatohepatitis. Am J Gastroenterol. 2007;102:1931-1938. [PMID: 17511754 DOI: 10.1111/j.1572-0241.2007.01322.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 6.9] [Reference Citation Analysis]
46 Delitala AP, Capobianco G, Delitala G, Cherchi PL, Dessole S. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet 2017;296:405-19. [DOI: 10.1007/s00404-017-4429-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 10.4] [Reference Citation Analysis]
47 Cesaretti M, Addeo P, Schiavo L, Anty R, Iannelli A. Assessment of Liver Graft Steatosis: Where Do We Stand? Liver Transpl. 2019;25:500-509. [PMID: 30380197 DOI: 10.1002/lt.25379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
48 Yang Z, Zhang H, Niu Y, Zhang W, Zhu L, Li X, Lu S, Fan J, Li X, Ning G, Qin L, Su Q. Circulating periostin in relation to insulin resistance and nonalcoholic fatty liver disease among overweight and obese subjects. Sci Rep 2016;6:37886. [PMID: 27885258 DOI: 10.1038/srep37886] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
49 Shikora SA, Edgerton C, Harris D, Buchwald H. Metabolic surgery. Current Problems in Surgery 2021. [DOI: 10.1016/j.cpsurg.2021.101059] [Reference Citation Analysis]
50 Leporq B, Ratiney H, Pilleul F, Beuf O. Liver fat volume fraction quantification with fat and water T1 and T 2* estimation and accounting for NMR multiple components in patients with chronic liver disease at 1.5 and 3.0 T. Eur Radiol 2013;23:2175-86. [PMID: 23588583 DOI: 10.1007/s00330-013-2826-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
51 Munteanu MA, Mircea PA. From NAFLD to Cardiovascular Disease. Is it (Still) the Metabolic Syndrome? Clujul Med 2014;87:80-6. [PMID: 26528002 DOI: 10.15386/cjmed-277] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Junker AE, Gluud L, Holst JJ, Knop FK, Vilsbøll T. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J Intern Med 2016;279:485-93. [PMID: 26728692 DOI: 10.1111/joim.12462] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
53 Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, Dhibar T, Bhattacharya B, Bhattacharya D, Manna B. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology. 2010;51:1593-1602. [PMID: 20222092 DOI: 10.1002/hep.23567] [Cited by in Crossref: 250] [Cited by in F6Publishing: 233] [Article Influence: 20.8] [Reference Citation Analysis]
54 Vernuccio F, Whitney SA, Ravindra K, Marin D. CT and MR imaging evaluation of living liver donors. Abdom Radiol (NY) 2021;46:17-28. [PMID: 31901101 DOI: 10.1007/s00261-019-02385-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Kara M, Dogru T, Genc H, Sertoglu E, Celebi G, Gurel H, Kayadibi H, Cicek AF, Ercin CN, Sonmez A. Neutrophil-to-lymphocyte ratio is not a predictor of liver histology in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:1144-1148. [PMID: 26062078 DOI: 10.1097/meg.0000000000000405] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
56 Colak Y, Senates E, Ozturk O, Doganay HL, Coskunpinar E, Oltulu YM, Eren A, Sahin O, Ozkanli S, Enc FY. Association of serum lipoprotein-associated phospholipase A2 level with nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2012;10:103-109. [PMID: 22112193 DOI: 10.1089/met.2011.0111] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
57 Shi JP, Fan JG, Wu R, Gao XQ, Zhang L, Wang H, Farrell GC. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol. 2008;23:1419-1425. [PMID: 18853998 DOI: 10.1111/j.1440-1746.2008.05531.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 4.9] [Reference Citation Analysis]
58 Siddiqui B, Kamran M, Tikmani SS, Azmat R, Mushtaq Z, Zafar SB, Khan MT, Yakoob J, Abbas Z. Frequency and risk factors of non-alcoholic fatty liver disease in Helicobacter pylori-infected dyspeptic patients: A cross-sectional study. SAGE Open Med 2021;9:20503121211025421. [PMID: 34211711 DOI: 10.1177/20503121211025421] [Reference Citation Analysis]
59 Nakade Y, Murotani K, Inoue T, Kobayashi Y, Yamamoto T, Ishii N, Ohashi T, Ito K, Fukuzawa Y, Yoneda M. Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis. Hepatol Res. 2017;47:1417-1428. [PMID: 28257594 DOI: 10.1111/hepr.12887] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 7.4] [Reference Citation Analysis]
60 Srinivasa Babu A, Wells ML, Teytelboym OM, Mackey JE, Miller FH, Yeh BM, Ehman RL, Venkatesh SK. Elastography in Chronic Liver Disease: Modalities, Techniques, Limitations, and Future Directions. Radiographics. 2016;36:1987-2006. [PMID: 27689833 DOI: 10.1148/rg.2016160042] [Cited by in Crossref: 92] [Cited by in F6Publishing: 77] [Article Influence: 15.3] [Reference Citation Analysis]
61 Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103:71-83. [PMID: 19914930 DOI: 10.1093/qjmed/hcp158] [Cited by in Crossref: 392] [Cited by in F6Publishing: 366] [Article Influence: 30.2] [Reference Citation Analysis]
62 Daudén E, Castañeda S, Suárez C, García-campayo J, Blasco A, Aguilar M, Ferrándiz C, Puig L, Sánchez-carazo J. Abordaje integral de la comorbilidad del paciente con psoriasis. Actas Dermo-Sifiliográficas 2012;103:1-64. [DOI: 10.1016/s0001-7310(12)70001-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
63 Wu HT, Lu FH, Ou HY, Su YC, Hung HC, Wu JS, Yang YC, Wu CL, Chang CJ. The role of hepassocin in the development of non-alcoholic fatty liver disease. J Hepatol 2013;59:1065-72. [PMID: 23792031 DOI: 10.1016/j.jhep.2013.06.004] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
64 Kirovski G, Dorn C, Huber H, Moleda L, Niessen C, Wobser H, Schacherer D, Buechler C, Wiest R, Hellerbrand C. Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation. Exp Mol Pathol. 2011;91:780-783. [PMID: 21855538 DOI: 10.1016/j.yexmp.2011.08.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
65 Bedogni G, Miglioli L, Masutti F, Ferri S, Castiglione A, Lenzi M, Crocè LS, Granito A, Tiribelli C, Bellentani S. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Am J Gastroenterol 2008;103:2248-53. [PMID: 18637095 DOI: 10.1111/j.1572-0241.2008.01948.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
66 Grattagliano I, Ubaldi E, Napoli L, Marulli CF, Nebiacolombo C, Cottone C, Portincasa P. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The “VARES” Italian multicenter study. Annals of Hepatology 2013;12:70-7. [DOI: 10.1016/s1665-2681(19)31387-0] [Cited by in Crossref: 12] [Article Influence: 1.3] [Reference Citation Analysis]
67 Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-24. [PMID: 20648476 DOI: 10.1002/hep.23784] [Cited by in Crossref: 290] [Cited by in F6Publishing: 276] [Article Influence: 24.2] [Reference Citation Analysis]
68 Kang MK, Kang BH, Kim JH. Nonalcoholic Fatty Liver Disease Is Associated with the Presence and Morphology of Subclinical Coronary Atherosclerosis. Yonsei Med J 2015;56:1288-95. [PMID: 26256971 DOI: 10.3349/ymj.2015.56.5.1288] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
69 Almeda-Valdes P, Aguilar Olivos NE, Barranco-Fragoso B, Uribe M, Méndez-Sánchez N. The Role of Dendritic Cells in Fibrosis Progression in Nonalcoholic Fatty Liver Disease. Biomed Res Int. 2015;2015:768071. [PMID: 26339640 DOI: 10.1155/2015/768071] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
70 Karageorgos SA, Stratakou S, Koulentaki M, Voumvouraki A, Mantaka A, Samonakis D, Notas G, Kouroumalis EA. Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study. Ann Gastroenterol 2017;30:357-63. [PMID: 28469367 DOI: 10.20524/aog.2017.0135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
71 Zelber-Sagi S, Webb M, Assy N, Blendis L, Yeshua H, Leshno M, Ratziu V, Halpern Z, Oren R, Santo E. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol 2013; 19(1): 57-64 [PMID: 23326163 DOI: 10.3748/wjg.v19.i1.57] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 62] [Article Influence: 7.6] [Reference Citation Analysis]
72 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
73 St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol. 2009;24:399-407. [PMID: 19067776 DOI: 10.1111/j.1440-1746.2008.05694.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 4.6] [Reference Citation Analysis]
74 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obes Facts. 2016;9:65-90. [PMID: 27055256 DOI: 10.1159/000443344] [Cited by in Crossref: 129] [Cited by in F6Publishing: 119] [Article Influence: 21.5] [Reference Citation Analysis]
75 Turola E, Petta S, Vanni E, Milosa F, Valenti L, Critelli R, Miele L, Maccio L, Calvaruso V, Fracanzani AL. Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis. Dis Model Mech. 2015;8:1037-1046. [PMID: 26183212 DOI: 10.1242/dmm.019950] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
76 Han EN, Cheong ES, Lee JI, Kim MC, Byrne CD, Sung KC. Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study. Clin Hypertens 2015;21:22. [PMID: 26893932 DOI: 10.1186/s40885-015-0032-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
77 Kirovski G, Schacherer D, Wobser H, Huber H, Niessen C, Beer C, Schölmerich J, Hellerbrand C. Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics. Int J Clin Exp Med. 2010;3:202-210. [PMID: 20827318 DOI: 10.1055/s-0029-1246560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
78 Caballería L, Arteaga I, Pera G, Rodríguez L, Alumà A, Auladell MA, Torán P. [Risk factors associated with non-alcoholic fatty liver disease: a case-control study]. Med Clin (Barc) 2013;141:233-9. [PMID: 23601740 DOI: 10.1016/j.medcli.2012.11.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
79 Miele L, Forgione A, Gasbarrini G, Grieco A. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149:114-125. [PMID: 17320797 DOI: 10.1016/j.trsl.2006.11.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
80 Bakulin IG, Sandler YG, Keyan VA, Rotin DL. [A new non-invasive method for assessing steatosis in chronic liver diseases]. Ter Arkh 2016;88:49-57. [PMID: 27030184 DOI: 10.17116/terarkh201688249-57] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
81 Panchal SK, Ward L, Brown L. Ellagic acid attenuates high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. Eur J Nutr. 2013;52:559-568. [PMID: 22538930 DOI: 10.1007/s00394-012-0358-9] [Cited by in Crossref: 89] [Cited by in F6Publishing: 83] [Article Influence: 8.9] [Reference Citation Analysis]
82 Xu M, Zheng XM, Jiang F, Qiu WQ. MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease. J Cell Biochem 2018;119:5864-74. [PMID: 29575055 DOI: 10.1002/jcb.26776] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
83 Kelishadi R, Farajian S, Mirlohi M. Probiotics as a novel treatment for non-alcoholic Fatty liver disease; a systematic review on the current evidences. Hepat Mon 2013;13:e7233. [PMID: 23885277 DOI: 10.5812/hepatmon.7233] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
84 Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, Park SW, Kim SW. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 2011;34:727-9. [PMID: 21278140 DOI: 10.2337/dc10-1991] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 8.5] [Reference Citation Analysis]
85 Leo M, Galante A, Pagnamenta A, Ruinelli L, Ponziani F, Gasbarrini A, De Gottardi A. Hepatocellular liver injury in hospitalized patients affected by COVID-19: presence of different risk factors at different time points. Digestive and Liver Disease 2021. [DOI: 10.1016/j.dld.2021.12.014] [Reference Citation Analysis]
86 Zsóri G, Illés D, Ivány E, Kosár K, Holzinger G, Tajti M, Pálinkás E, Szabovik G, Nagy A, Palkó A, Czakó L. In New-Onset Diabetes Mellitus, Metformin Reduces Fat Accumulation in the Liver, But Not in the Pancreas or Pericardium. Metab Syndr Relat Disord 2019;17:289-95. [PMID: 31013454 DOI: 10.1089/met.2018.0086] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
87 Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009;37:2087-94. [PMID: 19651758 DOI: 10.1124/dmd.109.027466] [Cited by in Crossref: 188] [Cited by in F6Publishing: 184] [Article Influence: 14.5] [Reference Citation Analysis]
88 Kim NH, Kim JH, Kim YJ, Yoo HJ, Kim HY, Seo JA, Kim NH, Choi KM, Baik SH, Choi DS, Kim SG. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int. 2014;34:604-611. [PMID: 24382309 DOI: 10.1111/liv.12454] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
89 Vassilatou E, Vassiliadi DA, Salambasis K, Lazaridou H, Koutsomitopoulos N, Kelekis N, Kassanos D, Hadjidakis D, Dimitriadis G. Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease. Eur J Endocrinol 2015;173:739-47. [PMID: 26340970 DOI: 10.1530/EJE-15-0567] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
90 Li T, Geng L, Chen X, Miskowiec M, Li X, Dong B. Branched-chain amino acids alleviate nonalcoholic steatohepatitis in rats. Appl Physiol Nutr Metab. 2013;38:836-843. [PMID: 23855271 DOI: 10.1139/apnm-2012-0496] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
91 Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol 2012; 18(3): 237-243 [PMID: 22294826 DOI: 10.3748/wjg.v18.i3.237] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 69] [Article Influence: 7.0] [Reference Citation Analysis]
92 Zhang W, Yang Z, Niu Y, Li X, Zhu L, Lu S, Zhang H, Fan J, Ning G, Qin L, Su Q. Association of calf circumference with insulin resistance and non-alcohol fatty liver disease: the REACTION study. BMC Endocr Disord 2017;17:28. [PMID: 28558676 DOI: 10.1186/s12902-017-0176-4] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
93 Cobbold JFL, Patel D, Taylor-robinson SD. Assessment of inflammation and fibrosis in non-alcoholic fatty liver disease by imaging-based techniques: Imaging in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2012;27:1281-92. [DOI: 10.1111/j.1440-1746.2012.07127.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
94 Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1798-1810. [PMID: 27003600 DOI: 10.1053/j.gastro.2016.03.009] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 11.5] [Reference Citation Analysis]
95 Mostofinejad Z, Akheruzzaman M, Abu Bakkar Siddik M, Patkar P, Dhurandhar NV, Hegde V. Antidiabetic E4orf1 protein prevents hepatic steatosis and reduces markers of aging-related cellular damage in high fat fed older mice. BMJ Open Diabetes Res Care 2021;9:e002096. [PMID: 33941552 DOI: 10.1136/bmjdrc-2020-002096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Stroffolini T, Sagnelli E, Sagnelli C, Morisco F, Babudieri S, Furlan C, Pirisi M, Russello M, Smedile A, Pisaturo M, Almasio PL. Decreasing role of HCV and HBV infections as aetiological factors of hepatocellular carcinoma in Italy. Infection. 2019;. [PMID: 31028627 DOI: 10.1007/s15010-019-01308-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
97 Spite M, Clària J, Serhan CN. Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab 2014;19:21-36. [PMID: 24239568 DOI: 10.1016/j.cmet.2013.10.006] [Cited by in Crossref: 261] [Cited by in F6Publishing: 247] [Article Influence: 29.0] [Reference Citation Analysis]
98 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
99 Bedogni G, Nobili V, Tiribelli C. Epidemiology of fatty liver: An update. World J Gastroenterol 2014; 20(27): 9050-9054 [PMID: 25083078 DOI: 10.3748/wjg.v20.i27.9050] [Cited by in F6Publishing: 42] [Reference Citation Analysis]
100 Tsuchiya T, Naitoh T, Nagao M, Tanaka N, Watanabe K, Imoto H, Miyachi T, Motoi F, Unno M. Increased Bile Acid Signals After Duodenal-Jejunal Bypass Improve Non-alcoholic Steatohepatitis (NASH) in a Rodent Model of Diet-Induced NASH. Obes Surg 2018;28:1643-52. [PMID: 29235014 DOI: 10.1007/s11695-017-3065-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
101 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 165] [Cited by in F6Publishing: 164] [Article Influence: 55.0] [Reference Citation Analysis]
102 Hamaguchi M, Takeda N, Kojima T, Ohbora A, Kato T, Sarui H, Fukui M, Nagata C, Takeda J. Identification of individuals with non-alcoholic fatty liver disease by the diagnostic criteria for the metabolic syndrome. World J Gastroenterol 2012; 18(13): 1508-1516 [PMID: 22509083 DOI: 10.3748/wjg.v18.i13.1508] [Cited by in CrossRef: 52] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
103 Pan L, Huang P, Xie X, Xu J, Guo D, Jiang Y. Reply to "Does MAFLD really increase the severity of COVID-19?". Dig Liver Dis 2021;53:168. [PMID: 33187919 DOI: 10.1016/j.dld.2020.10.034] [Reference Citation Analysis]
104 Cuthbertson DJ, Weickert MO, Lythgoe D, Sprung VS, Dobson R, Shoajee-Moradie F, Umpleby M, Pfeiffer AF, Thomas EL, Bell JD. External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals. Eur J Endocrinol. 2014;171:561-569. [PMID: 25298375 DOI: 10.1530/eje-14-0112] [Cited by in Crossref: 75] [Cited by in F6Publishing: 37] [Article Influence: 10.7] [Reference Citation Analysis]
105 Nakadate K, Motojima K, Tanaka-nakadate S. Dilatation of Sinusoidal Capillary and Swelling of Sinusoidal Fenestration in Obesity: An Ultrastructural Study. Ultrastructural Pathology 2013;39:30-7. [DOI: 10.3109/01913123.2014.947010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
106 Moriya A, Iwasaki Y, Ohguchi S, Kayashima E, Mitsumune T, Taniguchi H, Ando M, Yamamoto K. Roles of alcohol consumption in fatty liver: A longitudinal study. Journal of Hepatology 2015;62:921-7. [DOI: 10.1016/j.jhep.2014.11.025] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 8.4] [Reference Citation Analysis]
107 Cichoż-Lach H, Celiński K, Prozorow-Król B, Swatek J, Słomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit 2012;18:CR735-40. [PMID: 23197236 DOI: 10.12659/msm.883601] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
108 Sesti G, Sciacqua A, Fiorentino TV, Perticone M, Succurro E, Perticone F. Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis. PLoS One 2014;9:e104941. [PMID: 25111713 DOI: 10.1371/journal.pone.0104941] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
109 Koo DJ, Lee MY, Jung I, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY. Baseline homeostasis model assessment of insulin resistance associated with fibrosis progression in patients with nonalcoholic fatty liver disease without diabetes: A cohort study. PLoS One 2021;16:e0255535. [PMID: 34432804 DOI: 10.1371/journal.pone.0255535] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist’s perspective. Expert Rev Gastroenterol Hepatol. 2011;5:223-231. [PMID: 21476917 DOI: 10.1586/egh.11.8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
111 Xia SF, Le GW, Wang P, Qiu YY, Jiang YY, Tang X. Regressive Effect of Myricetin on Hepatic Steatosis in Mice Fed a High-Fat Diet. Nutrients 2016;8:E799. [PMID: 27973423 DOI: 10.3390/nu8120799] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
112 Mori S, Arima N, Ito M, Fujiyama S, Kamo Y, Ueki Y. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One 2018;13:e0203084. [PMID: 30142184 DOI: 10.1371/journal.pone.0203084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
113 Wlazlo N, van Greevenbroek MM, Ferreira I, Jansen EH, Feskens EJ, van der Kallen CJ, Schalkwijk CG, Bravenboer B, Stehouwer CD. Activated complement factor 3 is associated with liver fat and liver enzymes: the CODAM study. Eur J Clin Invest. 2013;43:679-688. [PMID: 23586841 DOI: 10.1111/eci.12093] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
114 Liu Y, Zhou D, Zhang F, Tu Y, Xia Y, Wang H, Zhou B, Zhang Y, Wu J, Gao X, He Z, Zhai Q. Liver Patt1 deficiency protects male mice from age-associated but not high-fat diet-induced hepatic steatosis. J Lipid Res 2012;53:358-67. [PMID: 22231784 DOI: 10.1194/jlr.M019257] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
115 Okanoue T, Umemura A, Yasui K, Itoh Y. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in Japan. J Gastroenterol Hepatol. 2011;26 Suppl 1:153-162. [PMID: 21199527 DOI: 10.1111/j.1440-1746.2010.06547.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 6.8] [Reference Citation Analysis]
116 Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009;8 Suppl 1:S4-S8. [PMID: 19381118 DOI: 10.1016/s1665-2681(19)31820-4] [Cited by in Crossref: 188] [Cited by in F6Publishing: 1] [Article Influence: 14.5] [Reference Citation Analysis]
117 Li Z, Xue J, Chen P, Chen L, Yan S, Liu L. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies. J Gastroenterol Hepatol. 2014;29:42-51. [PMID: 24219010 DOI: 10.1111/jgh.12428] [Cited by in Crossref: 125] [Cited by in F6Publishing: 124] [Article Influence: 15.6] [Reference Citation Analysis]
118 Xie Y, Wang M, Zhang Y, Zhang S, Tan A, Gao Y, Liang Z, Shi D, Huang Z, Zhang H. Serum uric acid and non-alcoholic fatty liver disease in non-diabetic Chinese men. PLoS One. 2013;8:e67152. [PMID: 23935829 DOI: 10.1371/journal.pone.0067152] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
119 Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010;:CD007340. [PMID: 20091629 DOI: 10.1002/14651858.CD007340.pub2] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 8.3] [Reference Citation Analysis]
120 Neuschwander-tetri BA. Non-alcoholic steatohepatitis: . Current Opinion in Endocrinology & Diabetes 2006;13:119-26. [DOI: 10.1097/01.med.0000216959.98385.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
121 Dunn W, Angulo P, Sanderson S, Jamil LH, Stadheim L, Rosen C, Malinchoc M, Kamath PS, Shah VH. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology. 2006;131:1057-1063. [PMID: 17030176 DOI: 10.1053/j.gastro.2006.08.020] [Cited by in Crossref: 80] [Cited by in F6Publishing: 60] [Article Influence: 5.0] [Reference Citation Analysis]
122 Rabinowich L, Shibolet O. Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease. Biomed Res Int 2015;2015:168905. [PMID: 26273591 DOI: 10.1155/2015/168905] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
123 Arora A, Sharma P. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:145-155. [PMID: 25755423 DOI: 10.1016/s0973-6883(12)60103-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
124 Sanyal AJ, Mathurin P, Nagy LA. Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease. Gastroenterology. 2016;150:1695-1697. [PMID: 27155520 DOI: 10.1053/j.gastro.2016.04.038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
125 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1712-1723. [PMID: 24587650 DOI: 10.3478/wjg.v20.i7.1712] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
126 Trunečka P, Míková I, Dlouhá D, Hubáček JA, Honsová E, Kolesár L, Lánská V, Fraňková S, Šperl J, Jirsa M, Poledne R. Donor PNPLA3 rs738409 genotype is a risk factor for graft steatosis. A post-transplant biopsy-based study. Dig Liver Dis 2018;50:490-5. [PMID: 29396131 DOI: 10.1016/j.dld.2017.12.030] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
127 Adams LA, Angulo P. Role of Liver Biopsy and Serum Markers of Liver Fibrosis in Non-alcoholic Fatty Liver Disease. Clinics in Liver Disease 2007;11:25-35. [DOI: 10.1016/j.cld.2007.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
128 Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11-20. [PMID: 28930295 DOI: 10.1038/nrgastro.2017.109] [Cited by in Crossref: 1421] [Cited by in F6Publishing: 1332] [Article Influence: 284.2] [Reference Citation Analysis]
129 Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-854. [PMID: 17393509 DOI: 10.1002/hep.21496] [Cited by in Crossref: 1507] [Cited by in F6Publishing: 1351] [Article Influence: 100.5] [Reference Citation Analysis]
130 Yoon CY, Lee M, Kim SU, Lim H, Chang TI, Kee YK, Han SG, Han IM, Kwon YE, Park KS, Lee MJ, Park JT, Han SH, Ahn SH, Kang SW, Yoo TH. Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study. Kidney Res Clin Pract 2017;36:48-57. [PMID: 28392997 DOI: 10.23876/j.krcp.2017.36.1.48] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
131 Oliva-Pascual-Vaca Á, González-González C, Oliva-Pascual-Vaca J, Piña-Pozo F, Ferragut-Garcías A, Fernández-Domínguez JC, Heredia-Rizo AM. Visceral Origin: An Underestimated Source of Neck Pain. A Systematic Scoping Review. Diagnostics (Basel) 2019;9:E186. [PMID: 31726685 DOI: 10.3390/diagnostics9040186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
132 Hossain IA, Rahman Shah MM, Rahman MK, Ali L. Gamma glutamyl transferase is an independent determinant for the association of insulin resistance with nonalcoholic fatty liver disease in Bangladeshi adults. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2016;10:S25-9. [DOI: 10.1016/j.dsx.2015.09.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
133 Ding C, Tang Y, Zhu W, Huang P, Lian P, Ran J, Huang X. Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis. Acta Diabetol. [DOI: 10.1007/s00592-021-01830-7] [Reference Citation Analysis]
134 Qiu T, Pei P, Yao X, Jiang L, Wei S, Wang Z, Bai J, Yang G, Gao N, Yang L, Qi S, Yan R, Liu X, Sun X. Taurine attenuates arsenic-induced pyroptosis and nonalcoholic steatohepatitis by inhibiting the autophagic-inflammasomal pathway. Cell Death Dis 2018;9:946. [PMID: 30237538 DOI: 10.1038/s41419-018-1004-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
135 Xiao J, Guo R, Fung ML, Liong EC, Tipoe GL. Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. Hepatobiliary Pancreat Dis Int. 2013;12:125-135. [PMID: 23558065 DOI: 10.1016/s1499-3872(13)60021-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
136 Arias-Loste MT, Iruzubieta P, Puente Á, Ramos D, Santa Cruz C, Estébanez Á, Llerena S, Alonso-Martín C, San Segundo D, Álvarez L, López Useros A, Fábrega E, López-Hoyos M, Crespo J. Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2016;17:E1878. [PMID: 27834919 DOI: 10.3390/ijms17111878] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
137 Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene. 2006;25:3756-3770. [PMID: 16799617 DOI: 10.1038/sj.onc.1209557] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 5.3] [Reference Citation Analysis]
138 Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Seminars in Diagnostic Pathology 2005;22:330-8. [DOI: 10.1053/j.semdp.2006.04.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.4] [Reference Citation Analysis]
139 Hashemi Kani A, Alavian SM, Esmaillzadeh A, Adibi P, Azadbakht L. Dietary Quality Indices and Biochemical Parameters Among Patients With Non Alcoholic Fatty Liver Disease (NAFLD). Hepat Mon 2013;13:e10943. [PMID: 24065998 DOI: 10.5812/hepatmon.10943] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
140 Haub S, Kanuri G, Volynets V, Brune T, Bischoff SC, Bergheim I. Serotonin reuptake transporter (SERT) plays a critical role in the onset of fructose-induced hepatic steatosis in mice. Am J Physiol Gastrointest Liver Physiol. 2010;298:G335-G344. [PMID: 19713474 DOI: 10.1152/ajpgi.00088.2009] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 4.6] [Reference Citation Analysis]
141 Ruffillo G, Fassio E, Alvarez E, Landeira G, Longo C, Domínguez N, Gualano G. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. Journal of Hepatology 2011;54:160-3. [DOI: 10.1016/j.jhep.2010.06.028] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
142 Franzini M, Fornaciari I, Fierabracci V, Elawadi HA, Bolognesi V, Maltinti S, Ricchiuti A, De Bortoli N, Marchi S, Pompella A. Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. Liver Int. 2012;32:629-634. [PMID: 22098947 DOI: 10.1111/j.1478-3231.2011.02673.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
143 Yu XY, Zhao Y, Song XX, Song ZY. Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population. J Zhejiang Univ Sci B. 2014;15:879-887. [PMID: 25294377 DOI: 10.1631/jzus.b1400028] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
144 Zeb I, Li D, Nasir K, Katz R, Larijani VN, Budoff MJ. Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis. Acad Radiol 2012;19:811-8. [PMID: 22521729 DOI: 10.1016/j.acra.2012.02.022] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 8.5] [Reference Citation Analysis]
145 Nasr P, Hilliges A, Thorelius L, Kechagias S, Ekstedt M. Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology 2016;51:1126-32. [DOI: 10.3109/00365521.2016.1172336] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
146 Junker AE, Gluud LL, van Hall G, Holst JJ, Knop FK, Vilsbøll T. Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. Journal of Hepatology 2016;64:908-15. [DOI: 10.1016/j.jhep.2015.11.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
147 Scorletti E, Calder PC, Byrne CD. Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. Endocrine 2011;40:332-43. [DOI: 10.1007/s12020-011-9530-x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
148 Spruss A, Henkel J, Kanuri G, Blank D, Püschel GP, Bischoff SC, Bergheim I. Female mice are more susceptible to nonalcoholic fatty liver disease: sex-specific regulation of the hepatic AMP-activated protein kinase-plasminogen activator inhibitor 1 cascade, but not the hepatic endotoxin response. Mol Med. 2012;18:1346-1355. [PMID: 22952059 DOI: 10.2119/molmed.2012.00223] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 5.2] [Reference Citation Analysis]
149 Chen MJ, Ho HN. Hepatic manifestations of women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2016;37:119-28. [PMID: 27107966 DOI: 10.1016/j.bpobgyn.2016.03.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
150 Caballería L, Pera G, Auladell MA, Torán P, Muñoz L, Miranda D, Alumà A, Casas JD, Sánchez C, Gil D, Aubà J, Tibau A, Canut S, Bernad J, Aizpurua MM. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. European Journal of Gastroenterology & Hepatology 2010;22:24-32. [DOI: 10.1097/meg.0b013e32832fcdf0] [Cited by in Crossref: 123] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
151 Fiorentino TV, Marini MA, Succurro E, Andreozzi F, Sciacqua A, Hribal ML, Perticone F, Sesti G. Association between hemoglobin glycation index and hepatic steatosis in non-diabetic individuals. Diabetes Res Clin Pract 2017;134:53-61. [PMID: 28993156 DOI: 10.1016/j.diabres.2017.09.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
152 Festi D, Schiumerini R, Marasco G, Scaioli E, Pasqui F, Colecchia A. Non-invasive diagnostic approach to non-alcoholic fatty liver disease: current evidence and future perspectives. Expert Review of Gastroenterology & Hepatology 2015;9:1039-53. [DOI: 10.1586/17474124.2015.1049155] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
153 Uhanova J, Minuk G, Lopez Ficher F, Chandok N. Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients. Can J Gastroenterol Hepatol 2016;2016:6420408. [PMID: 27446857 DOI: 10.1155/2016/6420408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
154 St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2009;50:68-76. [PMID: 19444870 DOI: 10.1002/hep.22940] [Cited by in Crossref: 200] [Cited by in F6Publishing: 179] [Article Influence: 15.4] [Reference Citation Analysis]
155 Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer. 2009;9:271. [PMID: 19656391 DOI: 10.1186/1471-2407-9-271] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
156 Piemonte F, Petrini S, Gaeta LM, Tozzi G, Bertini E, Devito R, Boldrini R, Marcellini M, Ciacco E, Nobili V. Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2008;23:e457-64. [DOI: 10.1111/j.1440-1746.2007.05070.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
157 Amarapurkar A, Ghansar T. Fatty liver: Experience from western India. Annals of Hepatology 2007;6:37-40. [DOI: 10.1016/s1665-2681(19)31951-9] [Cited by in Crossref: 14] [Article Influence: 0.9] [Reference Citation Analysis]
158 Ji Y, Liang Y, Mak JC, Ip MS. Obstructive sleep apnea, intermittent hypoxia and non-alcoholic fatty liver disease. Sleep Medicine 2022. [DOI: 10.1016/j.sleep.2022.04.006] [Reference Citation Analysis]
159 Kiziltas S, Ata P, Colak Y, Mesçi B, Senates E, Enc F, Ulasoglu C, Tuncer I, Oguz A. TLR4 gene polymorphism in patients with nonalcoholic fatty liver disease in comparison to healthy controls. Metab Syndr Relat Disord. 2014;12:165-170. [PMID: 24443993 DOI: 10.1089/met.2013.0120] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
160 Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Königsrainer A, Maier KP, Bischoff SC, Bergheim I. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008;138:1452-5. [PMID: 18641190 DOI: 10.1093/jn/138.8.1452] [Cited by in Crossref: 289] [Cited by in F6Publishing: 270] [Article Influence: 20.6] [Reference Citation Analysis]
161 Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol 2014; 6(5): 274-283 [PMID: 24868321 DOI: 10.4254/wjh.v6.i5.274] [Cited by in Crossref: 160] [Cited by in F6Publishing: 146] [Article Influence: 20.0] [Reference Citation Analysis]
162 Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers 2015;1. [DOI: 10.1038/nrdp.2015.80] [Cited by in Crossref: 302] [Cited by in F6Publishing: 288] [Article Influence: 43.1] [Reference Citation Analysis]
163 Patel S, Lawlor DA, Ferreira DL, Hughes AD, Chaturvedi N, Callaway M, Day C, Sattar N, Fraser A. The association of nonalcoholic fatty liver disease with central and peripheral blood pressure in adolescence: findings from a cross-sectional study. J Hypertens 2015;33:546-52; discussion 553. [PMID: 25426570 DOI: 10.1097/HJH.0000000000000445] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
164 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
165 Koh ZJ, Salgaonkar HP, Lee WJJ, Kim GW, Tan CH, Cheng A, Lomanto D, So JBY, Dan YY, Shabbir A. Improvement in Non-alcoholic Fatty Liver Disease Score Correlates with Weight Loss in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy: a Two-Centre Study from an Asian Cohort. Obes Surg 2019;29:862-8. [PMID: 30515622 DOI: 10.1007/s11695-018-3581-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
166 Edgerton CA, McGillicuddy JW, DuBay D, Nadig SN. Utilization of the Iliac Artery as Inflow in the Morbidly Obese During Orthotopic Liver Transplantation: A Case Report. Transplant Proc 2017;49:1624-7. [PMID: 28838452 DOI: 10.1016/j.transproceed.2017.05.004] [Reference Citation Analysis]
167 Unalp-Arida A, Ruhl CE. Liver fibrosis scores predict liver disease mortality in the United States population. Hepatology. 2017;66:84-95. [PMID: 28195363 DOI: 10.1002/hep.29113] [Cited by in Crossref: 75] [Cited by in F6Publishing: 68] [Article Influence: 15.0] [Reference Citation Analysis]
168 Takino JI, Nagamine K, Hori T, Sakasai-Sakai A, Takeuchi M. Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol 2015; 7(23): 2459-2469 [PMID: 26483867 DOI: 10.4254/wjh.v7.i23.2459] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
169 Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obesity Reviews 2009;10:412-9. [DOI: 10.1111/j.1467-789x.2009.00594.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
170 Okada K, Yanagawa T, Warabi E, Yamastu K, Uwayama J, Takeda K, Utsunomiya H, Yoshida H, Shoda J, Ishii T. The α-glucosidase inhibitor acarbose prevents obesity and simple steatosis in sequestosome 1/A170/p62 deficient mice. Hepatology Research 2009;39:490-500. [DOI: 10.1111/j.1872-034x.2008.00478.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
171 Bugianesi E, Bellentani S, Bedogni G, Tiribelli C. Clinical update on non-alcoholic fatty liver disease and steatohepatitis. Annals of Hepatology 2008;7:157-60. [DOI: 10.1016/s1665-2681(19)31873-3] [Cited by in Crossref: 9] [Article Influence: 0.6] [Reference Citation Analysis]
172 Villela-Nogueira CA, Leite NC, Cardoso CR, Salles GF. NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms? Int J Mol Sci 2016;17:E460. [PMID: 27104526 DOI: 10.3390/ijms17040460] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
173 Wagnerberger S, Spruss A, Kanuri G, Volynets V, Stahl C, Bischoff SC, Bergheim I. Toll-like receptors 1-9 are elevated in livers with fructose-induced hepatic steatosis. Br J Nutr. 2012;107:1727-1738. [PMID: 22018861 DOI: 10.1017/s0007114511004983] [Cited by in Crossref: 84] [Cited by in F6Publishing: 48] [Article Influence: 7.6] [Reference Citation Analysis]
174 Goessling W, Massaro JM, Vasan RS, D'Agostino RB, Ellison RC, Fox CS. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 2008;135:1935-1944, 1944.e1. [PMID: 19010326 DOI: 10.1053/j.gastro.2008.09.018] [Cited by in Crossref: 213] [Cited by in F6Publishing: 198] [Article Influence: 15.2] [Reference Citation Analysis]
175 Gluud LL, Knop FK, Vilsbøll T. Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open. 2014;4:e005325. [PMID: 25526792 DOI: 10.1136/bmjopen-2014-005325] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
176 Khanal UP, Paudel B, Gurung G, Hu YS, Kuo CW. Correlational Study of Nonalcoholic Fatty Liver Disease Diagnosed by Ultrasonography with Lipid Profile and Body Mass Index in Adult Nepalese Population. J Med Ultrasound 2019;27:19-25. [PMID: 31031531 DOI: 10.4103/JMU.JMU_53_18] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
177 Bertoli S, Leone A, Vignati L, Spadafranca A, Bedogni G, Vanzulli A, Rodeschini E, Battezzati A. Metabolic correlates of subcutaneous and visceral abdominal fat measured by ultrasonography: a comparison with waist circumference. Nutr J 2016;15:2. [PMID: 26732788 DOI: 10.1186/s12937-015-0120-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
178 Lin IT, Lee MY, Wang CW, Wu DW, Chen SC. Gender Differences in the Relationships among Metabolic Syndrome and Various Obesity-Related Indices with Nonalcoholic Fatty Liver Disease in a Taiwanese Population. Int J Environ Res Public Health 2021;18:857. [PMID: 33498329 DOI: 10.3390/ijerph18030857] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
179 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
180 Mouralidarane A, Lin CI, Suleyman N, Soeda J, Oben JA. Practical management of the increasing burden of non-alcoholic fatty liver disease. Frontline Gastroenterol 2010;1:149-55. [PMID: 28839568 DOI: 10.1136/fg.2009.000935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
181 Moriyama K, Urata N, Masuda Y, Oda K, Okuno C, Yamada C, Takashimizu S, Kubo A, Kishimoto N, Nishizaki Y. Usefulness of Triglyceride to High-Density Lipoprotein Ratio and Alanine Aminotransferase for Predicting Insulin Resistance and Metabolic Syndrome in the Japanese Population. Metab Syndr Relat Disord 2021;19:225-32. [PMID: 33577395 DOI: 10.1089/met.2020.0121] [Reference Citation Analysis]
182 Patel S, Lawlor DA, Callaway M, Macdonald-Wallis C, Sattar N, Fraser A. Association of maternal diabetes/glycosuria and pre-pregnancy body mass index with offspring indicators of non-alcoholic fatty liver disease. BMC Pediatr 2016;16:47. [PMID: 27036545 DOI: 10.1186/s12887-016-0585-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
183 Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, Janssen HL. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol. 2012;57:1305-1311. [PMID: 22871499 DOI: 10.1016/j.jhep.2012.07.028] [Cited by in Crossref: 135] [Cited by in F6Publishing: 115] [Article Influence: 13.5] [Reference Citation Analysis]
184 Parsi A, Torkashvand M, Hajiani E, Rahimlou M, Sadeghi N. The effects of crocus sativus extract on serum lipid profile and liver enzymes in patients with non-alcoholic fatty liver disease: A randomized placebo-controlled study. Obesity Medicine 2020;17:100165. [DOI: 10.1016/j.obmed.2019.100165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
185 Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25:883-889. [PMID: 17402991 DOI: 10.1111/j.1365-2036.2007.03246.x] [Cited by in Crossref: 239] [Cited by in F6Publishing: 232] [Article Influence: 15.9] [Reference Citation Analysis]
186 Chen P, Li Y, Xiao L. Berberine ameliorates nonalcoholic fatty liver disease by decreasing the liver lipid content via reversing the abnormal expression of MTTP and LDLR. Exp Ther Med 2021;22:1109. [PMID: 34504563 DOI: 10.3892/etm.2021.10543] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Krakoff J, Clark JM, Crandall JP, Wilson C, Molitch ME, Brancati FL, Edelstein SL, Knowler WC; Diabetes Prevention Program Research Group. Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. Obesity (Silver Spring) 2010;18:1762-7. [PMID: 20186137 DOI: 10.1038/oby.2010.21] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
188 Varganova DL, Pavlov CS, Casazza G, Nikolova D, Gluud C; Cochrane Hepato-Biliary Group. Essential phospholipids for people with non-alcoholic fatty liver disease. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013301] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
189 Michopoulos S, Chouzouri VI, Manios ED, Grapsa E, Antoniou Z, Papadimitriou CA, Zakopoulos N, Dimopoulos AM. Untreated newly diagnosed essential hypertension is associated with nonalcoholic fatty liver disease in a population of a hypertensive center. Clin Exp Gastroenterol 2016;9:1-9. [PMID: 26834493 DOI: 10.2147/CEG.S92714] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
190 Jiang ZG, Robson SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res. 2013;27:1-13. [PMID: 23554788 DOI: 10.7555/jbr.27.20120077] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
191 Pires LB, Rocha R, Vargas D, Daltro C, Cotrim HP. Non-alcoholic fatty liver disease in patients infected with human immunodeficiency virus: a systematic review. Rev Assoc Med Bras (1992) 2020;66:81-6. [PMID: 32130386 DOI: 10.1590/1806-9282.66.1.81] [Reference Citation Analysis]
192 Pakravan H, Ahmadian M, Fani A, Aghaee D, Brumanad S, Pakzad B. The Effects of Melatonin in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial. Adv Biomed Res 2017;6:40. [PMID: 28503495 DOI: 10.4103/2277-9175.204593] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
193 Önnerhag K, Nilsson PM, Lindgren S. Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD. Scand J Gastroenterol. 2014;49:1111-1118. [PMID: 24990583 DOI: 10.3109/00365521.2014.934911] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
194 Zhang WY, Piao XX, Jin HY, Li CH, Jin AH, Han HM. Protective effect of boschniakia rossica ethanol extract on nonalcoholic fatty liver disease in rats and mechanisms involved. Shijie Huaren Xiaohua Zazhi 2012; 20(32): 3087-3094 [DOI: 10.11569/wcjd.v20.i32.3087] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
195 Al-Gayyar MM, Shams ME, Barakat EA. Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: impact of nonalcoholic fatty liver disease. Pharm Biol. 2012;50:297-303. [PMID: 22103753 DOI: 10.3109/13880209.2011.604088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
196 Caraceni P, Domenicali M, Giannone F, Bernardi M. The role of the endocannabinoid system in liver diseases. Best Pract Res Clin Endocrinol Metab. 2009;23:65-77. [PMID: 19285261 DOI: 10.1016/j.beem.2008.10.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
197 Lee YW, Yarrington CD. Obstetric Outcomes in Women with Nonalcoholic Fatty Liver Disease. Metabolic Syndrome and Related Disorders 2017;15:387-92. [DOI: 10.1089/met.2017.0058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
198 Alam S, Fahim SM, Chowdhury MAB, Hassan MZ, Azam G, Mustafa G, Ahsan M, Ahmad N. Prevalence and risk factors of non-alcoholic fatty liver disease in Bangladesh. JGH Open 2018;2:39-46. [PMID: 30483562 DOI: 10.1002/jgh3.12044] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
199 van der Poorten D, George J. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis. Clin Liver Dis. 2008;12:805-824, ix. [PMID: 18984468 DOI: 10.1016/j.cld.2008.07.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
200 Wang Y, Jiang ZZ, Chen M, Wu MJ, Guo HL, Sun LX, Wang H, Zhang S, Wang T, Zhang LY. Protective effect of total flavonoid C-glycosides from Abrus mollis extract on lipopolysaccharide-induced lipotoxicity in mice. Chin J Nat Med 2014;12:461-8. [PMID: 24969528 DOI: 10.1016/S1875-5364(14)60072-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
201 Armstrong MJ, Houlihan DD, Bentham L, Shaw JC, Cramb R, Olliff S, Gill PS, Neuberger JM, Lilford RJ, Newsome PN. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012;56:234-40. [PMID: 21703178 DOI: 10.1016/j.jhep.2011.03.020] [Cited by in Crossref: 170] [Cited by in F6Publishing: 149] [Article Influence: 15.5] [Reference Citation Analysis]
202 Vassilatou E, Lafoyianni S, Vryonidou A, Ioannidis D, Kosma L, Katsoulis K, Papavassiliou E, Tzavara I. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod. 2010;25:212-220. [PMID: 19887498 DOI: 10.1093/humrep/dep380] [Cited by in Crossref: 81] [Cited by in F6Publishing: 79] [Article Influence: 6.2] [Reference Citation Analysis]
203 Franzini M, Fornaciari I, Vico T, Moncini M, Cellesi V, Meini M, Emdin M, Paolicchi A. High-sensitivity γ-glutamyltransferase fraction pattern in alcohol addicts and abstainers. Drug Alcohol Depend. 2013;127:239-242. [PMID: 22749559 DOI: 10.1016/j.drugalcdep.2012.06.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
204 He L, Yuan FH, Chen T, Huang Q, Wang Y, Liu ZG. ER stress-mediated cell damage contributes to the release of EDA+ fibronectin from hepatocytes in nonalcoholic fatty liver disease. J Huazhong Univ Sci Technolog Med Sci 2017;37:217-25. [PMID: 28397039 DOI: 10.1007/s11596-017-1718-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
205 Janičko M, Veselíny E, Orenčák R, Husťak R, Fedačko J, Dražilová S, Madarasová-gecková A, Mareková M, Pella D, Kristián P, Rác M, Jarčuška P. Redefining the alanine aminotransferase upper limit of normal improves the prediction of metabolic syndrome risk. European Journal of Gastroenterology & Hepatology 2015;27:405-11. [DOI: 10.1097/meg.0000000000000297] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
206 Ferro Y, Carè I, Mazza E, Provenzano F, Colica C, Torti C, Romeo S, Pujia A, Montalcini T. Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals. Clin Mol Hepatol 2017;23:249-59. [PMID: 28750503 DOI: 10.3350/cmh.2017.0019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
207 Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med. 2015;5:7-13. [PMID: 26528424 DOI: 10.15280/jlm.2015.5.1.7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
208 Ting Y, Chiou Y, Jiang Y, Pan M, Lin Z, Huang Q. Safety evaluation of tangeretin and the effect of using emulsion-based delivery system: Oral acute and 28-day sub-acute toxicity study using mice. Food Research International 2015;74:140-50. [DOI: 10.1016/j.foodres.2015.04.031] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
209 Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, Mcclain CJ, Bischoff SC. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. Journal of Hepatology 2008;48:983-92. [DOI: 10.1016/j.jhep.2008.01.035] [Cited by in Crossref: 340] [Cited by in F6Publishing: 322] [Article Influence: 24.3] [Reference Citation Analysis]
210 Chen C, Huang M, Yang J, Nien C, Yang C, Yeh Y, Yueh S. Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease in an Adult Population of Taiwan: Metabolic Significance of Nonalcoholic Fatty Liver Disease in Nonobese Adults: . Journal of Clinical Gastroenterology 2006;40:745-52. [DOI: 10.1097/00004836-200609000-00016] [Cited by in Crossref: 200] [Cited by in F6Publishing: 165] [Article Influence: 12.5] [Reference Citation Analysis]
211 Mbata O, Abo El-Magd NF, El-Remessy AB. Obesity, metabolic syndrome and diabetic retinopathy: Beyond hyperglycemia. World J Diabetes 2017; 8(7): 317-329 [PMID: 28751954 DOI: 10.4239/wjd.v8.i7.317] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
212 Mokhtari Z, Gibson DL, Hekmatdoost A. Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. Adv Nutr 2017;8:240-52. [PMID: 28298269 DOI: 10.3945/an.116.013151] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 14.0] [Reference Citation Analysis]
213 Birjandi M, Ayatollahi SM, Pourahmad S, Safarpour AR. Prediction and Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) and Identification of Its Associated Factors Using the Classification Tree Method. Iran Red Crescent Med J 2016;18:e32858. [PMID: 28191344 DOI: 10.5812/ircmj.32858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
214 Yang W, Xu H, Yu X, Wang Y. Association between retinal artery lesions and nonalcoholic fatty liver disease. Hepatol Int 2015;9:278-82. [PMID: 25788195 DOI: 10.1007/s12072-015-9607-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
215 Song L, Zhao XG, Ouyang PL, Guan Q, Yang L, Peng F, Du H, Yin F, Yan W, Yu WJ, Yan H. Combined effect of n -3 fatty acids and phytosterol esters on alleviating hepatic steatosis in non-alcoholic fatty liver disease subjects: a double-blind placebo-controlled clinical trial. Br J Nutr 2020;123:1148-58. [DOI: 10.1017/s0007114520000495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
216 Lu H, Zeng L, Liang B, Shu X, Xie D. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res. 2009;40:571-575. [PMID: 20082871 DOI: 10.1016/j.arcmed.2009.07.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
217 Constantinescu C, SĂndulescu L, SĂftoiu A. The Role of Elastography in Non-Alcoholic Fatty Liver Disease. Curr Health Sci J 2020;46:255-69. [PMID: 33304627 DOI: 10.12865/CHSJ.46.03.07] [Reference Citation Analysis]
218 Sun W, Zhang D, Sun J, Xu B, Sun K, Wang T, Ren C, Li J, Chen Y, Xu M, Bi Y, Xu Q, Wang W, Gu Y, Ning G. Association between non-alcoholic fatty liver disease and autonomic dysfunction in a Chinese population. QJM 2015;108:617-24. [PMID: 25614616 DOI: 10.1093/qjmed/hcv006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
219 Rosmorduc O. Relationship between hepatocellular carcinoma, metabolic syndrome and non-alcoholic fatty liver disease: which clinical arguments? Ann Endocrinol (Paris). 2013;74:115-120. [PMID: 23597944 DOI: 10.1016/j.ando.2013.02.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
220 Hassanian M, Al-Mulhim A, Al-Sabhan A, Al-Amro S, Bamehriz F, Abdo A, Al Khalidi H, Aldoheyan TA. The effect of bariatric surgeries on nonalcoholic fatty liver disease. Saudi J Gastroenterol 2014;20:270-8. [PMID: 25253361 DOI: 10.4103/1319-3767.141684] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
221 Huh JH, Lee KJ, Lim JS, Lee MY, Park HJ, Kim MY, Kim JW, Chung CH, Shin JY, Kim HS, Kwon SO, Baik SK. High Dietary Sodium Intake Assessed by Estimated 24-h Urinary Sodium Excretion Is Associated with NAFLD and Hepatic Fibrosis. PLoS One 2015;10:e0143222. [PMID: 26571018 DOI: 10.1371/journal.pone.0143222] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
222 Gorman S, Black LJ, Feelisch M, Hart PH, Weller R. Can skin exposure to sunlight prevent liver inflammation? Nutrients 2015;7:3219-39. [PMID: 25951129 DOI: 10.3390/nu7053219] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
223 Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes. 2012;3:279-288. [PMID: 22572877 DOI: 10.4161/gmic.19625] [Cited by in Crossref: 431] [Cited by in F6Publishing: 384] [Article Influence: 43.1] [Reference Citation Analysis]
224 Kučera O, Al-Dury S, Lotková H, Roušar T, Rychtrmoc D, Červinková Z. Steatotic rat hepatocytes in primary culture are more susceptible to the acute toxic effect of acetaminophen. Physiol Res 2012;61:S93-101. [PMID: 23130907 DOI: 10.33549/physiolres.932395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
225 Bellarosa C, Bedogni G, Bianco A, Cicolini S, Caroli D, Tiribelli C, Sartorio A. Association of Serum Bilirubin Level with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study of 1672 Obese Children. J Clin Med 2021;10:2812. [PMID: 34202304 DOI: 10.3390/jcm10132812] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Vasconcelos ACCG, Vasconcelos DFP, Pereira da Silva FR, de Carvalho França LF, Alves EHP, Lenardo DD, dos Santos Pessoa L, Novaes PD, Luiz dos Reis Barbosa A, Mani A, Mariano FS, Medeiros JR, de Oliveira AP. Periodontitis causes abnormalities in the liver of rats. J Periodontol 2019;90:295-305. [DOI: 10.1002/jper.18-0226] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
227 Bedogni G, Tamini S, Caroli D, Cicolini S, Domenicali M, Sartorio A. Development and Internal Validation of Fatty Liver Prediction Models in Obese Children and Adolescents. J Clin Med 2021;10:1470. [PMID: 33918271 DOI: 10.3390/jcm10071470] [Reference Citation Analysis]
228 Thakkar N, Slizgi JR, Brouwer KLR. Effect of Liver Disease on Hepatic Transporter Expression and Function. J Pharm Sci 2017;106:2282-94. [PMID: 28465155 DOI: 10.1016/j.xphs.2017.04.053] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
229 Li M, Xu Y, Xu M, Ma L, Wang T, Liu Y, Dai M, Chen Y, Lu J, Liu J. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab. 2012;97:2033-2038. [PMID: 22466338 DOI: 10.1210/jc.2011-3010] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 7.6] [Reference Citation Analysis]
230 Schattenberg JM, Galle PR, Schuchmann M. Apoptosis in liver disease. Liver Int 2006;26:904-11. [DOI: 10.1111/j.1478-3231.2006.01324.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 5.1] [Reference Citation Analysis]
231 Hsu CY, Lee YH, Liu PH, Hsia CY, Huang YH, Lin HC, Chiou YY, Lee FY, Huo TI. Decrypting cryptogenic hepatocellular carcinoma: clinical manifestations, prognostic factors and long-term survival by propensity score model. PLoS One 2014;9:e89373. [PMID: 24586728 DOI: 10.1371/journal.pone.0089373] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
232 Šeda O, Cahová M, Míková I, Šedová L, Daňková H, Heczková M, Brátová M, Ďásková N, Erhartová D, Čapek V, Chylíková B, Trunečka P. Hepatic Gene Expression Profiles Differentiate Steatotic and Non-steatotic Grafts in Liver Transplant Recipients. Front Endocrinol (Lausanne) 2019;10:270. [PMID: 31114547 DOI: 10.3389/fendo.2019.00270] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
233 Talavera-Urquijo E, Beisani M, Balibrea JM, Alverdy JC. Is bariatric surgery resolving NAFLD via microbiota-mediated bile acid ratio reversal? A comprehensive review. Surg Obes Relat Dis 2020;16:1361-9. [PMID: 32336663 DOI: 10.1016/j.soard.2020.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
234 Mouralidarane A, Oben JA, Soeda J. Pathophysiology and clinical management of non-alcoholic fatty liver disease. Medicine 2011;39:592-6. [DOI: 10.1016/j.mpmed.2011.07.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
235 Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Digestive and Liver Disease 2009;41:615-25. [DOI: 10.1016/j.dld.2009.01.004] [Cited by in Crossref: 174] [Cited by in F6Publishing: 174] [Article Influence: 13.4] [Reference Citation Analysis]
236 Cholongitas E, Pavlopoulou I, Papatheodoridi M, Markakis GE, Bouras E, Haidich AB, Papatheodoridis G. Epidemiology of nonalcoholic fatty liver disease in Europe: a systematic review and meta-analysis. Ann Gastroenterol 2021;34:404-14. [PMID: 33948067 DOI: 10.20524/aog.2021.0604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
237 Liao CC, Ou TT, Huang HP, Wang CJ. The inhibition of oleic acid induced hepatic lipogenesis and the promotion of lipolysis by caffeic acid via up-regulation of AMP-activated kinase. J Sci Food Agric 2014;94:1154-62. [PMID: 24027117 DOI: 10.1002/jsfa.6386] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
238 Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, Fallahzadeh MK, Maharlouei N, Babaeinejad M, Mehravar S. Non alcoholic fatty liver disease in southern Iran: a population based study. Hepat Mon. 2013;13:e9248. [PMID: 23922564 DOI: 10.5812/hepatmon.9248] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
239 Jenks SJ, Conway BR, Hor TJ, Williamson RM, Mclachlan S, Robertson C, Morling JR, Strachan MWJ, Price JF. Hepatic steatosis and non-alcoholic fatty liver disease are not associated with decline in renal function in people with Type 2 diabetes. Diabet Med 2014;31:1039-46. [DOI: 10.1111/dme.12456] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
240 Shriki JE, Seyal AR, Dighe MK, Yeh MM, Jalikis FG, Andeen NK, Lall C, Bhargava P. CT of Atypical and Uncommon Presentations of Hepatocellular Carcinoma. AJR Am J Roentgenol 2015;205:W411-23. [PMID: 26397348 DOI: 10.2214/AJR.14.14000] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
241 Milic S, Štimac D. Nonalcoholic Fatty Liver Disease/Steatohepatitis: Epidemiology, Pathogenesis, Clinical Presentation and Treatment. Dig Dis 2012;30:158-62. [DOI: 10.1159/000336669] [Cited by in Crossref: 124] [Cited by in F6Publishing: 122] [Article Influence: 12.4] [Reference Citation Analysis]
242 Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009;116:539-564. [PMID: 19243311 DOI: 10.1042/cs20080253] [Cited by in Crossref: 160] [Cited by in F6Publishing: 74] [Article Influence: 12.3] [Reference Citation Analysis]
243 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
244 Fan J, Li F, Cai X, Peng Y, Ao Q, Gao Y. The importance of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers: Increased prevalence of fatty liver. Journal of Gastroenterology and Hepatology 2007;22:663-8. [DOI: 10.1111/j.1440-1746.2007.04892.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
245 Zhang S, Tun HM, Zhang D, Chau H, Huang F, Kwok H, Wong DK, Mak L, Yuen M, Seto W. Alleviation of Hepatic Steatosis: Dithizone-Related Gut Microbiome Restoration During Paneth Cell Dysfunction. Front Microbiol 2022;13:813783. [DOI: 10.3389/fmicb.2022.813783] [Reference Citation Analysis]
246 Leikin-Frenkel A, Goldiner I, Leikin-Gobbi D, Rosenberg R, Bonen H, Litvak A, Bernheim J, Konikoff FM, Gilat T. Treatment of preestablished diet-induced fatty liver by oral fatty acid-bile acid conjugates in rodents. Eur J Gastroenterol Hepatol 2008;20:1205-13. [PMID: 18989145 DOI: 10.1097/MEG.0b013e3282fc9743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.2] [Reference Citation Analysis]
247 Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol 2017; 8(2): 11-26 [PMID: 28573064 DOI: 10.4291/wjgp.v8.i2.11] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 9.4] [Reference Citation Analysis]
248 Pan JJ, Qu HQ, Rentfro A, McCormick JB, Fisher-Hoch SP, Fallon MB. Prevalence of metabolic syndrome and risks of abnormal serum alanine aminotransferase in Hispanics: a population-based study. PLoS One. 2011;6:e21515. [PMID: 21720553 DOI: 10.1371/journal.pone.0021515] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
249 Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144-1165. [PMID: 24716201 DOI: 10.1002/hep.26972] [Cited by in Crossref: 429] [Cited by in F6Publishing: 322] [Article Influence: 53.6] [Reference Citation Analysis]
250 Gkolfakis P, Dimitriadis G, Triantafyllou K. Gut microbiota and non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2015;14:572-81. [PMID: 26663004 DOI: 10.1016/s1499-3872(15)60026-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
251 Horwath JA, Hurr C, Butler SD, Guruju M, Cassell MD, Mark AL, Davisson RL, Young CN. Obesity-induced hepatic steatosis is mediated by endoplasmic reticulum stress in the subfornical organ of the brain. JCI Insight 2017;2:90170. [PMID: 28422749 DOI: 10.1172/jci.insight.90170] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
252 Schwenger KJ, Clermont-Dejean N, Allard JP. The role of the gut microbiome in chronic liver disease: the clinical evidence revised. JHEP Rep 2019;1:214-26. [PMID: 32039372 DOI: 10.1016/j.jhepr.2019.04.004] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 9.7] [Reference Citation Analysis]
253 Ding LY, Liang LZ, Zhao YX, Yang YN, Liu F, Ding QR, Luo LJ. Porphyromonas gingivalis-derived lipopolysaccharide causes excessive hepatic lipid accumulation via activating NF-κB and JNK signaling pathways. Oral Dis 2019;25:1789-97. [PMID: 31283861 DOI: 10.1111/odi.13153] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
254 Bae JC, Han JM, Cho JH, Kwon H, Park SE, Park CY, Lee WY, Oh KW, Kwon S, Park SW, Rhee EJ. The persistence of fatty liver has a differential impact on the development of diabetes: The Kangbuk Samsung Health Study. Diabetes Res Clin Pract 2018;135:1-6. [PMID: 29111276 DOI: 10.1016/j.diabres.2017.10.019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
255 Wáng YXJ, Wang X, Wu P, Wang Y, Chen W, Chen H, Li J. Topics on quantitative liver magnetic resonance imaging. Quant Imaging Med Surg 2019;9:1840-90. [PMID: 31867237 DOI: 10.21037/qims.2019.09.18] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
256 Pimentel SK, Strobel R, Gonçalves CG, Sakamoto DG, Ivano FH, Coelho JCU. Evaluation of the nonalcoholic fat liver disease fibrosis score for patients undergoing bariatric surgery. Arq Gastroenterol 2010;47:170-3. [DOI: 10.1590/s0004-28032010000200010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
257 Zhang J, Liu Z, Zhang X, Zhang L, Jin X. Association between urine retinol-binding protein levels and nonalcoholic fatty liver disease: A cross-sectional study in Chinese population. J Clin Lab Anal 2018;32:e22359. [PMID: 29194759 DOI: 10.1002/jcla.22359] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
258 Mu Y, Ogawa T, Kawada N. Reversibility of fibrosis, inflammation, and endoplasmic reticulum stress in the liver of rats fed a methionine–choline-deficient diet. Lab Invest 2010;90:245-56. [DOI: 10.1038/labinvest.2009.123] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
259 Ursini F, Russo E, Mauro D, Abenavoli L, Ammerata G, Serrao A, Grembiale RD, De Sarro G, Olivieri I, D'angelo S. Complement C3 and fatty liver disease in Rheumatoid arthritis patients: a cross-sectional study. Eur J Clin Invest 2017;47:728-35. [PMID: 28796299 DOI: 10.1111/eci.12798] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
260 Wu SJ, Zhu GQ, Ye BZ, Kong FQ, Zheng ZX, Zou H, Shi KQ, Lin L, Braddock M, Huang WJ, Chen YP, Zheng MH. Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. Medicine (Baltimore). 2015;94:e802. [PMID: 25929934 DOI: 10.1097/md.0000000000000802] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
261 Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M. Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. Biomed Rep 2014;2:633-6. [PMID: 25054002 DOI: 10.3892/br.2014.309] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
262 Li YF, Tang XL, Ling WH. 1,25-dihydroxyvitamin D3 inhibits fibrosis in mice with NAFLD induced by a methionine-choline-deficient diet. Shijie Huaren Xiaohua Zazhi 2012; 20(33): 3191-3196 [DOI: 10.11569/wcjd.v20.i33.3191] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
263 Beltzer C, Quante M, Rheinberger M, Baba HA, Saner F, Fend F, Biet T, Königsrainer A, Nadalin S. [Percutaneous liver biopsy before organ removal-Impact on organ allocation and costs in liver transplantation]. Chirurg 2021;92:49-61. [PMID: 32430545 DOI: 10.1007/s00104-020-01192-w] [Reference Citation Analysis]
264 Ferro D, Baratta F, Pastori D, Cocomello N, Colantoni A, Angelico F, Del Ben M. New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress. Nutrients 2020;12:E2762. [PMID: 32927776 DOI: 10.3390/nu12092762] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
265 Ito Y, Kenmochi T, Shibutani S, Egawa T, Hayashi S, Nagashima A, Kitagawa Y. Evaluation of Predictive Factors in Patients with Nonalcoholic Fatty Liver Disease after Pancreaticoduodenectomy. The American Surgeon 2014;80:500-4. [DOI: 10.1177/000313481408000523] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
266 Geisler CE, Renquist BJ. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones. J Endocrinol. 2017;234:R1-R21. [PMID: 28428362 DOI: 10.1530/joe-16-0513] [Cited by in Crossref: 58] [Cited by in F6Publishing: 31] [Article Influence: 11.6] [Reference Citation Analysis]
267 Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017-1025. [PMID: 26997539 DOI: 10.1016/j.metabol.2016.01.012] [Cited by in Crossref: 186] [Cited by in F6Publishing: 171] [Article Influence: 31.0] [Reference Citation Analysis]
268 Sturzeneker MC, Ioshii SO, Villela Baroncini LA, Précoma DB. Olmesartan severely weakened the development of NASH in an animal model of hypercholesterolemia. Atherosclerosis 2011;216:97-102. [PMID: 21338989 DOI: 10.1016/j.atherosclerosis.2011.01.047] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
269 Ertle J, Dechêne A, Sowa J, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn W, Canbay A. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis: Absence of Cirrhosis in NASH-Derived HCC. Int J Cancer 2011;128:2436-43. [DOI: 10.1002/ijc.25797] [Cited by in Crossref: 290] [Cited by in F6Publishing: 281] [Article Influence: 26.4] [Reference Citation Analysis]
270 Naik A, Belič A, Zanger UM, Rozman D. Molecular Interactions between NAFLD and Xenobiotic Metabolism. Front Genet 2013;4:2. [PMID: 23346097 DOI: 10.3389/fgene.2013.00002] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
271 Komolafe O, Buzzetti E, Linden A, Best LM, Madden AM, Roberts D, Chase TJ, Fritche D, Freeman SC, Cooper NJ, Sutton AJ, Milne EJ, Wright K, Pavlov CS, Davidson BR, Tsochatzis E, Gurusamy KS. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. Cochrane Database Syst Rev 2021;7:CD013157. [PMID: 34280304 DOI: 10.1002/14651858.CD013157.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
272 Domenici FA, Brochado MJ, Martinelli Ade L, Zucoloto S, da Cunha SF, Vannucchi H. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients. Gene. 2013;529:326-331. [PMID: 23891824 DOI: 10.1016/j.gene.2013.06.091] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
273 Antonucci L, Porcu C, Iannucci G, Balsano C, Barbaro B. Non-Alcoholic Fatty Liver Disease and Nutritional Implications: Special Focus on Copper. Nutrients 2017;9:E1137. [PMID: 29057834 DOI: 10.3390/nu9101137] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
274 Ko JS. Nonalcoholic Fatty Liver Disease. Korean J Gastroenterol 2010;56:6. [DOI: 10.4166/kjg.2010.56.1.6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
275 Zhao HY, Li J, Xu M, Wang TG, Sun WW, Chen Y, Bi YF, Wang WQ, Ning G. Elevated whole blood viscosity is associated with insulin resistance and non-alcoholic fatty liver. Clin Endocrinol (Oxf). 2015;83:806-811. [PMID: 25823525 DOI: 10.1111/cen.12776] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
276 Lee YH, Bang H, Park YM, Bae JC, Lee BW, Kang ES, Cha BS, Lee HC, Balkau B, Lee WY, Kim DJ. Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores. PLoS One 2014;9:e107584. [PMID: 25216184 DOI: 10.1371/journal.pone.0107584] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
277 Wang LR, Liu WY, Wu SJ, Zhu GQ, Lin YQ, Braddock M, Zhang DC, Zheng MH. Parabolic relationship between sex-specific serum high sensitive C reactive protein and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. Oncotarget 2016;7:14241-50. [PMID: 26894972 DOI: 10.18632/oncotarget.7401] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
278 Cacciola I, Scoglio R, Alibrandi A, Squadrito G, Raimondo G; SIMG-Messina Hypertransaminasemia Study Group. Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care. Intern Emerg Med 2017;12:181-6. [DOI: 10.1007/s11739-016-1535-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
279 Mato JM, Lu SC. Where are we in the search for noninvasive nonalcoholic steatohepatitis biomarkers? Hepatology. 2011;54:1115-1117. [PMID: 21898494 DOI: 10.1002/hep.24642] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
280 Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 2020;158:1851-64. [PMID: 32061595 DOI: 10.1053/j.gastro.2020.01.052] [Cited by in Crossref: 120] [Cited by in F6Publishing: 136] [Article Influence: 60.0] [Reference Citation Analysis]
281 García-Ruiz C, Fernández-Checa JC. Mitochondrial Oxidative Stress and Antioxidants Balance in Fatty Liver Disease. Hepatol Commun 2018;2:1425-39. [PMID: 30556032 DOI: 10.1002/hep4.1271] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 14.0] [Reference Citation Analysis]
282 Addeo P, Naegel B, Terrone A, Faitot F, Schaaf C, Bachellier P, Noblet V. Analysis of factors associated with discrepancies between predicted and observed liver weight in liver transplantation. Liver Int 2021;41:1379-88. [PMID: 33555130 DOI: 10.1111/liv.14819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
283 Lee SK, Yoon DW, Lee SW, Kim JY, Kim JK, Shin C. Non-alcoholic fatty liver disease among sasang constitutional types: a population-based study in Korea. BMC Complement Altern Med 2015;15:399. [PMID: 26547840 DOI: 10.1186/s12906-015-0925-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
284 Verbeek J, Spincemaille P, Vanhorebeek I, Van den Berghe G, Vander Elst I, Windmolders P, van Pelt J, van der Merwe S, Bedossa P, Nevens F, Cammue B, Thevissen K, Cassiman D. Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. Lipids Health Dis. 2017;16:46. [PMID: 28231800 DOI: 10.1186/s12944-017-0432-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
285 Omolekulo TE, Michael OS, Olatunji LA. Dipeptidyl peptidase-4 inhibition protects the liver of insulin-resistant female rats against triglyceride accumulation by suppressing uric acid. Biomed Pharmacother 2019;110:869-77. [PMID: 30557836 DOI: 10.1016/j.biopha.2018.12.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
286 Bedogni G, Kahn HS, Bellentani S, Tiribelli C. A simple index of lipid overaccumulation is a good marker of liver steatosis. BMC Gastroenterol. 2010;10:98. [PMID: 20738844 DOI: 10.1186/1471-230x-10-98] [Cited by in Crossref: 123] [Cited by in F6Publishing: 57] [Article Influence: 10.3] [Reference Citation Analysis]
287 Im AR, Kim YH, Lee HW, Song KH. Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model. J Med Food 2016;19:495-503. [PMID: 27152979 DOI: 10.1089/jmf.2015.3623] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
288 Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600-606. [PMID: 16899321 DOI: 10.1016/j.jhep.2006.06.013] [Cited by in Crossref: 340] [Cited by in F6Publishing: 299] [Article Influence: 21.3] [Reference Citation Analysis]
289 Masarone M, Rosato V, Dallio M, Gravina AG, Aglitti A, Loguercio C, Federico A, Persico M. Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev 2018;2018:9547613. [PMID: 29991976 DOI: 10.1155/2018/9547613] [Cited by in Crossref: 205] [Cited by in F6Publishing: 209] [Article Influence: 51.3] [Reference Citation Analysis]
290 Loomba R, Hwang SJ, O'Donnell CJ, Ellison RC, Vasan RS, D'Agostino RB Sr, Liang TJ, Fox CS. Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study. Gastroenterology 2008;134:953-9. [PMID: 18395076 DOI: 10.1053/j.gastro.2008.01.037] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
291 Almobarak AO, Barakat S, Suliman EA, Elmadhoun WM, Mohamed NA, Abobaker IO, Noor SK, Bushara SO, Ahmed MH. Prevalence of and predictive factors for nonalcoholic fatty liver disease in Sudanese individuals with type 2 diabetes: Is metabolic syndrome the culprit? Arab J Gastroenterol 2015;16:54-8. [PMID: 26174761 DOI: 10.1016/j.ajg.2015.06.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
292 Caserta CA, Pendino GM, Amante A, Vacalebre C, Fiorillo MT, Surace P, Messineo A, Surace M, Alicante S, Cotichini R, Zuin M, Rosmini F, Mele A, Marcucci F. Cardiovascular Risk Factors, Nonalcoholic Fatty Liver Disease, and Carotid Artery Intima-Media Thickness in an Adolescent Population in Southern Italy. American Journal of Epidemiology 2010;171:1195-202. [DOI: 10.1093/aje/kwq073] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
293 Dinani A, Sanyal A. Nonalcoholic fatty liver disease: implications for cardiovascular risk. Cardiovasc Endocrinol 2017;6:62-72. [PMID: 31646122 DOI: 10.1097/XCE.0000000000000126] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
294 Ju DY, Choe YG, Cho YK, Shin DS, Yoo SH, Yim SH, Lee JY, Park JH, Kim HJ, Park DI. The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults. Clin Mol Hepatol. 2013;19:140-147. [PMID: 23837138 DOI: 10.3350/cmh.2013.19.2.140] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
295 Sonnweber T, Pizzini A, Nairz M, Weiss G, Tancevski I. Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases. Int J Mol Sci 2018;19:E3285. [PMID: 30360467 DOI: 10.3390/ijms19113285] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 19.5] [Reference Citation Analysis]
296 Hong M, Li S, Tan HY, Wang N, Tsao SW, Feng Y. Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects. Int J Mol Sci 2015;16:28705-45. [PMID: 26633388 DOI: 10.3390/ijms161226126] [Cited by in Crossref: 81] [Cited by in F6Publishing: 69] [Article Influence: 11.6] [Reference Citation Analysis]
297 Fujisawa K, Takami T, Nagatomo T, Fukui Y, Hoshida H, Saeki I, Matsumoto T, Hidaka I, Yamamoto N, Sakaida I. Usefulness of adult medaka fish as a model for the evaluation of alcoholic fatty liver. Alcohol 2019;77:147-54. [PMID: 30660600 DOI: 10.1016/j.alcohol.2019.01.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
298 Kamboj P, Sarkar S, Gupta SK, Bisht N, Kumari D, Alam MJ, Barge S, Kashyap B, Deka B, Bharadwaj S, Rahman S, Dutta PP, Borah JC, Talukdar NC, Banerjee SK, Kumar Y. Methanolic Extract of Lysimachia Candida Lindl. Prevents High-Fat High-Fructose-Induced Fatty Liver in Rats: Understanding the Molecular Mechanism Through Untargeted Metabolomics Study. Front Pharmacol 2021;12:653872. [PMID: 33935766 DOI: 10.3389/fphar.2021.653872] [Reference Citation Analysis]
299 Jiang S, Yan C, Fang QC, Shao ML, Zhang YL, Liu Y, Deng YP, Shan B, Liu JQ, Li HT. Fibroblast growth factor 21 is regulated by the IRE1α-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J Biol Chem. 2014;289:29751-29765. [PMID: 25170079 DOI: 10.1074/jbc.M114.565960] [Cited by in Crossref: 114] [Cited by in F6Publishing: 75] [Article Influence: 14.3] [Reference Citation Analysis]
300 Caruso MG, Veronese N, Notarnicola M, Cisternino AM, Reddavide R, Inguaggiato R, Guerra V, Donghia R, Logroscino A, Rotolo O, Chiloiro M, Leandro G, De Leonardis G, Tutino V, Misciagna G, Bonfiglio C, Guerra R, Osella A. Fatty liver and mortality: a cohort population study in South Italy. BMJ Open 2019;9:e027379. [PMID: 31227533 DOI: 10.1136/bmjopen-2018-027379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
301 Parajuli S, Foley D, Djamali A, Mandelbrot D. Renal Function and Transplantation in Liver Disease. Transplantation 2015;99:1756-64. [PMID: 26308413 DOI: 10.1097/TP.0000000000000820] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
302 Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radical Biology and Medicine 2012;52:59-69. [DOI: 10.1016/j.freeradbiomed.2011.10.003] [Cited by in Crossref: 539] [Cited by in F6Publishing: 519] [Article Influence: 53.9] [Reference Citation Analysis]
303 Lorvand Amiri H, Agah S, Tolouei Azar J, Hosseini S, Shidfar F, Mousavi SN. Effect of daily calcitriol supplementation with and without calcium on disease regression in non-alcoholic fatty liver patients following an energy-restricted diet: Randomized, controlled, double-blind trial. Clin Nutr. 2017;36:1490-1497. [PMID: 27720403 DOI: 10.1016/j.clnu.2016.09.020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
304 Musso G, Gambino R, Cassader M. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev. 2010;11:430-445. [PMID: 19845871 DOI: 10.1111/j.1467-789x.2009.00657.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
305 Hagström H, Kechagias S, Ekstedt M. Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease. J Intern Med 2021. [PMID: 34118091 DOI: 10.1111/joim.13343] [Reference Citation Analysis]
306 Daudén E, Castañeda S, Suárez C, García-campayo J, Blasco A, Aguilar M, Ferrándiz C, Puig L, Sánchez-carazo J. Integrated Approach to Comorbidity in Patients With Psoriasis. Actas Dermo-Sifiliográficas (English Edition) 2012;103:1-64. [DOI: 10.1016/s1578-2190(12)70829-6] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
307 Lee JI, Kim MC, Moon BS, Song YS, Han EN, Lee HS, Son Y, Kim J, Han EJ, Park HJ, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. The Relationship between 10-Year Cardiovascular Risk Calculated Using the Pooled Cohort Equation and the Severity of Non-Alcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2016;31:86-92. [PMID: 26754585 DOI: 10.3803/EnM.2016.31.1.86] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
308 Attenberger UI, Morelli J, Budjan J, Henzler T, Sourbron S, Bock M, Riffel P, Hernando D, Ong MM, Schoenberg SO. Fifty Years of Technological Innovation: Potential and Limitations of Current Technologies in Abdominal Magnetic Resonance Imaging and Computed Tomography. Invest Radiol. 2015;50:584-593. [PMID: 26039773 DOI: 10.1097/rli.0000000000000173] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 2.8] [Reference Citation Analysis]
309 Kalantari H, Moradi F, Hassanzade A. Association between sonographic diagnosis of fatty liver with histopathologic abnormalities and liver biopsy findings in middle age patient with non-alcoholic fatty liver disease. Adv Biomed Res 2016;5:122. [PMID: 27563632 DOI: 10.4103/2277-9175.186985] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
310 Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59:859-871. [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044] [Cited by in Crossref: 223] [Cited by in F6Publishing: 203] [Article Influence: 24.8] [Reference Citation Analysis]
311 Wang X, Liu Z, Wang K, Wang Z, Sun X, Zhong L, Deng G, Song G, Sun B, Peng Z, Liu W. Additive Effects of the Risk Alleles of PNPLA3 and TM6SF2 on Non-alcoholic Fatty Liver Disease (NAFLD) in a Chinese Population. Front Genet 2016;7:140. [PMID: 27532011 DOI: 10.3389/fgene.2016.00140] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
312 Jung TW, Kang C, Goh J, Chae SI, Kim H, Lee TJ, Abd El‐aty A, Jeong JH. WISP1 promotes non‐alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling. J Cell Physiol 2018;233:6077-87. [DOI: 10.1002/jcp.26449] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
313 Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age? World J Gastroenterol 2014; 20(27): 9072-9089 [PMID: 25083080 DOI: 10.3748/wjg.v20.i27.9072] [Cited by in F6Publishing: 47] [Reference Citation Analysis]
314 de Lédinghen V, Ratziu V, Causse X, Le Bail B, Capron D, Renou C, Pilette C, Oules V, Gelsi E, Oberti F. Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. J Hepatol. 2006;45:592-599. [PMID: 16837098 DOI: 10.1016/j.jhep.2006.05.008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
315 Huh JH, Ahn SV, Koh SB, Choi E, Kim JY, Sung KC, Kim EJ, Park JB. A Prospective Study of Fatty Liver Index and Incident Hypertension: The KoGES-ARIRANG Study. PLoS One 2015;10:e0143560. [PMID: 26618774 DOI: 10.1371/journal.pone.0143560] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
316 Birjandi M, Ayatollahi SM, Pourahmad S. The Reliability of Classification of Terminal Nodes in GUIDE Decision Tree to Predict the Nonalcoholic Fatty Liver Disease. Comput Math Methods Med 2016;2016:3874086. [PMID: 28053651 DOI: 10.1155/2016/3874086] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
317 Bedogni G, Miglioli L, Masutti F, Castiglione A, Crocè LS, Tiribelli C, Bellentani S. Incidence and natural course of fatty liver in the general population: The Dionysos study. Hepatology 2007;46:1387-91. [DOI: 10.1002/hep.21827] [Cited by in Crossref: 146] [Cited by in F6Publishing: 133] [Article Influence: 9.7] [Reference Citation Analysis]
318 Morisco F, Vitaglione P, Amoruso D, Russo B, Fogliano V, Caporaso N. Foods and liver health. Molecular Aspects of Medicine 2008;29:144-50. [DOI: 10.1016/j.mam.2007.09.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
319 Cicero AFG, D’addato S, Reggi A, Reggiani GM, Borghi C. Hepatic Steatosis Index and Lipid Accumulation Product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study. Intern Emerg Med 2013;8:265-7. [DOI: 10.1007/s11739-012-0875-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
320 Sa R, Zhang W, Ge J, Wei X, Zhou Y, Landzberg DR, Wang Z, Han X, Chen L, Yin H. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers. J Mol Cell Biol. 2016;8:195-206. [PMID: 26993042 DOI: 10.1093/jmcb/mjw016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
321 He D, Yan L, Hu Y, Wu Q, Wu M, Choi JI, Tong H. Optimization of Porphyran Extraction from Pyropia yezoensis by Response Surface Methodology and Its Lipid-Lowering Effects. Mar Drugs 2021;19:53. [PMID: 33498781 DOI: 10.3390/md19020053] [Reference Citation Analysis]
322 Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli E, Bonato G, Marchesini-Reggiani G, Colecchia A. Review article: the diagnosis of non-alcoholic fatty liver disease -- availability and accuracy of non-invasive methods. Aliment Pharmacol Ther 2013;37:392-400. [PMID: 23278163 DOI: 10.1111/apt.12186] [Cited by in Crossref: 113] [Cited by in F6Publishing: 103] [Article Influence: 11.3] [Reference Citation Analysis]
323 Siegel AB, Wang S, Jacobson JS, Hershman DL, Lim EA, Yu J, Ferrante L, Devaraj KM, Remotti H, Scrudato S, Halazun K, Emond J, Dove L, Brown RS Jr, Neugut AI. Obesity and microvascular invasion in hepatocellular carcinoma. Cancer Invest 2010;28:1063-9. [PMID: 21077757 DOI: 10.3109/07357907.2010.483500] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
324 Khodadoostan M, Shariatifar B, Motamedi N, Abdolahi H. Comparison of liver enzymes level and sonographic findings value with liver biopsy findings in nonalcoholic fatty liver disease patients. Adv Biomed Res 2016;5:40. [PMID: 27099853 DOI: 10.4103/2277-9175.178785] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
325 Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H. Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 2012;33:812-41. [PMID: 22829562 DOI: 10.1210/er.2012-1003] [Cited by in Crossref: 153] [Cited by in F6Publishing: 136] [Article Influence: 15.3] [Reference Citation Analysis]
326 Zhang D, Xie L, Jia G, Cai S, Ji B, Liu Y, Wu W, Zhou F, Wang A, Chu L, Wei Y, Liu J, Gao F. Comparative study on antioxidant capacity of flavonoids and their inhibitory effects on oleic acid-induced hepatic steatosis in vitro. Eur J Med Chem 2011;46:4548-58. [PMID: 21824690 DOI: 10.1016/j.ejmech.2011.07.031] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
327 Cruz JF, Cruz MA, Machado Neto J, de Santana DS, Oliveira CC, Lima SO. Prevalence and sonographic changes compatible with fatty liver disease in patients referred for abdominal ultrasound examination in Aracaju, SE. Radiol Bras. 2016;49:1-5. [PMID: 26929453 DOI: 10.1590/0100-3984.2014.0124] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
328 Cruz MA, Cruz JF, Macena LB, de Santana DS, Oliveira CC, Lima SO, Franca AV. Association of the Nonalcoholic Hepatic Steatosis and Its Degrees With the Values of Liver Enzymes and Homeostasis Model Assessment-Insulin Resistance Index. Gastroenterology Res 2015;8:260-4. [PMID: 27785306 DOI: 10.14740/gr685w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
329 Claus M, Antoni C, Hofmann B. Factors associated with elevated alanine aminotransferase in employees of a German chemical company: results of a large cross-sectional study. BMC Gastroenterol 2021;21:25. [PMID: 33422007 DOI: 10.1186/s12876-021-01601-2] [Reference Citation Analysis]
330 Marchisello S, Di Pino A, Scicali R, Urbano F, Piro S, Purrello F, Rabuazzo AM. Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. Int J Mol Sci 2019;20:E1948. [PMID: 31010049 DOI: 10.3390/ijms20081948] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 17.0] [Reference Citation Analysis]
331 Soleimani D, Paknahad Z, Askari G, Iraj B, Feizi A. Effect of garlic powder consumption on body composition in patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Adv Biomed Res. 2016;5:2. [PMID: 26955623 DOI: 10.4103/2277-9175.174962] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
332 Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni C. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Research and Clinical Practice 2009;84:84-91. [DOI: 10.1016/j.diabres.2008.11.039] [Cited by in Crossref: 110] [Cited by in F6Publishing: 101] [Article Influence: 8.5] [Reference Citation Analysis]
333 Miptah HN, Ramli AS, Mohamad M, Hashim H, Tharek Z. Non-alcoholic fatty liver disease (NAFLD) and the cardiovascular disease (CVD) risk categories in primary care: is there an association? BMC Fam Pract 2020;21:238. [PMID: 33218301 DOI: 10.1186/s12875-020-01306-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
334 Li TT, Wang AP, Lu JX, Chen MY, Zhao CC, Tang ZH, Li LX, Jia WP. Prevalence and clinical characteristics of non-alcoholic fatty liver disease in newly diagnosed patients with ketosis-onset diabetes. Diabetes Metab 2018;44:437-43. [PMID: 29631765 DOI: 10.1016/j.diabet.2018.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
335 Kogiso T, Moriyoshi Y, Shimizu S, Nagahara H, Shiratori K. High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population. J Gastroenterol. 2009;44:313-321. [PMID: 19271113 DOI: 10.1007/s00535-009-0002-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
336 Pan MH, Lai CS, Tsai ML, Ho CT. Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds. Mol Nutr Food Res. 2014;58:147-171. [PMID: 24302567 DOI: 10.1002/mnfr.201300522] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 6.6] [Reference Citation Analysis]
337 Hashemi Kani A, Alavian SM, Haghighatdoost F, Azadbakht L. Diet macronutrients composition in nonalcoholic Fatty liver disease: a review on the related documents. Hepat Mon. 2014;14:e10939. [PMID: 24693306 DOI: 10.5812/hepatmon.10939] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
338 Black LJ, Jacoby P, She Ping-Delfos WC, Mori TA, Beilin LJ, Olynyk JK, Ayonrinde OT, Huang RC, Holt PG, Hart PH. Low serum 25-hydroxyvitamin D concentrations associate with non-alcoholic fatty liver disease in adolescents independent of adiposity. J Gastroenterol Hepatol. 2014;29:1215-1222. [PMID: 24611991 DOI: 10.1111/jgh.12541] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
339 Alam S, Anam K, Islam S, Mustafa G, Mamun AA, Ahmad N. Clinical, anthropometric, biochemical and histological character of nonalcoholic fatty liver disease without Insulin Resistance. J Clin Exp Hepatol 2019;9:176-81. [PMID: 31024199 DOI: 10.1016/j.jceh.2018.06.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
340 Valantinas J, Apanaviciene DA, Maroziene L, Sveikata A. The prevalence of metabolic risk factors among outpatients with diagnosed nonalcoholic fatty liver disease in Lithuania. Med Sci Monit 2012;18:PH57-62. [PMID: 22534719 DOI: 10.12659/msm.882722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
341 Linden MA, Lopez KT, Fletcher JA, Morris EM, Meers GM, Siddique S, Laughlin MH, Sowers JR, Thyfault JP, Ibdah JA, Rector RS. Combining metformin therapy with caloric restriction for the management of type 2 diabetes and nonalcoholic fatty liver disease in obese rats. Appl Physiol Nutr Metab 2015;40:1038-47. [PMID: 26394261 DOI: 10.1139/apnm-2015-0236] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
342 Nishi T, Babazono A, Maeda T, Imatoh T, Une H. Evaluation of the fatty liver index as a predictor for the development of diabetes among insurance beneficiaries with prediabetes. J Diabetes Investig 2015;6:309-16. [PMID: 25969716 DOI: 10.1111/jdi.12290] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
343 Zhang J, Dai EH, Jiang HQ. Role of the endocannabinoid system in the pathogenesis of cirrhosis. Shijie Huaren Xiaohua Zazhi 2012; 20(13): 1112-1117 [DOI: 10.11569/wcjd.v20.i13.1112] [Reference Citation Analysis]
344 Zhang Y, Jiang L, Hu W, Zheng Q, Xiang W. Mitochondrial dysfunction during in vitro hepatocyte steatosis is reversed by omega-3 fatty acid-induced up-regulation of mitofusin 2. Metabolism. 2011;60:767-775. [PMID: 20817187 DOI: 10.1016/j.metabol.2010.07.026] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
345 Hsieh MH, Wu KT, Chen YY, Yang JF, Lin WY, Chang NC, Lin CY, Huang CK, Wang CL, Chuang HY, Lin SC, Hsu YK, Tsai YS, Chuang WL, Yu ML, Dai CY. Higher NAFLD fibrosis score is associated with impaired eGFR. J Formos Med Assoc. 2020;119:496-503. [PMID: 31353118 DOI: 10.1016/j.jfma.2019.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
346 Míková I, Neřoldová M, Hubáček JA, Dlouhá D, Jirsa M, Honsová E, Sticová E, Lánská V, Špičák J, Trunečka P. Donor PNPLA3 and TM6SF2 Variant Alleles Confer Additive Risks for Graft Steatosis After Liver Transplantation. Transplantation 2020;104:526-34. [PMID: 31356578 DOI: 10.1097/TP.0000000000002876] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
347 Wang Y, Zhang P, Su X, Yu Q, Chen Y, Guan H, Liu E, Fan J. Establishment of a novel non‑alcoholic fatty liver disease model using cholesterol‑fed rabbits with reference to the potential role of endoplasmic reticulum stress. Mol Med Rep 2018;18:2898-904. [PMID: 30015906 DOI: 10.3892/mmr.2018.9258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
348 Sahibzada MUK, Zahoor M, Sadiq A, Ur Rehman F, Al-Mohaimeed AM, Shahid M, Naz S, Ullah R. Bioavailability and hepatoprotection enhancement of berberine and its nanoparticles prepared by liquid antisolvent method. Saudi J Biol Sci 2021;28:327-32. [PMID: 33424313 DOI: 10.1016/j.sjbs.2020.10.006] [Reference Citation Analysis]
349 Caballería L, Auladell MA, Torán P, Pera G, Miranda D, Alumà A, Casas JD, Muñoz L, Sanchez C, Tibau A, Birules M, Canut S, Bernad J, Aubà J, Aizpurua MM, Alcaraz E. Risk factors associated with non-alcoholic fatty liver disease in subjects from primary care units. A case-control study. BMC Gastroenterol 2008;8:44. [PMID: 18831772 DOI: 10.1186/1471-230X-8-44] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
350 Cordeiro A, Pereira S, Saboya CJ, Ramalho A. Relationship between Nonalcoholic Fatty Liver Disease and Vitamin D Nutritional Status in Extreme Obesity. Can J Gastroenterol Hepatol 2017;2017:9456897. [PMID: 28685131 DOI: 10.1155/2017/9456897] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
351 Lampignano L, Donghia R, Griseta C, Lagravinese G, Sciarra S, Zupo R, Castellana F, Bortone I, Guerra V, Tirelli S, De Nucci S, Tatoli R, Lozupone M, Sborgia G, Leo A, De Pergola G, Giannelli G, Panza F, Sardone R. Liver Health and Dementia in an Italian Older Population: Findings From the Salus in Apulia Study. Front Aging Neurosci 2021;13:748888. [PMID: 34955810 DOI: 10.3389/fnagi.2021.748888] [Reference Citation Analysis]
352 Zhang XQ, Pan Y, Yu CH, Xu CF, Xu L, Li YM, Chen WX. PDIA3 Knockdown Exacerbates Free Fatty Acid-Induced Hepatocyte Steatosis and Apoptosis. PLoS One. 2015;10:e0133882. [PMID: 26214517 DOI: 10.1371/journal.pone.0133882] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
353 Kühn JP, Meffert P, Heske C, Kromrey ML, Schmidt CO, Mensel B, Völzke H, Lerch MM, Hernando D, Mayerle J, Reeder SB. Prevalence of Fatty Liver Disease and Hepatic Iron Overload in a Northeastern German Population by Using Quantitative MR Imaging. Radiology 2017;284:706-16. [PMID: 28481195 DOI: 10.1148/radiol.2017161228] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 9.6] [Reference Citation Analysis]
354 Jeong EH, Jun DW, Cho YK, Choe YG, Ryu S, Lee SM, Jang EC. Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea. Clin Mol Hepatol 2013;19:266-72. [PMID: 24133664 DOI: 10.3350/cmh.2013.19.3.266] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 5.2] [Reference Citation Analysis]
355 Latenstein CSS, Alferink LJM, Darwish Murad S, Drenth JPH, van Laarhoven CJHM, de Reuver PR. The Association Between Cholecystectomy, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease: A Population-Based Study. Clin Transl Gastroenterol 2020;11:e00170. [PMID: 32352682 DOI: 10.14309/ctg.0000000000000170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
356 Tian CR, Qian L, Du CL, Shen XZ. Increased catabolism of nucleic acid in nonalcoholic fatty liver disease patients of different ages. Int J Biol Macromol 2014;65:107-9. [PMID: 24456899 DOI: 10.1016/j.ijbiomac.2014.01.025] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
357 Zuccotti GV, Cassatella C, Morelli A, Cucugliato MC, Catinello G, del Balzo V, Guidarelli L, Agostoni C, Mameli C, Troiano E, Bedogni G. Nutrient intake in Italian infants and toddlers from North and South Italy: the Nutrintake 636 study. Nutrients 2014;6:3169-86. [PMID: 25111122 DOI: 10.3390/nu6083169] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
358 Kanuri G, Ladurner R, Skibovskaya J, Spruss A, Königsrainer A, Bischoff SC, Bergheim I. Expression of toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int. 2015;35:562-568. [PMID: 24351080 DOI: 10.1111/liv.12442] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
359 van Meer S, van Erpecum KJ, Sprengers D, Klümpen HJ, Jansen PL, Ijzermans JN, Siersema PD, de Man RA, Verheij J. Hepatocellular carcinoma in noncirrhotic livers is associated with steatosis rather than steatohepatitis: potential implications for pathogenesis. Eur J Gastroenterol Hepatol 2016;28:955-62. [PMID: 27196679 DOI: 10.1097/MEG.0000000000000641] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
360 Kooshki F, Moradi F, Karimi A, Niazkar HR, Khoshbaten M, Maleki V, Pourghassem Gargari B. Chromium picolinate balances the metabolic and clinical markers in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol 2021;33:1298-306. [PMID: 32804855 DOI: 10.1097/MEG.0000000000001830] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
361 Tsai PY, Yen CJ, Li YC, Chiu TY, Chen CY, Jan CF. Association between abnormal liver function and risk factors for metabolic syndrome among freshmen. J Adolesc Health. 2007;41:132-137. [PMID: 17659216 DOI: 10.1016/j.jadohealth.2007.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
362 Petta S, Grimaudo S, Cammà C, Cabibi D, Di Marco V, Licata G, Pipitone RM, Craxì A. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J Hepatol. 2012;56:1356-1362. [PMID: 22314430 DOI: 10.1016/j.jhep.2012.01.007] [Cited by in Crossref: 61] [Cited by in F6Publishing: 65] [Article Influence: 6.1] [Reference Citation Analysis]
363 Nishi T, Babazono A, Maeda T, Imatoh T, Une H. Effects of Eating Fast and Eating Before Bedtime on the Development of Nonalcoholic Fatty Liver Disease. Population Health Management 2016;19:279-83. [DOI: 10.1089/pop.2015.0088] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
364 Buscarini E, Conte D, Cannizzaro R, Bazzoli F, De Boni M, Delle Fave G, Farinati F, Ravelli P, Testoni PA, Lisiero M. White paper of Italian Gastroenterology: delivery of services for digestive diseases in Italy: weaknesses and strengths. Dig Liver Dis. 2014;46:579-589. [PMID: 24913902 DOI: 10.1016/j.dld.2014.02.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
365 Chen Z, Han CK, Pan LL, Zhang HJ, Ma ZM, Huang ZF, Chen S, Zhuang XJ, Li ZB, Li XY. Serum alanine aminotransferase independently correlates with intrahepatic triglyceride contents in obese subjects. Dig Dis Sci. 2014;59:2470-2476. [PMID: 24861033 DOI: 10.1007/s10620-014-3214-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
366 Moreira MEC, de Oliveira Araújo F, de Sousa AR, Toledo RCL, Dos Anjos Benjamin L, Veloso MP, de Souza Reis K, Dos Santos MH, Martino HSD. Bacupari peel extracts (Garcinia brasiliensis) reduces the biometry, lipogenesis and hepatic steatosis in obese rats. Food Res Int 2018;114:169-77. [PMID: 30361013 DOI: 10.1016/j.foodres.2018.08.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
367 Bae JC, Cho YK, Lee WY, Seo HI, Rhee EJ, Park SE, Park CY, Oh KW, Sung KC, Kim BI. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol. 2010;105:2389-2395. [PMID: 20628364 DOI: 10.1038/ajg.2010.275] [Cited by in Crossref: 68] [Cited by in F6Publishing: 59] [Article Influence: 5.7] [Reference Citation Analysis]
368 Peng TC, Wu LW, Chen WL, Liaw FY, Chang YW, Kao TW. Nonalcoholic fatty liver disease and sarcopenia in a Western population (NHANES III): The importance of sarcopenia definition. Clin Nutr 2019;38:422-8. [PMID: 29287676 DOI: 10.1016/j.clnu.2017.11.021] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 6.6] [Reference Citation Analysis]
369 Kamal S, Aldossari KK, Ghoraba D, Abdelhakam SM, Kamal AH, Bedewi M, Nabegh L, Bahnasy K, Hafez T. Clinicopathological and immunological characteristics and outcome of concomitant coeliac disease and non-alcoholic fatty liver disease in adults: a large prospective longitudinal study. BMJ Open Gastroenterol 2018;5:e000150. [PMID: 29503733 DOI: 10.1136/bmjgast-2017-000150] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
370 Wagnerberger S, Spruss A, Kanuri G, Stahl C, Schröder M, Vetter W, Bischoff SC, Bergheim I. Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model. J Nutr Biochem. 2013;24:531-538. [PMID: 22749137 DOI: 10.1016/j.jnutbio.2012.01.014] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 7.5] [Reference Citation Analysis]
371 Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. [PMID: 17081293 DOI: 10.1186/1471-230x-6-33] [Cited by in Crossref: 937] [Cited by in F6Publishing: 443] [Article Influence: 58.6] [Reference Citation Analysis]
372 Schwenger KJP, Ghorbani Y, Li C, Fischer SE, Jackson TD, Okrainec A, Allard JP. Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease in Obese Patients Undergoing Bariatric Surgery. OBES SURG 2020;30:2572-8. [DOI: 10.1007/s11695-020-04514-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
373 Morales-Luna E, Pérez-Ramírez IF, Salgado LM, Castaño-Tostado E, Gómez-Aldapa CA, Reynoso-Camacho R. The main beneficial effect of roselle (Hibiscus sabdariffa) on obesity is not only related to its anthocyanin content. J Sci Food Agric 2019;99:596-605. [PMID: 29943479 DOI: 10.1002/jsfa.9220] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
374 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell'Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Dig Liver Dis 2021:S1590-8658(21)00214-0. [PMID: 34924319 DOI: 10.1016/j.dld.2021.04.029] [Reference Citation Analysis]
375 Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes. 2012;2012:483135. [PMID: 23320150 DOI: 10.1155/2012/483135] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
376 Mancini M, Salomone Megna A, Ragucci M, De Luca M, Marino Marsilia G, Nardone G, Coccoli P, Prinster A, Mannelli L, Vergara E, Monti S, Liuzzi R, Incoronato M. Reproducibility of shear wave elastography (SWE) in patients with chronic liver disease. PLoS One. 2017;12:e0185391. [PMID: 29023554 DOI: 10.1371/journal.pone.0185391] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
377 Wongsaensook A, Sukeepaisarnjaroen W, Sukeepaisarnjaroen W, Kularbkaew C. Significant clinical risks and the benefits of liver biopsies in Srinagarind Hospital, Khon Kaen University, Thailand: Lessons learned from the past to the present. IMAS 2012;4:92-7. [DOI: 10.1556/imas.4.2012.2.6] [Reference Citation Analysis]
378 Siow W, van der Poorten D, George J. Epidemiological Trends in NASH as a Cause for Liver Transplant. Curr Hepatology Rep 2016;15:67-74. [DOI: 10.1007/s11901-016-0294-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
379 Argalia G, Ventura C, Tosi N, Campioni D, Tagliati C, Tufillaro M, Cucco M, Svegliati Baroni G, Giovagnoni A. Comparison of point shear wave elastography and transient elastography in the evaluation of patients with NAFLD. Radiol Med 2022. [PMID: 35290569 DOI: 10.1007/s11547-022-01475-8] [Reference Citation Analysis]
380 Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis. 2012;32:22-29. [PMID: 22418885 DOI: 10.1055/s-0032-1306423] [Cited by in Crossref: 122] [Cited by in F6Publishing: 116] [Article Influence: 12.2] [Reference Citation Analysis]
381 Leiber L, Boursier J, Michalak S, Roullier V, Fizanne L, Chaigneau J, Roux J, Moal V, Flamment M, Bazeries P, Ducluzeau P, Aube C. MRI versus histological methods for time course monitoring of steatosis amount in a murine model of NAFLD. Diagnostic and Interventional Imaging 2015;96:915-22. [DOI: 10.1016/j.diii.2015.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
382 Omolekulo TE, Michael OS, Olatunji LA. Sodium acetate improves disrupted glucoregulation and hepatic triglyceride content in insulin-resistant female rats: involvement of adenosine deaminase and dipeptidyl peptidase-4 activities. Naunyn Schmiedebergs Arch Pharmacol 2019;392:103-16. [PMID: 30280312 DOI: 10.1007/s00210-018-1569-2] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
383 Reichold A, Brenner SA, Förster-Fromme K, Bergheim I, Mollenhauer J, Bischoff SC. Dmbt1 does not affect a Western style diet-induced liver damage in mice. J Clin Biochem Nutr 2013;53:145-9. [PMID: 24249968 DOI: 10.3164/jcbn.13-31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
384 Kiziltas S. Toll-like receptors in pathophysiology of liver diseases. World J Hepatol 2016; 8(32): 1354-1369 [PMID: 27917262 DOI: 10.4254/wjh.v8.i32.1354] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 9.5] [Reference Citation Analysis]
385 Chen YS, Chen D, Shen C, Chen M, Jin CH, Xu CF, Yu CH, Li YM. A novel model for predicting fatty liver disease by means of an artificial neural network. Gastroenterol Rep (Oxf) 2021;9:31-7. [PMID: 33747524 DOI: 10.1093/gastro/goaa035] [Reference Citation Analysis]
386 Wlazlo N, van Greevenbroek MMJ, Ferreira I, Bravenboer B, Stehouwer CDA. The diagnosis of non-alcoholic fatty liver disease: Letters to the Editors. Alimentary Pharmacology & Therapeutics 2012;35:204-5. [DOI: 10.1111/j.1365-2036.2011.04909.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
387 Spruss A, Kanuri G, Stahl C, Bischoff SC, Bergheim I. Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Lab Invest. 2012;92:1020-1032. [PMID: 22525431 DOI: 10.1038/labinvest.2012.75] [Cited by in Crossref: 101] [Cited by in F6Publishing: 100] [Article Influence: 10.1] [Reference Citation Analysis]
388 Park MJ, Kim DI, Choi JH, Heo YR, Park SH. New role of irisin in hepatocytes: The protective effect of hepatic steatosis in vitro. Cell Signal 2015;27:1831-9. [PMID: 25917316 DOI: 10.1016/j.cellsig.2015.04.010] [Cited by in Crossref: 76] [Cited by in F6Publishing: 79] [Article Influence: 10.9] [Reference Citation Analysis]
389 Albhaisi S, Sanyal A. Recent advances in understanding and managing non-alcoholic fatty liver disease. F1000Res 2018;7:F1000 Faculty Rev-720. [PMID: 29946426 DOI: 10.12688/f1000research.14421.1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
390 Wang X, Xie J, Pang J, Zhang H, Chen X, Lin J, Li Q, Chen Q, Ma J, Xu X, Yang Y, Ling W, Chen Y. Serum SHBG Is Associated With the Development and Regression of Nonalcoholic Fatty Liver Disease: A Prospective Study. J Clin Endocrinol Metab 2020;105:dgz244. [PMID: 31793624 DOI: 10.1210/clinem/dgz244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
391 Zelber-Sagi S, Ben-Assuli O, Rabinowich L, Goldstein A, Magid A, Shalev V, Shibolet O, Chodick G. The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort. Liver Int. 2015;35:2408-2415. [PMID: 25845417 DOI: 10.1111/liv.12842] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
392 Lefkowitch JH. Hepatobiliary pathology. Curr Opin Gastroenterol 2006;22:198-208. [PMID: 16550033 DOI: 10.1097/01.mog.0000218955.55688.af] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
393 Matsui S, Yasui T, Kasai K, Keyama K, Kato T, Uemura H, Kuwahara A, Matsuzaki T, Irahara M. Changes of liver enzymes and triglyceride during the menopausal transition in Japanese women. J Obstet Gynaecol 2016;36:806-11. [PMID: 27167882 DOI: 10.3109/01443615.2016.1154516] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
394 Nobili V, Alisi A, Vania A, Tiribelli C, Pietrobattista A, Bedogni G. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med. 2009;7:21. [PMID: 19409076 DOI: 10.1186/1741-7015-7-21] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 6.3] [Reference Citation Analysis]
395 Hsu CC, Ness E, Kowdley KV. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. Adv Nutr. 2017;8:253-265. [PMID: 28298270 DOI: 10.3945/an.116.013730] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
396 Chen YJ, Chen KW, Shih YL, Su FY, Lin YP, Meng FC, Lin F, Yu YS, Han CL, Wang CH, Lin JW, Hsieh TY, Li YH, Lin GM. Chronic hepatitis B, nonalcoholic steatohepatitis and physical fitness of military males: CHIEF study. World J Gastroenterol 2017; 23(25): 4587-4594 [PMID: 28740347 DOI: 10.3748/wjg.v23.i25.4587] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
397 Teshome G, Ambachew S, Fasil A, Abebe M. Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review. Hepat Med 2020;12:139-51. [PMID: 33061687 DOI: 10.2147/HMER.S265631] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
398 Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl. 2006;12:523-534. [PMID: 16555318 DOI: 10.1002/lt.20738] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 6.5] [Reference Citation Analysis]
399 Ahn JS, Sinn DH, Gwak GY, Kim JM, Kwon CH, Joh JW, Paik YH, Choi MS, Lee JH, Koh KC. Steatosis among living liver donors without evidence of fatty liver on ultrasonography: potential implications for preoperative liver biopsy. Transplantation. 2013;95:1404-1409. [PMID: 23542472 DOI: 10.1097/tp.0b013e31828d1588] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
400 Tomic D, Kemp WW, Roberts SK. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies. Eur J Gastroenterol Hepatol 2018;30:1103-15. [PMID: 30113367 DOI: 10.1097/MEG.0000000000001235] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
401 Schwenger KJP, Fischer SE, Jackson TD, Okrainec A, Allard JP. Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet. OBES SURG 2018;28:1109-16. [DOI: 10.1007/s11695-017-2980-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
402 Rimini M, Casadei-Gardini A, Ravaioli A, Rovesti G, Conti F, Borghi A, Dall'Aglio AC, Bedogni G, Domenicali M, Giacomoni P, Tiribelli C, Bucchi L, Falcini F, Foschi FG, Bagnacavallo Study Group. Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study. J Clin Med 2020;9:E1177. [PMID: 32325965 DOI: 10.3390/jcm9041177] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
403 Everhart JE, Bambha KM. Fatty liver: think globally. Hepatology 2010;51:1491-3. [PMID: 20432252 DOI: 10.1002/hep.23659] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
404 Nobili V, Marcellini M, Devito R, Ciampalini P, Piemonte F, Comparcola D, Sartorelli MR, Angulo P. NAFLD in children: a prospective clinical-pathological study and effect of lifestyle advice. Hepatology. 2006;44:458-465. [PMID: 16871574 DOI: 10.1002/hep.21262] [Cited by in Crossref: 221] [Cited by in F6Publishing: 200] [Article Influence: 13.8] [Reference Citation Analysis]
405 Ratziu V, Voiculescu M, Poynard T. Touching some firm ground in the epidemiology of NASH. J Hepatol. 2012;56:23-25. [PMID: 21875499 DOI: 10.1016/j.jhep.2011.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
406 Delgado JS. Evolving trends in nonalcoholic fatty liver disease. Eur J Intern Med. 2008;19:75-82. [PMID: 18249301 DOI: 10.1016/j.ejim.2007.02.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
407 Rosmorduc O, Fartoux L. HCC and NASH: how strong is the clinical demonstration? Clin Res Hepatol Gastroenterol 2012;36:202-8. [PMID: 22326764 DOI: 10.1016/j.clinre.2011.12.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
408 Cacciapuoti F, Scognamiglio A, Palumbo R, Forte R, Cacciapuoti F. Silymarin in non alcoholic fatty liver disease. World J Hepatol 2013; 5(3): 109-113 [PMID: 23556042 DOI: 10.4254/wjh.v5.i3.109] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
409 Sangouni AA, Ghavamzadeh S, Jamalzehi A. A narrative review on effects of vitamin D on main risk factors and severity of Non-Alcoholic Fatty Liver Disease. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019;13:2260-5. [DOI: 10.1016/j.dsx.2019.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
410 Adams LA. Nonalcoholic Fatty Liver Disease and Diabetes Mellitus. Endocrine Research 2009;32:59-69. [DOI: 10.1080/07435800701743885] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
411 Lee YJ, Shim JY, Moon BS, Shin YH, Jung DH, Lee JH, Lee HR. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57:196-203. [PMID: 21750929 DOI: 10.1007/s10620-011-1819-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
412 Ahmed MH, Abu EO, Byrne CD. Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes. 2010;4:129-137. [PMID: 20299294 DOI: 10.1016/j.pcd.2010.02.004] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
413 Miura H, Ijichi M, Ando Y, Hayama K, IIhara K, Yamada H, Bandai Y. A rapidly progressive and fatal case of nonalcoholic steatohepatitis following pancreaticoduodenectomy. Clin J Gastroenterol. 2013;6:470-475. [PMID: 26182139 DOI: 10.1007/s12328-013-0421-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
414 Chen Y, Pandiri I, Joe Y, Kim HJ, Kim SK, Park J, Ryu J, Cho GJ, Park JW, Ryter SW, Chung HT. Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis. Oxid Med Cell Longev 2016;2016:3949813. [PMID: 27057275 DOI: 10.1155/2016/3949813] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
415 Abd El-Wahab EW, Zein El-Abedin RA, Ahmed WM, Shatat HZ. Validation of a Non-Laboratory Based Screening Tool for Predicting Non-Alcoholic Fatty Liver Disease in an Egyptian Setting. Am J Med Sci 2020;360:662-77. [PMID: 32739036 DOI: 10.1016/j.amjms.2020.06.020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
416 Ehrlich A, Tsytkin-Kirschenzweig S, Ioannidis K, Ayyash M, Riu A, Note R, Ouedraogo G, Vanfleteren J, Cohen M, Nahmias Y. Microphysiological flux balance platform unravels the dynamics of drug induced steatosis. Lab Chip 2018;18:2510-22. [PMID: 29992215 DOI: 10.1039/c8lc00357b] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
417 Petrasek J, Csak T, Szabo G. Toll-like receptors in liver disease. Adv Clin Chem. 2013;59:155-201. [PMID: 23461136 DOI: 10.1016/b978-0-12-405211-6.00006-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 32] [Article Influence: 5.9] [Reference Citation Analysis]
418 Paquette M, Gauthier D, Chamberland A, Prat A, De Lucia Rolfe E, Rasmussen JJ, Kaduka L, Seidah NG, Bernard S, Christensen DL, Baass A. Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis. Clin Biochem 2020;77:20-5. [PMID: 31972148 DOI: 10.1016/j.clinbiochem.2020.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
419 Hijona E, Hijona L, Arenas JI, Bujanda L. Inflammatory mediators of hepatic steatosis. Mediators Inflamm 2010;2010:837419. [PMID: 20300479 DOI: 10.1155/2010/837419] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 4.7] [Reference Citation Analysis]
420 Acharya UR, Fujita H, Sudarshan VK, Mookiah MRK, Koh JE, Tan JH, Hagiwara Y, Chua CK, Junnarkar SP, Vijayananthan A, Ng KH. An integrated index for identification of fatty liver disease using radon transform and discrete cosine transform features in ultrasound images. Information Fusion 2016;31:43-53. [DOI: 10.1016/j.inffus.2015.12.007] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 5.2] [Reference Citation Analysis]
421 Lin H, Zhang X, Li G, Wong GL, Wong VW. Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:972-82. [PMID: 34966660 DOI: 10.14218/JCTH.2021.00201] [Reference Citation Analysis]
422 Terán Lantarón A, Crespo García J. [Non-alcoholic fatty liver disease. How and who to screen]. Gastroenterol Hepatol 2011;34:278-88. [PMID: 21429628 DOI: 10.1016/j.gastrohep.2010.11.010] [Reference Citation Analysis]
423 Pozzato C, Radaelli G, Dall’Asta C, Verduci E, Villa A, Villa C, Scaglioni S, Riva E, Pontiroli AE, Cornalba G. MRI in identifying hepatic steatosis in obese children and relation to ultrasonography and metabolic findings. J Pediatr Gastroenterol Nutr. 2008;47:493-499. [PMID: 18852643 DOI: 10.1097/MPG.0b013e31817b6e10] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
424 Bettermann K, Hohensee T, Haybaeck J. Steatosis and steatohepatitis: complex disorders. Int J Mol Sci. 2014;15:9924-9944. [PMID: 24897026 DOI: 10.3390/ijms15069924] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
425 Wah-Kheong C, Khean-Lee G. Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease. Hepatol Int. 2013;7:65-71. [PMID: 26201622 DOI: 10.1007/s12072-012-9384-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
426 Nagaoki Y, Hyogo H, Aikata H, Tanaka M, Naeshiro N, Nakahara T, Honda Y, Miyaki D, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K. Recent trend of clinical features in patients with hepatocellular carcinoma. Hepatol Res. 2012;42:368-375. [PMID: 22151896 DOI: 10.1111/j.1872-034x.2011.00929.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
427 Schwartz S, Lucas J, DeLegge MH. Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice. touchREV Endocrinol 2021;17:112-20. [PMID: 35118457 DOI: 10.17925/EE.2021.17.2.112] [Reference Citation Analysis]
428 Xiao J, Han N, Yang D, Zhao H. Liver steatosis in Chinese HIV-infected patients with hypertriglyceridemia: characteristics and independent risk factors. Virol J 2013;10:261. [PMID: 23941464 DOI: 10.1186/1743-422X-10-261] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
429 Mlynarsky L, Schlesinger D, Lotan R, Webb M, Halpern Z, Santo E, Shibolet O, Zelber-Sagi S. Non-alcoholic fatty liver disease is not associated with a lower health perception. World J Gastroenterol 2016; 22(17): 4362-4372 [PMID: 27158205 DOI: 10.3748/wjg.v22.i17.4362] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
430 Lian J, Watts R, Quiroga AD, Beggs MR, Alexander RT, Lehner R. Ces1d deficiency protects against high-sucrose diet-induced hepatic triacylglycerol accumulation. J Lipid Res 2019;60:880-91. [PMID: 30737251 DOI: 10.1194/jlr.M092544] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
431 Wengert S, Oeztuerk S, Haenle MM, Koenig W, Imhof A, Boehm BO, Wilhelm M, Mao R, Mason RA, Kratzer W. Association of proinsulin and hepatic steatosis in a random, population-based sample. Eur J Endocrinol. 2013;168:195-202. [PMID: 23136404 DOI: 10.1530/eje-12-0605] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
432 Ahmed MH, Byrne CD. Non-Alcoholic Fatty Liver Disease. In: Byrne CD, Wild SH, editors. The Metabolic Syndrome. Oxford: Wiley-Blackwell; 2011. pp. 245-77. [DOI: 10.1002/9781444347319.ch15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
433 Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113-119. [PMID: 18384521 DOI: 10.1111/j.1478-3231.2008.01718.x] [Cited by in Crossref: 304] [Cited by in F6Publishing: 287] [Article Influence: 21.7] [Reference Citation Analysis]
434 Ishiba H, Sumida Y, Kataoka S, Kuroda M, Akabame S, Tomiyasu K, Tanaka M, Arai M, Taketani H, Seko Y, Okajima A, Hara T, Umemura A, Nishikawa T, Yamaguchi K, Moriguchi M, Mitsuyoshi H, Yasui K, Itoh Y. Association of coronary artery calcification with liver fibrosis in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res. 2016;46:1107-1117. [PMID: 26853695 DOI: 10.1111/hepr.12665] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
435 Lombardi R, Onali S, Thorburn D, Davidson BR, Gurusamy KS, Tsochatzis E. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011640. [PMID: 28358980 DOI: 10.1002/14651858.CD011640.pub2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
436 Oh S, Cho Y, Kang M, Yoo T, Park J, Kim H, Park D, Sohn C, Jeon W, Kim B, Son B, Shin J. The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease. Metabolism 2006;55:1604-9. [DOI: 10.1016/j.metabol.2006.07.021] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 4.9] [Reference Citation Analysis]
437 Matthew Morris E, Fletcher JA, Thyfault JP, Scott Rector R. The role of angiotensin II in nonalcoholic steatohepatitis. Molecular and Cellular Endocrinology 2013;378:29-40. [DOI: 10.1016/j.mce.2012.04.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
438 Xu L, Xu C, Yu C, Miao M, Zhang X, Zhu Z, Ding X, Li Y. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS One. 2012;7:e44136. [PMID: 22952901 DOI: 10.1371/journal.pone.0044136] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
439 Sangouni AA, Ghavamzadeh S. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. Diabetes Metab Syndr 2019;13:2917-22. [PMID: 31425956 DOI: 10.1016/j.dsx.2019.07.063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
440 Shen L, Liu Z, Gong J, Zhang L, Wang L, Magdalou J, Chen L, Wang H. Prenatal ethanol exposure programs an increased susceptibility of non-alcoholic fatty liver disease in female adult offspring rats. Toxicol Appl Pharmacol 2014;274:263-73. [PMID: 24275070 DOI: 10.1016/j.taap.2013.11.009] [Cited by in Crossref: 67] [Cited by in F6Publishing: 65] [Article Influence: 7.4] [Reference Citation Analysis]
441 Petta S, Miele L, Bugianesi E, Cammà C, Rosso C, Boccia S, Cabibi D, Di Marco V, Grimaudo S, Grieco A, Pipitone RM, Marchesini G, Craxì A. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. PLoS One 2014;9:e87523. [PMID: 24498332 DOI: 10.1371/journal.pone.0087523] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 9.8] [Reference Citation Analysis]
442 Arriga R, Pacifici F, Capuani B, Coppola A, Orlandi A, Scioli MG, Pastore D, Andreadi A, Sbraccia P, Tesauro M, Daniele ND, Sconocchia G, Donadel G, Bellia A, Della-Morte D, Lauro D. Peroxiredoxin 6 Is a Key Antioxidant Enzyme in Modulating the Link between Glycemic and Lipogenic Metabolism. Oxid Med Cell Longev 2019;2019:9685607. [PMID: 31949886 DOI: 10.1155/2019/9685607] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
443 Hossain N, Kanwar P, Mohanty SR. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract 2016;2016:7109270. [PMID: 27006654 DOI: 10.1155/2016/7109270] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
444 Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, Trapani S, Floreani A, Marra F, Brunetto MR, Taliani G, Villa E; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int 2021;41:1713-33. [PMID: 33982400 DOI: 10.1111/liv.14943] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
445 Ryoo JH, Hong HP, Park SK, Ham WT, Chung JY. The Risk for Insulin Resistance according to the Degree of Non-Alcoholic Fatty Liver Disease in Korean Men. J Korean Med Sci 2016;31:1761-7. [PMID: 27709854 DOI: 10.3346/jkms.2016.31.11.1761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
446 Ha AW, Kim WK. The effect of fucoxanthin rich power on the lipid metabolism in rats with a high fat diet. Nutr Res Pract. 2013;7:287-293. [PMID: 23964316 DOI: 10.4162/nrp.2013.7.4.287] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
447 Nugent C, Younossi ZM. Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2007;4:432-41. [DOI: 10.1038/ncpgasthep0879] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 4.2] [Reference Citation Analysis]
448 Ekstedt M, Franzén LE, Mathiesen UL, Kechagias S. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. Scand J Gastroenterol. 2012;47:108-115. [PMID: 22126450 DOI: 10.3109/00365521.2011.634024] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
449 Glass LM, Dickson RC, Anderson JC, Suriawinata AA, Putra J, Berk BS, Toor A. Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60:1024-1030. [PMID: 25354830 DOI: 10.1007/s10620-014-3380-3] [Cited by in Crossref: 80] [Cited by in F6Publishing: 66] [Article Influence: 10.0] [Reference Citation Analysis]
450 Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033] [Cited by in Crossref: 190] [Cited by in F6Publishing: 172] [Article Influence: 31.7] [Reference Citation Analysis]
451 Chen J, Wu L, Yang G, Zhang C, Liu X, Sun X, Chen X, Wang N. The influence of PM2.5 exposure on non-alcoholic fatty liver disease. Life Sci 2021;270:119135. [PMID: 33513397 DOI: 10.1016/j.lfs.2021.119135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
452 Pararasa C, Bailey CJ, Griffiths HR. Ageing, adipose tissue, fatty acids and inflammation. Biogerontology 2015;16:235-48. [PMID: 25367746 DOI: 10.1007/s10522-014-9536-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
453 O’Brien J, Powell LW. Non-alcoholic fatty liver disease: is iron relevant? Hepatol Int. 2012;6:332-341. [PMID: 22020821 DOI: 10.1007/s12072-011-9304-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
454 Chen S, Liu C, Li S, Huang H, Tsai C, Jou H. Effects of Therapeutic Lifestyle Program on Ultrasound-diagnosed Nonalcoholic Fatty Liver Disease. Journal of the Chinese Medical Association 2008;71:551-8. [DOI: 10.1016/s1726-4901(08)70168-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
455 Wang G, Wang Q, Bai J, Li G, Tao K, Wang G, Xia Z. RYGB increases postprandial gastric nesfatin-1 and rapid relieves NAFLD via gastric nerve detachment. PLoS One 2020;15:e0243640. [PMID: 33301513 DOI: 10.1371/journal.pone.0243640] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
456 Cichon K, Schön CA. Influences on the amount of intraperitoneal haemorrhage after blunt liver injury: a retrospective autopsy study. Eur J Gastroenterol Hepatol 2012;24:1333-40. [PMID: 22872075 DOI: 10.1097/MEG.0b013e3283579445] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
457 Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-690. [PMID: 24042449 DOI: 10.1038/nrgastro.2013.171] [Cited by in Crossref: 926] [Cited by in F6Publishing: 894] [Article Influence: 102.9] [Reference Citation Analysis]
458 Park EY, Lim MK, Oh JK, Cho H, Bae MJ, Yun EH, Kim DI, Shin HR. Independent and supra-additive effects of alcohol consumption, cigarette smoking, and metabolic syndrome on the elevation of serum liver enzyme levels. PLoS One. 2013;8:e63439. [PMID: 23667618 DOI: 10.1371/journal.pone.0063439] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
459 Van De Wier B, Koek GH, Bast A, Haenen GRMM. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Critical Reviews in Food Science and Nutrition 2015;57:834-55. [DOI: 10.1080/10408398.2014.952399] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 11.0] [Reference Citation Analysis]
460 Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 2010;15 Suppl 4:14-22. [PMID: 21115577 DOI: 10.1634/theoncologist.2010-s4-14] [Cited by in Crossref: 293] [Cited by in F6Publishing: 161] [Article Influence: 26.6] [Reference Citation Analysis]
461 Shin J, Choi SJ, Lee HR, Han K, Chang J, Jeong S, Choi Y, Lee D, Shin DW. Non-Alcoholic Fatty Liver Disease and the Risk of Diabetes Mellitus by Menopausal Status: A Nationwide Cohort Study. JPM 2022;12:546. [DOI: 10.3390/jpm12040546] [Reference Citation Analysis]
462 Khang AR, Lee HW, Yi D, Kang YH, Son SM. The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea National Health and Nutrition Examination Survey 2010-2011. Diabetes Metab Syndr Obes 2019;12:181-90. [PMID: 30774403 DOI: 10.2147/DMSO.S189544] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
463 Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring). 2009;17:2162-2168. [PMID: 19390517 DOI: 10.1038/oby.2009.126] [Cited by in Crossref: 127] [Cited by in F6Publishing: 117] [Article Influence: 9.8] [Reference Citation Analysis]
464 Wiggans MG, Lordan JT, Shahtahmassebi G, Aroori S, Bowles MJ, Stell DA. The Interaction between Diabetes, Body Mass Index, Hepatic Steatosis, and Risk of Liver Resection: Insulin Dependent Diabetes Is the Greatest Risk for Major Complications. HPB Surg 2014;2014:586159. [PMID: 25202167 DOI: 10.1155/2014/586159] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
465 Ciapaite J, van den Broek NM, Te Brinke H, Nicolay K, Jeneson JA, Houten SM, Prompers JJ. Differential effects of short- and long-term high-fat diet feeding on hepatic fatty acid metabolism in rats. Biochim Biophys Acta 2011;1811:441-51. [PMID: 21621638 DOI: 10.1016/j.bbalip.2011.05.005] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.7] [Reference Citation Analysis]
466 Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, Chen MH, Hu PJ. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007;13:6419-24. [PMID: 18081233 DOI: 10.3748/wjg.v13.i47.6419] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
467 Mukhopadhya I, Hansen R, El-Omar EM, Hold GL. IBD-what role do Proteobacteria play? Nat Rev Gastroenterol Hepatol 2012;9:219-30. [PMID: 22349170 DOI: 10.1038/nrgastro.2012.14] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
468 Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(7): 1712-1723 [PMID: 24587650 DOI: 10.3748/wjg.v20.i7.1712] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 73] [Article Influence: 9.8] [Reference Citation Analysis]
469 Cheng CH, Chu CY, Chen HL, Lin IT, Wu CH, Lee YK, Hu PJ, Bair MJ. Subgroup analysis of the predictive ability of aspartate aminotransferase to platelet ratio index (APRI) and fibrosis-4 (FIB-4) for assessing hepatic fibrosis among patients with chronic hepatitis C. J Microbiol Immunol Infect 2020;53:542-9. [PMID: 31831303 DOI: 10.1016/j.jmii.2019.09.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
470 Spruss A, Kanuri G, Wagnerberger S, Haub S, Bischoff SC, Bergheim I. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology. 2009;50:1094-1104. [PMID: 19637282 DOI: 10.1002/hep.23122] [Cited by in Crossref: 352] [Cited by in F6Publishing: 351] [Article Influence: 27.1] [Reference Citation Analysis]
471 Hatziagelaki E, Karageorgopoulos DE, Chounta A, Tsiavou A, Falagas ME, Dimitriadis G. Predictors of impaired glucose regulation in patients with non-alcoholic fatty liver disease. Exp Diabetes Res 2012;2012:351974. [PMID: 21960993 DOI: 10.1155/2012/351974] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
472 Krstic J, Galhuber M, Schulz TJ, Schupp M, Prokesch A. p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine. Int J Mol Sci 2018;19:E921. [PMID: 29558460 DOI: 10.3390/ijms19030921] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
473 Tomizawa M, Kawanabe Y, Shinozaki F, Sato S, Motoyoshi Y, Sugiyama T, Yamamoto S, Sueishi M. Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liver. Exp Ther Med 2014;8:759-62. [PMID: 25120595 DOI: 10.3892/etm.2014.1798] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
474 Singh SP, Misra B, Kar SK, Panigrahi MK, Misra D, Bhuyan P, Pattnaik K, Meher C, Agrawal O, Rout N, Swain M. Nonalcoholic fatty liver disease (NAFLD) without insulin resistance: Is it different?Clin Res Hepatol Gastroenterol. 2015;39:482-488. [PMID: 25543522 DOI: 10.1016/j.clinre.2014.08.014] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
475 Ballan R, Battistini C, Xavier-Santos D, Saad SMI. Interactions of probiotics and prebiotics with the gut microbiota. Prog Mol Biol Transl Sci 2020;171:265-300. [PMID: 32475525 DOI: 10.1016/bs.pmbts.2020.03.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
476 Abenavoli L, Milic N, Peta V, Alfieri F, De Lorenzo A, Bellentani S. Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet. World J Gastroenterol 2014; 20(45): 16831-16840 [PMID: 25492997 DOI: 10.3748/wjg.v20.i45.16831] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
477 Lee K, Sung JA, Kim JS, Park TJ. The roles of obesity and gender on the relationship between metabolic risk factors and non-alcoholic fatty liver disease in Koreans. Diabetes Metab Res Rev. 2009;25:150-155. [PMID: 19117027 DOI: 10.1002/dmrr.924] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
478 Cabibbo G, Maida M, Genco C, Antonucci M, Cammà C. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol. 2012;39:374-383. [PMID: 22846856 DOI: 10.1053/j.seminoncol.2012.05.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
479 Shen C, Zhao CY, Wang W, Wang YD, Sun H, Cao W, Yu WY, Zhang L, Ji R, Li M, Gao J. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gastroenterol. 2014;14:39. [PMID: 24559185 DOI: 10.1186/1471-230x-14-39] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
480 Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, Franchini M, Zoppini G, Muggeo M. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564-1570. [PMID: 18385424 DOI: 10.1681/asn.2007101155] [Cited by in Crossref: 122] [Cited by in F6Publishing: 51] [Article Influence: 8.7] [Reference Citation Analysis]
481 Tallarico V, Recinella G, Magalotti D, Muscari A, Zoli M, Bianchi G. Prognostic value of non-alcoholic fatty liver disease in the elderly patients. Aging Clin Exp Res 2020;32:2657-65. [PMID: 32008226 DOI: 10.1007/s40520-020-01487-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
482 Graus-Nunes F, Santos FO, Marinho TS, Miranda CS, Barbosa-da-Silva S, Souza-Mello V. Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model. World J Hepatol 2019; 11(4): 359-369 [PMID: 31114640 DOI: 10.4254/wjh.v11.i4.359] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
483 Bazick J, Donithan M, Neuschwander-Tetri BA, Kleiner D, Brunt EM, Wilson L, Doo E, Lavine J, Tonascia J, Loomba R. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care. 2015;38:1347-1355. [PMID: 25887357 DOI: 10.2337/dc14-1239] [Cited by in Crossref: 101] [Cited by in F6Publishing: 85] [Article Influence: 14.4] [Reference Citation Analysis]
484 Motamed N, Rabiee B, Hemasi GR, Ajdarkosh H, Khonsari MR, Maadi M, Keyvani H, Zamani F. Body Roundness Index and Waist-to-Height Ratio are Strongly Associated With Non-Alcoholic Fatty Liver Disease: A Population-Based Study. Hepat Mon. 2016;16:e39575. [PMID: 27822266 DOI: 10.5812/hepatmon.39575] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
485 Croci I, Coombes JS, Bucher Sandbakk S, Keating SE, Nauman J, Macdonald GA, Wisloff U. Non-alcoholic fatty liver disease: Prevalence and all-cause mortality according to sedentary behaviour and cardiorespiratory fitness. The HUNT Study. Prog Cardiovasc Dis 2019;62:127-34. [PMID: 30796942 DOI: 10.1016/j.pcad.2019.01.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
486 Hamad AA, Khalil AA, Connolly V, Ahmed MH. Relationship between non-alcoholic fatty liver disease and kidney function: A communication between two organs that needs further exploration. Arab Journal of Gastroenterology 2012;13:161-5. [DOI: 10.1016/j.ajg.2012.06.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
487 Loria P, Adinolfi L, Bellentani S, Bugianesi E, Grieco A, Fargion S, Gasbarrini A, Loguercio C, Lonardo A, Marchesini G, Marra F, Persico M, Prati D, Baroni GS. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. Digestive and Liver Disease 2010;42:272-82. [DOI: 10.1016/j.dld.2010.01.021] [Cited by in Crossref: 150] [Cited by in F6Publishing: 147] [Article Influence: 12.5] [Reference Citation Analysis]
488 Suzuki A, Abdelmalek MF. Nonalcoholic fatty liver disease in women. Womens Health (Lond). 2009;5:191-203. [PMID: 19245356 DOI: 10.2217/17455057.5.2.191] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 6.0] [Reference Citation Analysis]
489 Dou AX, Zong L, Zhou K, Chen T, Pan H, Zhang Q, Li JQ, Fang JY, Lu LG. Experimental study on nonalcoholic fatty liver disease treated by medical instrument on hepatic diseases of type Ⅰ DSG in rats. Shijie Huaren Xiaohua Zazhi 2008; 16(9): 935-940 [DOI: 10.11569/wcjd.v16.i9.935] [Reference Citation Analysis]
490 Woolsey SJ, Mansell SE, Kim RB, Tirona RG, Beaton MD. CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease. Drug Metab Dispos 2015;43:1484-90. [DOI: 10.1124/dmd.115.065979] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 9.1] [Reference Citation Analysis]
491 Unalp-arida A, Ruhl CE. Liver fat scores predict liver disease mortality in the United States population. Aliment Pharmacol Ther 2018;48:1003-16. [DOI: 10.1111/apt.14967] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
492 Tiao MM, Lin YJ, Yu HR, Sheen JM, Lin IC, Lai YJ, Tain YL, Huang LT, Tsai CC. Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system. Lipids Health Dis 2018;17:178. [PMID: 30055626 DOI: 10.1186/s12944-018-0824-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 8.8] [Reference Citation Analysis]
493 Liang J, Wang Y, Li H, Liu X, Qiu Q, Qi L. Combination of diabetes risk factors and hepatic steatosis in Chinese: the Cardiometabolic Risk in Chinese (CRC) Study. PLoS One 2014;9:e90101. [PMID: 24595017 DOI: 10.1371/journal.pone.0090101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
494 Spruss A, Kanuri G, Uebel K, Bischoff SC, Bergheim I. Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice. Antioxid Redox Signal. 2011;14:2121-2135. [PMID: 21083420 DOI: 10.1089/ars.2010.3263] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 5.3] [Reference Citation Analysis]
495 Petta S, Ciminnisi S, Di Marco V, Cabibi D, Cammà C, Licata A, Marchesini G, Craxì A. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;45:510-8. [DOI: 10.1111/apt.13889] [Cited by in Crossref: 100] [Cited by in F6Publishing: 96] [Article Influence: 16.7] [Reference Citation Analysis]
496 Xu D, Bai J, Zhang L, Shen L, Wang L, Liu Z, Xia L, Wang H. Prenatal nicotine exposure-induced intrauterine programming alteration increases the susceptibility of high-fat diet-induced non-alcoholic simple fatty liver in female adult offspring rats. Toxicol Res 2015;4:112-20. [DOI: 10.1039/c4tx00092g] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
497 Narciso-schiavon JL, Schiavon LDL, Carvalho-filho RJD, Hayashida DY, Wang JHJ, Souza TS, Emori CT, Ferraz MLG, Silva AEB. Clinical characteristics associated with hepatic steatosis on ultrasonography in patients with elevated alanine aminotransferase. Sao Paulo Med J 2010;128:342-7. [DOI: 10.1590/s1516-31802010000600006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
498 Athyros VG, Giouleme O, Ganotakis ES, Elisaf M, Tziomalos K, Vassiliadis T, Liberopoulos EN, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci. 2011;7:796-805. [PMID: 22291824 DOI: 10.5114/aoms.2011.25554] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
499 Tor J, Muga R. El hígado graso y el síndrome metabólico. Medicina Clínica 2013;141:252-3. [DOI: 10.1016/j.medcli.2013.02.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
500 Paschos P, Tziomalos K. Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol 2012; 4(12): 327-331 [PMID: 23355909 DOI: 10.4254/wjh.v4.i12.327] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 4.7] [Reference Citation Analysis]
501 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016;59:1121-40. [DOI: 10.1007/s00125-016-3902-y] [Cited by in Crossref: 206] [Cited by in F6Publishing: 186] [Article Influence: 34.3] [Reference Citation Analysis]
502 Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, Nitzan Kaluski D, Halpern Z, Oren R. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56:1145-1151. [PMID: 22245895 DOI: 10.1016/j.jhep.2011.12.011] [Cited by in Crossref: 148] [Cited by in F6Publishing: 137] [Article Influence: 14.8] [Reference Citation Analysis]
503 Rowell RJ, Anstee QM. An overview of the genetics, mechanisms and management of NAFLD and ALD. Clin Med (Lond). 2015;15 Suppl 6:s77-s82. [PMID: 26634687 DOI: 10.7861/clinmedicine.15-6-s77] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
504 de Alwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48 Suppl 1:S104-S112. [PMID: 18304679 DOI: 10.1016/j.jhep.2008.01.009] [Cited by in Crossref: 358] [Cited by in F6Publishing: 349] [Article Influence: 25.6] [Reference Citation Analysis]
505 Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: An update. World J Gastroenterol 2008; 14(2): 185-192 [PMID: 18186553 DOI: 10.3748/wjg.14.185] [Cited by in CrossRef: 198] [Cited by in F6Publishing: 193] [Article Influence: 14.1] [Reference Citation Analysis]
506 Sarkar S, Kumari D, Gupta SK, Sharma V, Mukhi S, Kamboj P, Sasibhushan V, Rai RK, Jatavallabhula SL, Mahajan D, Kumar Y, Kumar A, Dikshit M. Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids. Biomed Pharmacother 2021;144:112357. [PMID: 34794234 DOI: 10.1016/j.biopha.2021.112357] [Reference Citation Analysis]
507 Maglio C, Pirazzi C, Pujia A, Valenti L, Romeo S. The PNPLA3 I148M variant and chronic liver disease: When a genetic mutation meets nutrients. Food Research International 2014;63:239-43. [DOI: 10.1016/j.foodres.2014.01.055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
508 Pacifico L, Osborn JF, Bonci E, Pierimarchi P, Chiesa C. Association between Vitamin D Levels and Nonalcoholic Fatty Liver Disease: Potential Confounding Variables. Mini Rev Med Chem 2019;19:310-32. [PMID: 30360708 DOI: 10.2174/1389557518666181025153712] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
509 Lonardo A, Carani C, Carulli N, Loria P. ‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. J Hepatol. 2006;44:1196-1207. [PMID: 16618516 DOI: 10.1016/j.jhep.2006.03.005] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 5.2] [Reference Citation Analysis]
510 Ryoo JH, Choi JM, Moon SY, Suh YJ, Shin JY, Shin HC, Park SK. The clinical availability of non alcoholic fatty liver disease as an early predictor of the metabolic syndrome in Korean men: 5-year's prospective cohort study. Atherosclerosis 2013;227:398-403. [PMID: 23390894 DOI: 10.1016/j.atherosclerosis.2013.01.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
511 Xu C, Yu C, Xu L, Miao M, Li Y. High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PLoS One. 2010;5:e11578. [PMID: 20644649 DOI: 10.1371/journal.pone.0011578] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 7.3] [Reference Citation Analysis]
512 Pereira K, Salsamendi J, Casillas J. The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci 2015;5:32. [PMID: 26167390 DOI: 10.4103/2156-7514.157860] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
513 Kanuri G, Spruss A, Wagnerberger S, Bischoff SC, Bergheim I. Role of tumor necrosis factor α (TNFα) in the onset of fructose-induced nonalcoholic fatty liver disease in mice. J Nutr Biochem. 2011;22:527-534. [PMID: 20801629 DOI: 10.1016/j.jnutbio.2010.04.007] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 6.5] [Reference Citation Analysis]
514 Choe EY, Lee YH, Choi YJ, Huh BW, Lee BW, Kim SK, Kang ES, Cha BS, Lee EJ, Huh KB, Younossi ZM. Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes. J Gastroenterol Hepatol 2018;33:1082-91. [PMID: 28990251 DOI: 10.1111/jgh.14011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
515 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 178] [Article Influence: 16.3] [Reference Citation Analysis]
516 Manco M, Marcellini M, Devito R, Comparcola D, Sartorelli MR, Nobili V. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis. Int J Obes (Lond). 2008;32:381-387. [PMID: 18087267 DOI: 10.1038/sj.ijo.0803711] [Cited by in Crossref: 117] [Cited by in F6Publishing: 100] [Article Influence: 7.8] [Reference Citation Analysis]
517 Dai H, Wang W, Chen R, Chen Z, Lu Y, Yuan H. Lipid accumulation product is a powerful tool to predict non-alcoholic fatty liver disease in Chinese adults. Nutr Metab (Lond). 2017;14:49. [PMID: 28775758 DOI: 10.1186/s12986-017-0206-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]
518 Song C, Shi J, Zeng X, Zhang Y, Xie W, Chen Y. Sophocarpine alleviates hepatocyte steatosis through activating AMPK signaling pathway. Toxicology in Vitro 2013;27:1065-71. [DOI: 10.1016/j.tiv.2013.01.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
519 Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011;54:463-471. [PMID: 21538440 DOI: 10.1002/hep.24397] [Cited by in Crossref: 338] [Cited by in F6Publishing: 357] [Article Influence: 30.7] [Reference Citation Analysis]
520 Foschi FG, Bedogni G, Domenicali M, Giacomoni P, Dall'Aglio AC, Dazzani F, Lanzi A, Conti F, Savini S, Saini G, Bernardi M, Andreone P, Gastaldelli A, Casadei Gardini A, Tiribelli C, Bellentani S, Stefanini GF. Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. BMC Gastroenterol 2018;18:177. [PMID: 30486798 DOI: 10.1186/s12876-018-0906-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
521 Hu X, Huang Y, Bao Z, Wang Y, Shi D, Liu F, Gao Z, Yu X. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterol. 2012;12:123. [PMID: 22978800 DOI: 10.1186/1471-230x-12-123] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
522 Wu W, Liu X, Peng X, Xue R, Ji L, Shen X, Chen S, Gu J, Zhang S. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun 2014;448:50-5. [PMID: 24747563 DOI: 10.1016/j.bbrc.2014.04.048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
523 Chon CW, Kim BS, Cho YK, Sung KC, Bae JC, Kim TW, Won HS, Joo KJ. Effect of nonalcoholic Fatty liver disease on the development of type 2 diabetes in nonobese, nondiabetic korean men. Gut Liver. 2012;6:368-373. [PMID: 22844567 DOI: 10.5009/gnl.2012.6.3.368] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
524 Grattagliano I, Montezinho LP, Oliveira PJ, Frühbeck G, Gómez-Ambrosi J, Montecucco F, Carbone F, Wieckowski MR, Wang DQ, Portincasa P. Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease. Biochem Pharmacol 2019;160:34-45. [PMID: 30508523 DOI: 10.1016/j.bcp.2018.11.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
525 Levene AP, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology. 2012;61:141-152. [PMID: 22372457 DOI: 10.1111/j.1365-2559.2011.04145.x] [Cited by in Crossref: 114] [Cited by in F6Publishing: 108] [Article Influence: 11.4] [Reference Citation Analysis]
526 Williams R. Global challenges in liver disease. Hepatology 2006;44:521-6. [DOI: 10.1002/hep.21347] [Cited by in Crossref: 492] [Cited by in F6Publishing: 475] [Article Influence: 30.8] [Reference Citation Analysis]
527 Abd El Moety HA, Maharem DA, Gomaa SH. Serotonin: is it a marker for the diagnosis of hepatocellular carcinoma in cirrhotic patients? Alexandria Journal of Medicine 2013;49:369-78. [DOI: 10.1016/j.ajme.2013.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
528 Nah EH, Cho S, Park H, Noh D, Kwon E, Cho HI. Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study. PLoS One 2021;16:e0260477. [PMID: 34818372 DOI: 10.1371/journal.pone.0260477] [Reference Citation Analysis]
529 Hejlova I, Honsova E, Sticova E, Lanska V, Hucl T, Spicak J, Jirsa M, Trunecka P. Prevalence and risk factors of steatosis after liver transplantation and patient outcomes. Liver Transpl. 2016;22:644-655. [PMID: 26707008 DOI: 10.1002/lt.24393] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
530 DeLegge MH. Recruitment and Retention of Patients for Nonalcoholic Steatohepatitis Clinical Trials. Gastroenterol Clin North Am 2020;49:123-40. [PMID: 32033759 DOI: 10.1016/j.gtc.2019.09.006] [Reference Citation Analysis]
531 Bieghs V, Verheyen F, van Gorp PJ, Hendrikx T, Wouters K, Lütjohann D, Gijbels MJ, Febbraio M, Binder CJ, Hofker MH. Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells. PLoS One. 2012;7:e34378. [PMID: 22470565 DOI: 10.1371/journal.pone.0034378] [Cited by in Crossref: 75] [Cited by in F6Publishing: 78] [Article Influence: 7.5] [Reference Citation Analysis]
532 Lad A, Su RC, Breidenbach JD, Stemmer PM, Carruthers NJ, Sanchez NK, Khalaf FK, Zhang S, Kleinhenz AL, Dube P, Mohammed CJ, Westrick JA, Crawford EL, Palagama D, Baliu-Rodriguez D, Isailovic D, Levison B, Modyanov N, Gohara AF, Malhotra D, Haller ST, Kennedy DJ. Chronic Low Dose Oral Exposure to Microcystin-LR Exacerbates Hepatic Injury in a Murine Model of Non-Alcoholic Fatty Liver Disease. Toxins (Basel) 2019;11:E486. [PMID: 31450746 DOI: 10.3390/toxins11090486] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
533 An YM, Jun DW, Lee SM. Development and Application of Low-Carbohydrates and Low-Simple Sugar Nutrition Education Materials for Non-Alcoholic Fatty Liver Disease Patients. Clin Nutr Res 2015;4:250-8. [PMID: 26566520 DOI: 10.7762/cnr.2015.4.4.250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
534 Yang H, Li D, Song X, Liu F, Wang X, Ma Q, Zhang X, Li X. Joint associations of serum uric acid and ALT with NAFLD in elderly men and women: a Chinese cross-sectional study. J Transl Med 2018;16:285. [PMID: 30333032 DOI: 10.1186/s12967-018-1657-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
535 Liu J, Xu C, Ying L, Zang S, Zhuang Z, Lv H, Yang W, Luo Y, Ma X, Wang L. Relationship of serum uric acid level with non-alcoholic fatty liver disease and its inflammation progression in non-obese adults. Hepatol Res. 2017;47:E104-E112. [PMID: 27172177 DOI: 10.1111/hepr.12734] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
536 Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A. Microbiota and nonalcoholic steatohepatitis. Semin Immunopathol. 2014;36:115-132. [PMID: 24337650 DOI: 10.1007/s00281-013-0404-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
537 Al-Okbi SY, Mohamed DA, Hamed TE, Edris AE. Protective effect of clove oil and eugenol microemulsions on fatty liver and dyslipidemia as components of metabolic syndrome. J Med Food 2014;17:764-71. [PMID: 24611461 DOI: 10.1089/jmf.2013.0033] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
538 Jirapatnakul A, Reeves AP, Lewis S, Chen X, Ma T, Yip R, Chin X, Liu S, Perumalswami PV, Yankelevitz DF, Crane M, Branch AD, Henschke CI. Automated measurement of liver attenuation to identify moderate-to-severe hepatic steatosis from chest CT scans. Eur J Radiol 2020;122:108723. [PMID: 31778964 DOI: 10.1016/j.ejrad.2019.108723] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
539 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 605] [Article Influence: 53.1] [Reference Citation Analysis]
540 Simo KA, McKillop IH, McMillan MT, Ahrens WA, Walters AL, Thompson KJ, Kuwada TS, Martinie JB, Iannitti DA, Gersin KS, Sindram D. Does a calculated "NAFLD fibrosis score" reliably negate the need for liver biopsy in patients undergoing bariatric surgery? Obes Surg. 2014;24:15-21. [PMID: 23934335 DOI: 10.1007/s11695-013-1044-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
541 Huh JH, Kim JY, Choi E, Kim JS, Chang Y, Sung KC. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. PLoS One. 2017;12:e0180951. [PMID: 28738057 DOI: 10.1371/journal.pone.0180951] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
542 de Castro GS, Calder PC. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. Clinical Nutrition 2018;37:37-55. [DOI: 10.1016/j.clnu.2017.01.006] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 13.8] [Reference Citation Analysis]
543 Huh JH, Kim KJ, Kim SU, Han SH, Han K, Cha B, Chung CH, Lee B. Obesity is more closely related with hepatic steatosis and fibrosis measured by transient elastography than metabolic health status. Metabolism 2017;66:23-31. [DOI: 10.1016/j.metabol.2016.10.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
544 Paquette M, Bernard S. The Evolving Story of Multifactorial Chylomicronemia Syndrome. Front Cardiovasc Med 2022;9:886266. [DOI: 10.3389/fcvm.2022.886266] [Reference Citation Analysis]
545 Kechagias S, Zanjani S, Gjellan S, Leinhard OD, Kihlberg J, Smedby O, Johansson L, Kullberg J, Ahlström H, Lindström T. Effects of moderate red wine consumption on liver fat and blood lipids: a prospective randomized study. Ann Med. 2011;43:545-554. [PMID: 21599573 DOI: 10.3109/07853890.2011.588246] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
546 Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48:97-113. [PMID: 21875310 DOI: 10.3109/10408363.2011.596521] [Cited by in Crossref: 183] [Cited by in F6Publishing: 171] [Article Influence: 16.6] [Reference Citation Analysis]
547 Guo XF, Gao JL, Li JM, Li D. fat-1 mice prevent high-fat plus high-sugar diet-induced non-alcoholic fatty liver disease. Food Funct 2017;8:4053-61. [PMID: 28972610 DOI: 10.1039/c7fo01050h] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
548 Petta S, Di Marco V, Pipitone RM, Grimaudo S, Buscemi C, Craxì A, Buscemi S. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population. Liver Int 2018;38:2060-8. [DOI: 10.1111/liv.13743] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
549 Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51:1947-1953. [PMID: 18762907 DOI: 10.1007/s00125-008-1135-4] [Cited by in Crossref: 256] [Cited by in F6Publishing: 243] [Article Influence: 18.3] [Reference Citation Analysis]
550 Liu JQ, Zhang ZJ, Wang W, Lin KR, Liu G, Jiang CS, Chen ZP, Li HT, Lin WL. Risk factors for non-alcoholic fatty liver disease combined with type 2 diabetes mellitus in adolescents. Shijie Huaren Xiaohua Zazhi 2015; 23(11): 1812-1817 [DOI: 10.11569/wcjd.v23.i11.1812] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
551 Kuk JL, Saunders TJ, Davidson LE, Ross R. Age-related changes in total and regional fat distribution. Ageing Res Rev 2009;8:339-48. [PMID: 19576300 DOI: 10.1016/j.arr.2009.06.001] [Cited by in Crossref: 345] [Cited by in F6Publishing: 325] [Article Influence: 26.5] [Reference Citation Analysis]
552 Loria P, Lonardo A, Bellentani S, Day CP, Marchesini G, Carulli N. Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question. Nutr Metab Cardiovasc Dis. 2007;17:684-698. [PMID: 17560098 DOI: 10.1016/j.numecd.2007.01.007] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
553 Molnar MZ, Joglekar K, Jiang Y, Cholankeril G, Abdul MKM, Kedia S, Gonzalez HC, Ahmed A, Singal A, Bhamidimarri KR, Aithal GP, Duseja A, Wong VW, Gulnare A, Puri P, Nair S, Eason JD, Satapathy SK;  Global NAFLD Consortium. Association of Pretransplant Renal Function With Liver Graft and Patient Survival After Liver Transplantation in Patients With Nonalcoholic Steatohepatitis. Liver Transpl. 2019;25:399-410. [PMID: 30369023 DOI: 10.1002/lt.25367] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
554 Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis. 2017;49:471-483. [PMID: 28215516 DOI: 10.1016/j.dld.2017.01.147] [Cited by in Crossref: 161] [Cited by in F6Publishing: 152] [Article Influence: 32.2] [Reference Citation Analysis]
555 van Eekelen E, Beulens JWJ, Geelen A, Schrauwen-Hinderling VB, Lamb H, de Roos A, Rosendaal F, de Mutsert R. Consumption of Alcoholic and Sugar-Sweetened Beverages is Associated with Increased Liver Fat Content in Middle-Aged Men and Women. J Nutr 2019;149:649-58. [PMID: 30949667 DOI: 10.1093/jn/nxy313] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
556 Miele L, Vallone S, Cefalo C, La Torre G, Di Stasi C, Vecchio FM, D’Agostino M, Gabrieli ML, Vero V, Biolato M. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778-786. [PMID: 19664838 DOI: 10.1016/j.jhep.2009.06.008] [Cited by in Crossref: 128] [Cited by in F6Publishing: 112] [Article Influence: 9.8] [Reference Citation Analysis]
557 Tsai E, Lee TP. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2018;22:73-92. [PMID: 29128062 DOI: 10.1016/j.cld.2017.08.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
558 Carvalhana S, Machado MV, Cortez-Pinto H. Improving dietary patterns in patients with nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2012;15:468-473. [PMID: 22878240 DOI: 10.1097/mco.0b013e3283566614] [Cited by in Crossref: 30] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
559 Sert A, Pirgon O, Aypar E, Yılmaz H, Dündar B. Relationship between aspartate aminotransferase-to-platelet ratio index and carotid intima-media thickness in obese adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol 2013;5:182-8. [PMID: 24072087 DOI: 10.4274/Jcrpe.891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
560 Marjot T, Sbardella E, Moolla A, Hazlehurst JM, Tan GD, Ainsworth M, Cobbold JFL, Tomlinson JW. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital. Diabet Med 2018;35:89-98. [DOI: 10.1111/dme.13540] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
561 Pirazzi C, Adiels M, Burza MA, Mancina RM, Levin M, Ståhlman M, Taskinen M, Orho-melander M, Perman J, Pujia A, Andersson L, Maglio C, Montalcini T, Wiklund O, Borén J, Romeo S. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. Journal of Hepatology 2012;57:1276-82. [DOI: 10.1016/j.jhep.2012.07.030] [Cited by in Crossref: 174] [Cited by in F6Publishing: 170] [Article Influence: 17.4] [Reference Citation Analysis]
562 Szanto KB, Li J, Cordero P, Oben JA. Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019;12:357-367. [PMID: 30936733 DOI: 10.2147/dmso.s182331] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
563 Lee Y, Lee H, Shim J, Moon B, Lee J, Kim J. Relationship between white blood cell count and nonalcoholic fatty liver disease. Digestive and Liver Disease 2010;42:888-94. [DOI: 10.1016/j.dld.2010.04.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
564 Tamaki Y, Nakade Y, Yamauchi T, Makino Y, Yokohama S, Okada M, Aso K, Kanamori H, Ohashi T, Sato K, Nakao H, Haneda M, Yoneda M. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol. 2013;48:491-503. [PMID: 22886508 DOI: 10.1007/s00535-012-0651-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
565 Blonsky JJ, Harrison SA. Review article: nonalcoholic fatty liver disease and hepatitis C virus--partners in crime. Aliment Pharmacol Ther 2008;27:855-65. [PMID: 18315584 DOI: 10.1111/j.1365-2036.2008.03672.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
566 Li L, Zhang GF, Lee K, Lopez R, Previs SF, Willard B, McCullough A, Kasumov T. A Western diet induced NAFLD in LDLR(-/)(-) mice is associated with reduced hepatic glutathione synthesis. Free Radic Biol Med 2016;96:13-21. [PMID: 27036364 DOI: 10.1016/j.freeradbiomed.2016.03.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
567 Xu L, Duanmu Y, Blake GM, Zhang C, Zhang Y, Brown K, Wang X, Wang P, Zhou X, Zhang M, Wang C, Guo Z, Guglielmi G, Cheng X. Validation of goose liver fat measurement by QCT and CSE-MRI with biochemical extraction and pathology as reference. Eur Radiol 2018;28:2003-12. [PMID: 29238866 DOI: 10.1007/s00330-017-5189-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
568 Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J, Foster GR. Ethnicity and the diagnosis gap in liver disease: a population-based study. Br J Gen Pract 2014;64:e694-702. [PMID: 25348993 DOI: 10.3399/bjgp14X682273] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
569 Wang Y, Li YY, Nie YQ, Zhou YJ, Cao CY, Xu L. Association between metabolic syndrome and the development of non-alcoholic fatty liver disease. Exp Ther Med 2013;6:77-84. [PMID: 23935723 DOI: 10.3892/etm.2013.1090] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
570 Barbieri M, Esposito A, Angellotti E, Rizzo MR, Marfella R, Paolisso G. Association of genetic variation in adaptor protein APPL1/APPL2 loci with non-alcoholic fatty liver disease. PLoS One 2013;8:e71391. [PMID: 23977033 DOI: 10.1371/journal.pone.0071391] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
571 Lonardo A, Lombardini S, Scaglioni F, Ballestri S, Verrone AM, Bertolotti M, Carulli L, Ganazzi D, Carulli N, Loria P. Fatty liver, carotid disease and gallstones: A study of age-related associations. World J Gastroenterol 2006; 12(36): 5826-5833 [PMID: 17007049 DOI: 10.3748/wjg.v12.i36.5826] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
572 Patell R, Dosi R, Joshi H, Sheth S, Shah P, Jasdanwala S. Non-Alcoholic Fatty Liver Disease (NAFLD) in Obesity. J Clin Diagn Res 2014;8:62-6. [PMID: 24596725 DOI: 10.7860/JCDR/2014/6691.3953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
573 Ferreira VS, Pernambuco RB, Lopes EP, Morais CN, Rodrigues MC, Arruda MJ, Silva LM, Vilar L. Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol. 2010;54:362-368. [PMID: 20625647 DOI: 10.1590/s0004-27302010000400004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
574 Kanuri G, Landmann M, Priebs J, Spruss A, Löscher M, Ziegenhardt D, Röhl C, Degen C, Bergheim I. Moderate alcohol consumption diminishes the development of non-alcoholic fatty liver disease (NAFLD) in ob/ob mice. Eur J Nutr 2016;55:1153-64. [PMID: 26003186 DOI: 10.1007/s00394-015-0929-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
575 Almanza D, Gharaee-Kermani M, Zhilin-Roth A, Rodriguez-Nieves JA, Colaneri C, Riley T, Macoska JA. Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular Signature. Dig Dis Sci 2019;64:1257-69. [PMID: 30519850 DOI: 10.1007/s10620-018-5398-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
576 Porter SA, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Fox CS. Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2013;33:139-46. [PMID: 23162012 DOI: 10.1161/ATVBAHA.112.300075] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
577 Hu Z, Mei S, Xiang J, Zhou J, Li Z, Zhou L, Yan S, Wang W, Zheng S. Survival rates after liver transplantation using hypertensive donor grafts: an analysis of the Scientific Registry of Transplant Recipients database. J Hepatobiliary Pancreat Sci 2017;24:441-8. [PMID: 28544515 DOI: 10.1002/jhbp.466] [Reference Citation Analysis]
578 Tsai SF, Hung HC, Shih MM, Chang FC, Chung BC, Wang CY, Lin YL, Kuo YM. High-fat diet-induced increases in glucocorticoids contribute to the development of non-alcoholic fatty liver disease in mice. FASEB J 2022;36:e22130. [PMID: 34959259 DOI: 10.1096/fj.202101570R] [Reference Citation Analysis]
579 Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med. 2010;48:175-180. [PMID: 19961393 DOI: 10.1515/CCLM.2010.037] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
580 Varela-Rey M, Embade N, Ariz U, Lu SC, Mato JM, Martínez-Chantar ML. Non-alcoholic steatohepatitis and animal models: understanding the human disease. Int J Biochem Cell Biol. 2009;41:969-976. [PMID: 19027869 DOI: 10.1016/j.biocel.2008.10.027] [Cited by in Crossref: 83] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
581 Kahl S, Straßburger K, Nowotny B, Livingstone R, Klüppelholz B, Keßel K, Hwang JH, Giani G, Hoffmann B, Pacini G. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One. 2014;9:e94059. [PMID: 24732091 DOI: 10.1371/journal.pone.0094059] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 9.4] [Reference Citation Analysis]
582 Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93:S74-S80. [PMID: 18987273 DOI: 10.1210/jc.2008-1399] [Cited by in Crossref: 176] [Cited by in F6Publishing: 167] [Article Influence: 13.5] [Reference Citation Analysis]
583 Seki K, Kitade M, Nishimura N, Kaji K, Asada K, Namisaki T, Moriya K, Kawaratani H, Okura Y, Takaya H, Sawada Y, Sato S, Nakanishi K, Yoshiji H. Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model. Oncotarget 2018;9:28638-51. [PMID: 29983886 DOI: 10.18632/oncotarget.25587] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
584 Verbeek J, Jacobs A, Spincemaille P, Cassiman D. Development of a Representative Mouse Model with Nonalcoholic Steatohepatitis. Curr Protoc Mouse Biol 2016;6:201-10. [PMID: 27248435 DOI: 10.1002/cpmo.1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
585 Zhou YJ, Li YY, Nie YQ, Ma JX, Lu LG, Shi SL, Chen MH, Hu PJ. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol. 2007;13:6419-6424. [PMID: 18081233 DOI: org/10.3748/wjg.13.6419] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
586 Ruhl CE, Everhart JE. Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther. 2015;41:65-76. [PMID: 25376360 DOI: 10.1111/apt.13012] [Cited by in Crossref: 110] [Cited by in F6Publishing: 111] [Article Influence: 13.8] [Reference Citation Analysis]
587 Tobin D, Brevik-Andersen M, Qin Y, Innes JK, Calder PC. Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN). Nutrients 2018;10:E1126. [PMID: 30127297 DOI: 10.3390/nu10081126] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
588 Sartorio A, Del Col A, Agosti F, Mazzilli G, Bellentani S, Tiribelli C, Bedogni G. Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr. 2007;61:877-883. [PMID: 17151586 DOI: 10.1038/sj.ejcn.1602588] [Cited by in Crossref: 114] [Cited by in F6Publishing: 112] [Article Influence: 7.1] [Reference Citation Analysis]
589 Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17:863-869. [PMID: 17728149 DOI: 10.1016/j.annepidem.2007.05.013] [Cited by in Crossref: 197] [Cited by in F6Publishing: 191] [Article Influence: 13.1] [Reference Citation Analysis]
590 Unalp-Arida A, Ruhl CE. Noninvasive fatty liver markers predict liver disease mortality in the U.S. population. Hepatology 2016;63:1170-83. [PMID: 26663021 DOI: 10.1002/hep.28390] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 7.5] [Reference Citation Analysis]
591 Ryoo JH, Ham WT, Choi JM, Kang MA, An SH, Lee JK, Shin HC, Park SK. Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension. J Korean Med Sci 2014;29:973-9. [PMID: 25045230 DOI: 10.3346/jkms.2014.29.7.973] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
592 Kosters A, Sun D, Wu H, Tian F, Felix JC, Li W, Karpen SJ. Sexually dimorphic genome-wide binding of retinoid X receptor alpha (RXRα) determines male-female differences in the expression of hepatic lipid processing genes in mice. PLoS One 2013;8:e71538. [PMID: 23977068 DOI: 10.1371/journal.pone.0071538] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
593 Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, Mancini A. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biol 2018;15:467-79. [PMID: 29413959 DOI: 10.1016/j.redox.2018.01.009] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 20.3] [Reference Citation Analysis]
594 Sulaiman SA, Muhsin NIA, Jamal R. Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease. Front Physiol 2019;10:279. [PMID: 30941061 DOI: 10.3389/fphys.2019.00279] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
595 Patel KD, Abeysekera KW, Marlais M, Mcphail MJ, Thomas HC, Fitzpatrick JA, Lim AK, Taylor-robinson SD, Thomas EL. Recent advances in imaging hepatic fibrosis and steatosis. Expert Review of Gastroenterology & Hepatology 2014;5:91-104. [DOI: 10.1586/egh.10.85] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
596 Hsu CL, Wu FZ, Lin KH, Chen YH, Wu PC, Chen YH, Chen CS, Wang WH, Mar GY, Yu HC. Role of Fatty Liver Index and Metabolic Factors in the Prediction of Nonalcoholic Fatty Liver Disease in a Lean Population Receiving Health Checkup. Clin Transl Gastroenterol. 2019;10:1-8. [PMID: 31082856 DOI: 10.14309/ctg.0000000000000042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
597 Lu H, Liu H, Hu F, Zou L, Luo S, Sun L. Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis. Int J Endocrinol 2013;2013:124958. [PMID: 23690766 DOI: 10.1155/2013/124958] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
598 Jeong SK, Kim YK, Park JW, Shin YJ, Kim DS. Impact of visceral fat on the metabolic syndrome and nonalcoholic fatty liver disease. J Korean Med Sci. 2008;23:789-795. [PMID: 18955783 DOI: 10.3346/jkms.2008.23.5.789] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
599 Liao YJ, Chen TL, Lee TS, Wang HA, Wang CK, Liao LY, Liu RS, Huang SF, Chen YM. Glycine N-methyltransferase deficiency affects Niemann-Pick type C2 protein stability and regulates hepatic cholesterol homeostasis. Mol Med 2012;18:412-22. [PMID: 22183894 DOI: 10.2119/molmed.2011.00258] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
600 Híndi M, Levy C, Couto CA, Bejarano P, Mendes F. Primary biliary cirrhosis is more severe in overweight patients. J Clin Gastroenterol. 2013;47:e28-e32. [PMID: 23059407 DOI: 10.1097/mcg.0b013e318261e659] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
601 Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, Valenti L, Maraschi A, Catapano A, Fargion S. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med. 2008;121:72-78. [PMID: 18187076 DOI: 10.1016/j.amjmed.2007.08.041] [Cited by in Crossref: 144] [Cited by in F6Publishing: 141] [Article Influence: 10.3] [Reference Citation Analysis]
602 Nie J, Li CP. Mechanisms of microRNAs in regulation of apoptosis in non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2015; 23(15): 2389-2396 [DOI: 10.11569/wcjd.v23.i15.2389] [Reference Citation Analysis]
603 Sherif ZA, Saeed A, Ghavimi S, Nouraie SM, Laiyemo AO, Brim H, Ashktorab H. Global Epidemiology of Nonalcoholic Fatty Liver Disease and Perspectives on US Minority Populations. Dig Dis Sci. 2016;61:1214-1225. [PMID: 27038448 DOI: 10.1007/s10620-016-4143-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 13.8] [Reference Citation Analysis]
604 Xu M, Ge C, Qin Y, Gu T, Lv J, Wang S, Ma Y, Lou D, Li Q, Hu L, Nie X, Wang M, Huang P, Tan J. Activated TNF-α/RIPK3 signaling is involved in prolonged high fat diet-stimulated hepatic inflammation and lipid accumulation: inhibition by dietary fisetin intervention. Food Funct 2019;10:1302-16. [DOI: 10.1039/c8fo01615a] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 5.7] [Reference Citation Analysis]
605 Moseley RH. Therapy for nonalcoholic fatty liver disease. J Clin Gastroenterol 2008;42:332-5. [PMID: 18277910 DOI: 10.1097/MCG.0b013e31815e4079] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
606 Hübscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006;49:450-465. [PMID: 17064291 DOI: 10.1111/j.1365-2559.2006.02416.x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 168] [Article Influence: 11.3] [Reference Citation Analysis]
607 Lim LG, Cheng CL, Wee A, Lim SG, Lee YM, Sutedja DS, Da Costa M, Prabhakaran K, Wai CT. Prevalence and clinical associations of posttransplant fatty liver disease. Liver Int. 2007;27:76-80. [PMID: 17241384 DOI: 10.1111/j.1478-3231.2006.01396.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.2] [Reference Citation Analysis]
608 Kurek K, Piotrowska DM, Wiesiołek-Kurek P, Łukaszuk B, Chabowski A, Górski J, Zendzian-Piotrowska M. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver Int 2014;34:1074-83. [PMID: 24106929 DOI: 10.1111/liv.12331] [Cited by in Crossref: 81] [Cited by in F6Publishing: 84] [Article Influence: 9.0] [Reference Citation Analysis]
609 Bhatia H, Verma G, Datta M. miR-107 orchestrates ER stress induction and lipid accumulation by post-transcriptional regulation of fatty acid synthase in hepatocytes. Biochim Biophys Acta. 2014;1839:334-343. [PMID: 24560669 DOI: 10.1016/j.bbagrm.2014.02.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
610 Mosallaei Z, Mazidi M, Safariyan M, Norouzy A, Mohajeri SAR, Esmaily H, Bahari A, Ghayour-mobarhan M, Nematy M. Dietary intake and its relationship with non-alcoholic fatty liver disease (NAFLD). MNM 2015;8:139-48. [DOI: 10.3233/mnm-150032] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
611 Ayonrinde OT, Oddy WH, Adams LA, Mori TA, Beilin LJ, de Klerk N, Olynyk JK. Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents. Journal of Hepatology 2017;67:568-76. [DOI: 10.1016/j.jhep.2017.03.029] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 9.6] [Reference Citation Analysis]
612 Wei S, Qiu T, Wang N, Yao X, Jiang L, Jia X, Tao Y, Zhang J, Zhu Y, Yang G, Liu X, Liu S, Sun X. Ferroptosis mediated by the interaction between Mfn2 and IREα promotes arsenic-induced nonalcoholic steatohepatitis. Environmental Research 2020;188:109824. [DOI: 10.1016/j.envres.2020.109824] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
613 Xing J, Guan X, Zhang Q, Chen S, Wu S, Sun X. Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study. Obes Facts 2021;14:190-6. [PMID: 33780962 DOI: 10.1159/000514848] [Reference Citation Analysis]
614 Zhou YG, Tian N, Xie WN. Total cholesterol to high-density lipoprotein ratio and nonalcoholic fatty liver disease in a population with chronic hepatitis B. World J Hepatol 2022; 14(4): 791-801 [DOI: 10.4254/wjh.v14.i4.791] [Reference Citation Analysis]
615 Nishio T, Hatano E, Sakurai T, Taura K, Okuno M, Kasai Y, Seo S, Yasuchika K, Mori A, Kaido T, Uemoto S. Impact of Hepatic Steatosis on Disease-Free Survival in Patients with Non-B Non-C Hepatocellular Carcinoma Undergoing Hepatic Resection. Ann Surg Oncol 2015;22:2226-34. [PMID: 25395147 DOI: 10.1245/s10434-014-4181-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
616 Mcavoy NC, Ferguson JW, Campbell IW, Hayes PC. Review: Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment. Diabetes & Vascular Disease 2006;6:251-60. [DOI: 10.1177/14746514060060060201] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
617 Kamimura H, Sano M, Tsujimura T, Takeda Y, Komoro Y, Yokoyama J, Terai S. Rapid Onset of Weight Gain and Liver Dysfunction Successfully Treated With Nutrition and Exercise. Cureus 2021;13:e16530. [PMID: 34430140 DOI: 10.7759/cureus.16530] [Reference Citation Analysis]
618 Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl. 2009;15:1843-1851. [PMID: 19938117 DOI: 10.1002/lt.21943] [Cited by in Crossref: 80] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
619 Turer AT, Browning JD, Ayers CR, Das SR, Khera A, Vega GL, Grundy SM, Scherer PE. Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study. J Clin Endocrinol Metab. 2012;97:E982-E986. [PMID: 22438228 DOI: 10.1210/jc.2011-3305] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
620 Briskey D, Heritage M, Jaskowski LA, Peake J, Gobe G, Subramaniam VN, Crawford D, Campbell C, Vitetta L. Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2016;9:463-72. [PMID: 27366215 DOI: 10.1177/1756283X16645055] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
621 Tien PC, Kotler DP, Overton ET, Lewis CE, Rimland D, Bacchetti P, Scherzer R, Gripshover B; Study of Fat Redistribution and Metabolic Change in HIV Infection Investigators. Regional adipose tissue and elevations in serum aminotransferases in HIV-infected individuals. J Acquir Immune Defic Syndr 2008;48:169-76. [PMID: 18285711 DOI: 10.1097/QAI.0b013e3181685700] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
622 Croci I, Byrne NM, Choquette S, Hills AP, Chachay VS, Clouston AD, O'Moore-Sullivan TM, Macdonald GA, Prins JB, Hickman IJ. Whole-body substrate metabolism is associated with disease severity in patients with non-alcoholic fatty liver disease. Gut. 2013;62:1625-1633. [PMID: 23077135 DOI: 10.1136/gutjnl-2012-302789] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
623 Parker R, Oo YH, Adams DH. Management of patients with difficult autoimmune hepatitis. Therap Adv Gastroenterol. 2012;5:421-437. [PMID: 23152735 DOI: 10.1177/1756283X12450251] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
624 Ju C, Colgan SP, Eltzschig HK. Hypoxia-inducible factors as molecular targets for liver diseases. J Mol Med (Berl). 2016;94:613-627. [PMID: 27094811 DOI: 10.1007/s00109-016-1408-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 10.8] [Reference Citation Analysis]
625 Ozutsumi T, Namisaki T, Shimozato N, Kaji K, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Nakanishi K, Sato S, Sawada Y, Saikawa S, Kitagawa K, Takaya H, Kawaratani H, Kitade M, Moriya K, Noguchi R, Akahane T, Mitoro A, Yoshiji H. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis. Int J Mol Sci 2020;21:E2164. [PMID: 32245205 DOI: 10.3390/ijms21062164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
626 Reichold A, Brenner SA, Spruss A, Förster-Fromme K, Bergheim I, Bischoff SC. Bifidobacterium adolescentis protects from the development of nonalcoholic steatohepatitis in a mouse model. J Nutr Biochem 2014;25:118-25. [PMID: 24445036 DOI: 10.1016/j.jnutbio.2013.09.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
627 Pérez-Martínez L, Pérez-Matute P, Aguilera-Lizarraga J, Rubio-Mediavilla S, Narro J, Recio E, Ochoa-Callejero L, Oteo JA, Blanco JR. Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD). J Antimicrob Chemother. 2014;69:1903-1910. [PMID: 24651825 DOI: 10.1093/jac/dku071] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
628 Cicero AF, D’Addato S, Reggi A, Marchesini G, Borghi C. Gender difference in hepatic steatosis index and lipid accumulation product ability to predict incident metabolic syndrome in the historical cohort of the Brisighella Heart Study. Metab Syndr Relat Disord. 2013;11:412-416. [PMID: 23902132 DOI: 10.1089/met.2012.0147] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
629 Na H, Baek D, Lee S, Choi Y, Cho K, Park S, Kim Y, Kim S. Predictors Related to the Non-alcoholic Fatty Liver Disease. Korean J Fam Med 2010;31:94. [DOI: 10.4082/kjfm.2010.31.2.94] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
630 Rhee E, Lee W, Cho Y, Kim B, Sung K. Hyperinsulinemia and the Development of Nonalcoholic Fatty Liver Disease in Nondiabetic Adults. The American Journal of Medicine 2011;124:69-76. [DOI: 10.1016/j.amjmed.2010.08.012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
631 Kächele M, Wolff S, Kratzer W, Haenle M, Homann J, Trischler G, Koenig W, Imhof A. Presence of fatty liver and the relationship between alcohol consumption and markers of inflammation. Mediators Inflamm 2015;2015:278785. [PMID: 25788761 DOI: 10.1155/2015/278785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
632 Cortez-pinto H, de Moura MC, Day CP. Non-alcoholic steatohepatitis: From cell biology to clinical practice. Journal of Hepatology 2006;44:197-208. [DOI: 10.1016/j.jhep.2005.09.002] [Cited by in Crossref: 139] [Cited by in F6Publishing: 129] [Article Influence: 8.7] [Reference Citation Analysis]
633 Motamed N, Khoonsari M, Panahi M, Rezaie N, Maadi M, Safarnezhad Tameshkel F, Keyvani H, Karbalaie Niya MH, Ajdarkosh H, Miri SM, Zamani F. The Incidence and Risk Factors of Non-Alcoholic Fatty Liver Disease: A Cohort Study from Iran. Hepat Mon 2020;20. [DOI: 10.5812/hepatmon.98531] [Reference Citation Analysis]
634 Sellmann C, Jin CJ, Engstler AJ, De Bandt JP, Bergheim I. Oral citrulline supplementation protects female mice from the development of non-alcoholic fatty liver disease (NAFLD). Eur J Nutr 2017;56:2519-27. [PMID: 27496089 DOI: 10.1007/s00394-016-1287-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
635 Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2011;13:692-702. [DOI: 10.1111/j.1463-1326.2011.01403.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 7.3] [Reference Citation Analysis]
636 Song L, Li Y, Qu D, Ouyang P, Ding X, Wu P, Guan Q, Yang L. The regulatory effects of phytosterol esters (PSEs) on gut flora and faecal metabolites in rats with NAFLD. Food Funct 2020;11:977-91. [PMID: 31803887 DOI: 10.1039/c9fo01570a] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
637 Yu LY, Hu KC, Liu CJ, Hung CL, Bair MJ, Chen MJ, Wang HY, Wu MS, Shih SC, Liu CC. Helicobacter pylori infection combined with non-alcoholic fatty liver disease increase the risk of atherosclerosis: Focus in carotid artery plaque. Medicine (Baltimore) 2019;98:e14672. [PMID: 30817593 DOI: 10.1097/MD.0000000000014672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
638 Sharma S, Barrett F, Adamson J, Todd A, Megson IL, Zentler-Munro PL, MacRury SM. Diabetic fatty liver disease is associated with specific changes in blood-borne markers. Diabetes Metab Res Rev 2012;28:343-8. [PMID: 22576780 DOI: 10.1002/dmrr.2269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
639 Park SK, Seo MH, Shin HC, Ryoo JH. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013;57:1378-1383. [PMID: 23213066 DOI: 10.1002/hep.26183] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 11.0] [Reference Citation Analysis]
640 Zöhrer E, Alisi A, Jahnel J, Mosca A, Della Corte C, Crudele A, Fauler G, Nobili V. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. Appl Physiol Nutr Metab 2017;42:948-54. [PMID: 28511023 DOI: 10.1139/apnm-2016-0689] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 5.4] [Reference Citation Analysis]
641 Rotundo L, Persaud A, Feurdean M, Ahlawat S, Kim HS. The Association of leptin with severity of non-alcoholic fatty liver disease: A population-based study. Clin Mol Hepatol 2018;24:392-401. [PMID: 30068065 DOI: 10.3350/cmh.2018.0011] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
642 Bedogni G, Gastaldelli A, Manco M, De Col A, Agosti F, Tiribelli C, Sartorio A. Relationship between fatty liver and glucose metabolism: a cross-sectional study in 571 obese children. Nutr Metab Cardiovasc Dis. 2012;22:120-126. [PMID: 20880682 DOI: 10.1016/j.numecd.2010.05.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
643 Miyake T, Kumagi T, Hirooka M, Koizumi M, Furukawa S, Ueda T, Tokumoto Y, Ikeda Y, Abe M, Kitai K. Metabolic markers and ALT cutoff level for diagnosing nonalcoholic fatty liver disease: a community-based cross-sectional study. J Gastroenterol. 2012;47:696-703. [PMID: 22331365 DOI: 10.1007/s00535-012-0534-y] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
644 Riley P, O'Donohue J, Crook M. A growing burden: the pathogenesis, investigation and management of non-alcoholic fatty liver disease. J Clin Pathol 2007;60:1384-91. [PMID: 17483247 DOI: 10.1136/jcp.2006.044891] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
645 Sagawa H, Naiki-Ito A, Kato H, Naiki T, Yamashita Y, Suzuki S, Sato S, Shiomi K, Kato A, Kuno T, Matsuo Y, Kimura M, Takeyama H, Takahashi S. Connexin 32 and luteolin play protective roles in non-alcoholic steatohepatitis development and its related hepatocarcinogenesis in rats. Carcinogenesis 2015;36:1539-49. [PMID: 26494227 DOI: 10.1093/carcin/bgv143] [Cited by in Crossref: 6] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
646 Nocito A, Dahm F, Jochum W, Jang JH, Georgiev P, Bader M, Renner EL, Clavien P. Serotonin Mediates Oxidative Stress and Mitochondrial Toxicity in a Murine Model of Nonalcoholic Steatohepatitis. Gastroenterology 2007;133:608-18. [DOI: 10.1053/j.gastro.2007.05.019] [Cited by in Crossref: 101] [Cited by in F6Publishing: 98] [Article Influence: 6.7] [Reference Citation Analysis]
647 Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO)., Members of the guidelines panel., Coordinator., AISF Members., SID Members., SIO Members., Metodologists. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Nutr Metab Cardiovasc Dis 2022;32:1-16. [PMID: 34924246 DOI: 10.1016/j.numecd.2021.04.028] [Reference Citation Analysis]
648 Yang JW, Ji HF. Phytosterols as bioactive food components against nonalcoholic fatty liver disease. Crit Rev Food Sci Nutr 2021;:1-12. [PMID: 34871105 DOI: 10.1080/10408398.2021.2006137] [Reference Citation Analysis]
649 Cho HC. Prevalence and Factors Associated with Nonalcoholic Fatty Liver Disease in a Nonobese Korean Population. Gut Liver. 2016;10:117-125. [PMID: 26260755 DOI: 10.5009/gnl14444] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
650 Zhu JZ, Dai YN, Wang YM, Zhou QY, Yu CH, Li YM. Prevalence of Nonalcoholic Fatty Liver Disease and Economy. Dig Dis Sci 2015;60:3194-202. [PMID: 26017679 DOI: 10.1007/s10620-015-3728-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 7.9] [Reference Citation Analysis]
651 Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia. 2008;51:1781-1789. [PMID: 18726585 DOI: 10.1007/s00125-008-1116-7] [Cited by in Crossref: 158] [Cited by in F6Publishing: 133] [Article Influence: 11.3] [Reference Citation Analysis]
652 Caballería Rovira L, Torán Montserrat P, Auladell Llorens MA, Pera Blanco G. [Non-alcoholic hepatic steatosis. An update]. Aten Primaria 2008;40:419-24. [PMID: 18755103 DOI: 10.1157/13125408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
653 Nah EH, Park JY. Metabolic Characteristics and Associated Factors of Nonalcoholic Fatty Liver Disease Diagnosed at Medical Checkups. Ann Lab Med 2008;28:244-50. [DOI: 10.3343/kjlm.2008.28.3.244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
654 Sonmez A, Dogru T, Ercin CN, Genc H, Celebi G, Gurel H, Tapan S, Cicek AF, Barcin C, Haymana C, Kirik A, Rizzo M. Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease. Metabolites 2021;11:425. [PMID: 34203342 DOI: 10.3390/metabo11070425] [Reference Citation Analysis]
655 Gou XJ, Gao S, Chen L, Feng Q, Hu YY. A Metabolomic Study on the Intervention of Traditional Chinese Medicine Qushi Huayu Decoction on Rat Model of Fatty Liver Induced by High-Fat Diet. Biomed Res Int 2019;2019:5920485. [PMID: 30881991 DOI: 10.1155/2019/5920485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
656 Graffy PM, Pickhardt PJ. Quantification of hepatic and visceral fat by CT and MR imaging: relevance to the obesity epidemic, metabolic syndrome and NAFLD. Br J Radiol 2016;89:20151024. [PMID: 26876880 DOI: 10.1259/bjr.20151024] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
657 Sirota JC, McFann K, Targher G, Chonchol M, Jalal DI. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol. 2012;36:466-471. [PMID: 23128368 DOI: 10.1159/000343885] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
658 Liu Q, Pan R, Ding L, Zhang F, Hu L, Ding B, Zhu L, Xia Y, Dou X. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries. Int Immunopharmacol 2017;49:132-41. [PMID: 28577437 DOI: 10.1016/j.intimp.2017.05.026] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
659 Marchesini G, Marzocchi R. Metabolic Syndrome and NASH. Clin Liver Dis. 2007;11:105-117, ix. [PMID: 17544974 DOI: 10.1016/j.cld.2007.02.013] [Cited by in Crossref: 79] [Cited by in F6Publishing: 80] [Article Influence: 5.3] [Reference Citation Analysis]
660 Mehta SR. Advances in the treatment of nonalcoholic fatty liver disease. Ther Adv Endocrinol Metab. 2010;1:101-115. [PMID: 23148155 DOI: 10.1177/2042018810379587] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
661 Rados I, Badzek S, Golem H, Prejac J, Gorsic I, Kekez D, Librenjak N, Plestina S. Successful resection of hepatocellular cancer not amenable to Milan criteria and durable complete remission induced by systemic polichemotherapy after development of metastases - should we think about revising the current treatment guidelines in selected patients? World J Surg Oncol 2013;11:236. [PMID: 24053590 DOI: 10.1186/1477-7819-11-236] [Reference Citation Analysis]
662 Phan H, Richard A, Lazo M, Nelson WG, Denmeade SR, Groopman J, Kanarek N, Platz EA, Rohrmann S. The association of sex steroid hormone concentrations with non-alcoholic fatty liver disease and liver enzymes in US men. Liver Int 2021;41:300-10. [PMID: 32860311 DOI: 10.1111/liv.14652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
663 Petta S, Marrone O, Torres D, Buttacavoli M, Cammà C, Di Marco V, Licata A, Lo Bue A, Parrinello G, Pinto A, Salvaggio A, Tuttolomondo A, Craxì A, Bonsignore MR. Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. PLoS One 2015;10:e0142210. [PMID: 26672595 DOI: 10.1371/journal.pone.0142210] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
664 Li W, Zhu X, Song Y, Fan L, Wu L, Kabagambe EK, Hou L, Shrubsole MJ, Liu J, Dai Q. Intakes of magnesium, calcium and risk of fatty liver disease and prediabetes. Public Health Nutr 2018;21:2088-95. [PMID: 29607802 DOI: 10.1017/S1368980018000642] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
665 Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-ayuso RM, González R, Alvarez M, Hernández V, García-zattera MJ, Otarola F, Medina B, Rigotti A, Miquel JF, Marshall G, Nervi F. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver International 2009;29:82-8. [DOI: 10.1111/j.1478-3231.2008.01823.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 6.3] [Reference Citation Analysis]
666 König J, Wells J, Cani PD, García-Ródenas CL, MacDonald T, Mercenier A, Whyte J, Troost F, Brummer RJ. Human Intestinal Barrier Function in Health and Disease. Clin Transl Gastroenterol 2016;7:e196. [PMID: 27763627 DOI: 10.1038/ctg.2016.54] [Cited by in Crossref: 318] [Cited by in F6Publishing: 299] [Article Influence: 53.0] [Reference Citation Analysis]
667 Demir M, Lang S, Nierhoff D, Drebber U, Hardt A, Wedemeyer I, Schulte S, Quasdorff M, Goeser T, Töx U, Steffen H. Stepwise Combination of Simple Noninvasive Fibrosis Scoring Systems Increases Diagnostic Accuracy in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2013;47:719-26. [DOI: 10.1097/mcg.0b013e3182819a89] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
668 Di Maso V, Bellentani S. Is there an effective therapy available for non-alcoholic fatty liver disease? F1000 Med Rep 2009;1:50. [PMID: 20948730 DOI: 10.3410/M1-50] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
669 Dyson JK, Anstee QM, McPherson S. Republished: Non-alcoholic fatty liver disease: a practical approach to treatment. Postgrad Med J 2015;91:92-101. [PMID: 25655252 DOI: 10.1136/postgradmedj-2013-100404rep] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
670 Tayyem RF, Al-Dayyat HM, Rayyan YM. Relationship between lifestyle factors and nutritional status and non-alcoholic fatty liver disease among a group of adult Jordanians. Arab J Gastroenterol 2019;20:44-9. [PMID: 30872135 DOI: 10.1016/j.ajg.2019.01.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
671 Wainwright P, Byrne CD. Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. Int J Mol Sci. 2016;17:367. [PMID: 26978356 DOI: 10.3390/ijms17030367] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
672 Bauters D, Spincemaille P, Geys L, Cassiman D, Vermeersch P, Bedossa P, Scroyen I, Lijnen HR. ADAMTS5 deficiency protects against non-alcoholic steatohepatitis in obesity. Liver Int 2016;36:1848-59. [PMID: 27254774 DOI: 10.1111/liv.13181] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
673 Kim HK, Park JY, Lee KU, Lee GE, Jeon SH, Kim JH, Kim CH. Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. Am J Med Sci. 2009;337:98-102. [PMID: 19214024 DOI: 10.1097/maj.0b013e3181812879] [Cited by in Crossref: 48] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
674 Firneisz G, Varga T, Lengyel G, Fehér J, Ghyczy D, Wichmann B, Selmeci L, Tulassay Z, Rácz K, Somogyi A. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One. 2010;5:e12226. [PMID: 20805868 DOI: 10.1371/journal.pone.0012226] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 6.8] [Reference Citation Analysis]
675 Foschi FG, Conti F, Domenicali M, Giacomoni P, Borghi A, Bevilacqua V, Napoli L, Berardinelli D, Altini M, Cucchetti A, Ercolani G, Casadei-Gardini A, Bellentani S, Gastaldelli A, Tiribelli C, Bedogni G, Group BS. External Validation of Surrogate Indices of Fatty Liver in the General Population: the Bagnacavallo Study. J Clin Med 2021;10:520. [PMID: 33535679 DOI: 10.3390/jcm10030520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
676 European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-1402. [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004] [Cited by in Crossref: 1478] [Cited by in F6Publishing: 1378] [Article Influence: 246.3] [Reference Citation Analysis]
677 Kim J, Ha T, Kim S, Lee S, Ahn J. Red paprika ( Capsicum annuum L.) and its main carotenoid capsanthin ameliorate impaired lipid metabolism in the liver and adipose tissue of high-fat diet-induced obese mice. Journal of Functional Foods 2017;31:131-40. [DOI: 10.1016/j.jff.2017.01.044] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
678 Choi KM. Non-alcoholic Fatty Liver Disease and Adiponectin. Korean Diabetes J 2008;32:98. [DOI: 10.4093/kdj.2008.32.2.98] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
679 Jacobs A, Warda A, Verbeek J, Cassiman D, Spincemaille P. An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present. Current Protocols in Mouse Biology 2016;6:185-200. [DOI: 10.1002/cpmo.3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
680 Tamimi TI, Elgouhari HM, Alkhouri N, Yerian LM, Berk MP, Lopez R, Schauer PR, Zein NN, Feldstein AE. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol. 2011;54:1224-1229. [PMID: 21145805 DOI: 10.1016/j.jhep.2010.08.023] [Cited by in Crossref: 115] [Cited by in F6Publishing: 103] [Article Influence: 10.5] [Reference Citation Analysis]
681 He JX, Wang K, Zhou S, Fang XC, Zhang B, Yang Y, Wang N. Protective effect of ischemic postconditioning on ischemia reperfusion injury in steatotic rat livers. Ann Transl Med 2021;9:1295. [PMID: 34532432 DOI: 10.21037/atm-21-2275] [Reference Citation Analysis]
682 Sellmann C, Priebs J, Landmann M, Degen C, Engstler AJ, Jin CJ, Gärttner S, Spruss A, Huber O, Bergheim I. Diets rich in fructose, fat or fructose and fat alter intestinal barrier function and lead to the development